{"linksProcessed":0,"homePage":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/","origin":{"https://viivhealthcare-com-preview-cf5.gdsgsk.com/":{"status":"redirected","statusCode":"200,302","redirectedTo":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/":{"redirectedFrom":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Media","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Our Stories","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Australia","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Canada","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Netherlands","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Switzerland","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"France","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"United States","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Italy","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Germany","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Spain","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"About us","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/what-we-do/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"What we do","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/who-we-are/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Who we are","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/where-we-work/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Where we work","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/hiv-treatment-and-care/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"HIV Treatment and Care","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Our Medicines","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/medical-education-events/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Medical Education Events","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/medicines-in-development/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Medicines in development","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Advancing Science and R&D","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-research-and-develop-new-hiv-medicines/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"We research and develop new HIV medicines","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-collaborate-to-innovate/":{"redirectedFrom":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/our-approach-to-r-d0/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-are-committed-to-data-transparency/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"We are committed to data transparency","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Mapping an HIV Free Future","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/we-improve-access-to-our-medicines/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Access to Medicines","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/working-towards-90-90-90/":{"redirectedFrom":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/working-towards-unaids--90-90-90-targets-/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/policy-papers/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Policy Papers","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/paediatric-hiv-care/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Paediatric HIV Care","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Mapping an HIV Free Future Case Studies","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/":{"redirectedFrom":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/global-community-partnerships/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Positive Action Programmes","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-challenges/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Positive Action Challenges","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Case Studies","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/our-approach/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Our Approach","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/understanding-hiv-stigma-and-discrimination/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":" \n              \n               Understanding HIV stigma and discrimination  World AIDS Day   \n               ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":" \n              \n               Explore our HIV panorama 1 December is World AIDS Day  \n               ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/hiv-research-_-a-panoramic-view--using-science-to-improve-lives-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":" \n              \n               HIV research – a panoramic view World AIDS Day   \n               ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/championing-effective-hiv-care-for-plhiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":" \n              \n               Championing effective HIV care World AIDS Day   \n               ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/november/fast-track-cities-survey-data-provide-insights-into-quality-of-l/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Fast-Track Cities Survey Data Provide Insights into Quality of Life of People Living with HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/juluca-the-first-single-pill-2-drug-regimen-for-the-maintenance-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Juluca, the first single pill, 2-drug regimen, for the maintenance treatment of HIV, granted marketing approval by Japan Ministry of Health, Labour and Welfare","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/viiv-healthcare-receives-chmp-positive-opinion-for-tivicay-eu-la/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"ViiV Healthcare receives CHMP Positive Opinion for Tivicay EU label update with GEMINI study data for the 2-drug regimen of Tivicay + lamivudine","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/contact-us/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Contact Us","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/terms-of-use/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Terms of use","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/accessibility/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Accessibility","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/cookie-policy/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Cookie policy","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/privacy-notice/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Privacy notice","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/terms-and-conditions/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/","txt":"Terms and conditions","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/october/viiv-healthcare-announces-positive-phase-3-results-from-the-brig/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/october/viiv-healthcare-reports-positive-48-week-results-for-second-phas/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/viiv-healthcare-presents-three-year-data-for-investigational-lon/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare presents three year data for investigational long acting injectable two drug HIV regimen (1)","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/viiv-healthcare-submits-new-drug-application-to-us-fda-for-singl/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/viiv-healthcare-update-on-how-we-work-with-healthcare-profession/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare update on how we work with healthcare professionals","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/viiv-healthcare-submits-regulatory-application-to-european-medic/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare submits regulatory application to European Medicines Agency for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/viiv-healthcare-reports-positive-48-week-results-for-first-pivotal-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare reports positive 48-week results for first pivotal, phase III study for novel, long-acting, injectable HIV-treatment regimen","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/July/viiv-healthcare-s-commitments-to-accelerate-the-availability-of-dolutegravir-for-the-treatment-of-hiv-in-children/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare’s commitments to accelerate the availability of dolutegravir for the treatment of HIV in children","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/July/viiv-healthcare-announces-sword-100-week-data-for-juluca-dolutegravirrilpivirine-at-aids-2018/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/July/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen-has-similar-efficacy-to-a-three-drug-regimen-in-treatment-na%C3%AFve-hiv-patients-with-no-resistance/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare presents phase III data showing two drug regimen has similar efficacy to a three-drug regimen in treatment naïve HIV patients, with no resistance","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/July/innovative-public-private-partnership-initiative-to-accelerate-development-of-optimal-pediatric-formulations-of-dolutegravir-to-improve-the-lives-of-clhiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"Innovative public-private partnership initiative to accelerate development of optimal pediatric formulations of dolutegravir to improve the lives of CLHIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/July/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-at-aids-2018/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare shares data from landmark 2-drug regimen trials at AIDS 2018","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/June/viiv-healthcare-reports-positive-results-for-landmark-phase-iii-studies-for-dolutegravir-and-lamivudine/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare reports positive results for landmark phase III studies for dolutegravir and lamivudine","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/May/viiv-healthcare-reports-positive-results-for-landmark-phase-iii-studies-for-dolutegravir-and-lamivudine/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare receives EU marketing authorisation for Juluca (dolutegravir/rilpivirine), the first 2-drug regimen, once-daily, single-pill for the treatment of HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/March/viiv-healthcare-gains-chmp-positive-opinion-for-juluca-dolutegravirrilpivirine-in-europe/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/March/viiv-healthcare-announces-positive-new-dolutegravir-data-for-the-treatment-of-people-living-with-hiv-co-infected-with-tuberculosis/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces positive new dolutegravir data for the treatment of people living with HIV co-infected with tuberculosis","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/February/viiv-healthcare-launches-eighth-phase-iii-study-in-two-drug-regimen-programme-for-hiv-1-treatment/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare launches eighth phase III study in two-drug regimen programme for HIV-1 treatment","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/February/viiv-healthcare-files-patent-infringement-litigation-against-gilead-sciences-inc-over-bictegravir/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare files patent infringement litigation against Gilead Sciences Inc. over bictegravir","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/November/viiv-healthcare-announces-start-of-phase-iii-study-of-long-acting-cabotegravir-for-hiv-prevention-in-women/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces start of phase III study of long-acting cabotegravir for HIV prevention in women","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/November/viiv-healthcare-starts-third-phase-iii-hiv-treatment-study-investigating-long-acting-two-drug-regimen-of-cabotegravir-plus-rilpivirine/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare starts third phase III HIV treatment study investigating long-acting two-drug regimen of cabotegravir plus rilpivirine","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/November/viiv-healthcare-announces-us-fda-approval-for-juluca/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces US FDA approval for Juluca®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/October/viiv-healthcare-announces-positive-phase-3-results-from-the-brighte-study-of-fostemsavir-in-heavily-treatment-experienced-patients-with-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/October/new-results-from-the-positive-perspectives-global-survey-provide-insights-into-the-attitudes-and-perceptions-of-people-living-with-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"New results from the Positive Perspectives global survey provide insights into the attitudes and perceptions of people living with HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/tivicay-and-celsentri-now-included-in-the-essential-drug-list-in-russia/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"Tivicay® and Celsentri® now included in the Essential Drug List in Russia","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/July/viiv-healthcare-and-neat-id-announce-results-from-the-neat-022-study-at-the-international-aids-society-meeting-in-paris/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare and NEAT-ID announce results from the NEAT 022 study at the International AIDS Society meeting in Paris","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/July/viiv-healthcare-announces-superior-efficacy-of-dolutegravir-versus-lopinavirritonavir-in-second-line-hiv-treatment-in-resource-limited-settings/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces superior efficacy of dolutegravir versus lopinavir/ritonavir in second-line HIV treatment in resource-limited settings","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/July/phase-ii-study-results-showed-comparable-viral-suppression-rates-at-96-weeks-for-a-two-drug-regimen/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"Phase II study results showed comparable viral suppression rates at 96 weeks for a two-drug regimen","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/July/viiv-healthcare-shares-data-from-its-innovative-portfolio-with-hiv-community-at-ias-2017/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare shares data from its innovative portfolio with HIV community at IAS 2017","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/June/viiv-healthcare-s-positive-action-europe-programme-awards-grants-to-14-community-based-organisations/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare’s Positive Action Europe Programme awards grants to 14 community-based organisations","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/June/viiv-healthcare-submits-regulatory-applications-for-the-first-hiv-maintenance-regimen-comprising-only-two-medicines/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/honoring-the-memory-of-dr-mark-wainberg/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"In Memory Of HIV Pioneer: Dr. Mark Wainberg","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/March/viiv-healthcare-ranks-1-in-patientview-corporate-reputation-survey/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare ranks #1 in PatientView corporate reputation survey","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/February/viiv-healthcare-welcomes-european-commission-approval-of-dolutegravir-paediatric-type-ii-variation-and-extension-applications/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"Tivicay Paediatric HIV Treatment Variation Approval","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/February/viiv-healthcare-announces-detailed-positive-phase-iii-results-for-investigational-two-drug-regimen-of-dolutegravir-and-rilpivirine-for-hiv-treatment/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"Two-Drug Regimen","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/January/viiv-healthcare-awards-grants-to-msm-and-transgender-hiv-programmes-led-by-the-community-for-the-community/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"HIV Programs For MSM & Transgender","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/January/viiv-healthcare-re-affirms-its-continued-commitment-to-ending-mother-to-child-transmission-of-hiv-with-35-new-community-grants/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"Ending Mother To Child HIV Transmission","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/December/viiv-healthcare-announces-start-of-phase-iii-study-evaluating-long-acting-cabotegravir-for-hiv-prevention/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces start of phase III study evaluating long-acting cabotegravir for HIV prevention","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/December/viiv-healthcare-announces-positive-results-from-first-phase-iii-studies-of-two-drug-hiv-treatment-regimen/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces positive results from first phase III studies of two-drug HIV treatment regimen","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/December/viiv-healthcare-announces-chmp-positive-opinion-to-lower-the-age-and-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv-in-europe/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare Announces CHMP positive opinion to lower the age and weight limit for dolutegravir in children and adolescents living with HIV in Europe","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/December/dominique-limet-to-step-down-as-ceo-of-viiv-healthcare-deborah-waterhouse-to-succeed-him/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"Dominique Limet to step down as CEO of ViiV Healthcare; Deborah Waterhouse to succeed him","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/December/new-agreement-with-ministry-of-health-will-enable-access-to-dolutegravir-for-the-treatment-of-hiv-under-the-national-health-programme-in-brazil/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"New agreement with Ministry of Health will enable access to dolutegravir for the treatment of HIV under the national health programme in Brazil","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/November/viiv-healthcare-launches-phase-iii-programme-to-evaluate-a-long-acting-injectable-hiv-treatment-regimen/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare launches phase III programme to evaluate a long-acting, injectable HIV treatment regimen","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/October/viiv-healthcare-announces-fda-approval-of-selzentry-maraviroc-for-use-in-children-and-adolescents-living-with-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare Announces FDA Approval of SELZENTRY® (maraviroc) for Use in Children and Adolescents Living With HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/October/viiv-healthcare-s-positive-action-europe-invites-applications-for-2017-grants-scheme/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare’s Positive Action Europe Invites Applications for 2017 Grants Scheme","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/September/viiv-healthcare-welcomes-the-fda-s-tentative-approval-of-the-first-generic-dolutegravir-from-aurobindo-pharma/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare welcomes the FDA’s Tentative Approval of the first generic dolutegravir from Aurobindo Pharma","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/September/every-woman-every-child-and-viiv-healthcare-announce-the-winner-of-empowering-girls-in-emergency-settings-challenge-prize/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"Every Woman, Every Child and ViiV Healthcare Announce the Winner of ‘Empowering Girls in Emergency Settings’ Challenge Prize","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/September/new-hiv-awareness-in-primary-care-campaign-launched-to-increase-primary-care-hiv-testing/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"New HIV Awareness in Primary Care campaign launched to increase primary care HIV testing","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/August/viiv-healthcare-launches-phase-iii-programme-evaluating-a-two-drug-regimen-combining-dolutegravir-and-lamivudine-for-hiv-1-treatment/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/July/aria-study-shows-superior-efficacy-of-triumeq-for-treatment-na%C3%AFve-women-living-with-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ARIA study shows superior efficacy of Triumeq® for treatment-naïve women living with HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/June/viiv-healthcare-joins-penta-foundation-in-search-for-strategies-to-achieve-remission-in-children-living-with-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare joins PENTA Foundation in search for strategies to achieve remission in children living with HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/June/viiv-healthcare-announces-fda-approval-to-lower-the-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces FDA approval to lower the weight limit for dolutegravir in children and adolescents living with HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/June/viiv-healthcare-announces-public-tender-agreement-with-botswana-ministry-of-health-for-dolutegravir/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces public tender agreement with Botswana Ministry of Health for dolutegravir","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/May/viiv-healthcare-and-the-international-association-of-providers-of-aids-care-to-collaborate-on-fast-track-cities/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare and the International Association of Providers of AIDS Care to Collaborate on Fast-Track Cities","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/April/viiv-healthcare-extends-medicines-patent-pool-licence-agreement-for-dolutegravir-to-cover-all-lower-middle-income-countries/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare extends Medicines Patent Pool licence agreement for dolutegravir to cover all lower middle-income countries","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/April/global-partnership-launches-new-programme-with-goal-to-save-the-lives-of-thousands-of-children-affected-by-hiv-in-lesotho/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"Global partnership launches new programme with goal to save the lives of thousands of children affected by HIV in Lesotho","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/February/viiv-healthcare-announces-first-phase-ii-hiv-prevention-study-results-for-investigational-long-acting-injectable-cabotegravir/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces first phase II HIV prevention study results for investigational long-acting injectable cabotegravir","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/February/viiv-healthcare-announces-phase-ii-study-results-for-first-two-drug-long-acting-injectable-regimen-for-hiv-1-treatment/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/January/viiv-healthcare-to-progress-collaboration-with-janssen-to-develop-the-first-long-acting-two-drug-injectable-regimen-for-treatment-of-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare to progress collaboration with Janssen to develop the first long-acting, two drug injectable regimen for treatment of HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/December/viiv-healthcare-to-acquire-bristol-myers-squibb-hiv-rd-assets/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare to acquire Bristol-Myers Squibb HIV R&D assets","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/November/viiv-healthcare-highlights-its-continued-commitment-to-end-mother-to-child-transmission-of-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare highlights its continued commitment to end mother to child transmission of HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/November/viiv-healthcare-at-icasa-improving-access-to-hiv-treatment-and-care-for-people-everywhere/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare at ICASA: Improving Access to HIV Treatment and Care for People Everywhere","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/November/viiv-healthcare-gets-ready-for-africa-s-largest-hiv-aids-conference/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare gets ready for Africa’s largest HIV-AIDS Conference","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/November/viiv-healthcare-awards-additional-round-of-grants-to-support-innovative-hiv-programs-aimed-at-reducing-disparities-in-the-southern-us/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare Awards Additional Round of Grants to Support Innovative HIV Programs Aimed at Reducing Disparities in the Southern US","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/November/viiv-healthcare-announces-positive-headline-results-from-a-study-of-two-drug-injectable-regimen-for-hiv-maintenance-therapy/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces positive headline results from a study of two drug injectable regimen for HIV maintenance therapy","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/October/viiv-healthcare-awards-23-small-grants-to-help-alleviate-the-stigma-of-hiv-and-aids-in-the-msm-and-transgender-community-globally/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare awards 23 small grants to help alleviate the stigma of HIV and AIDS in the MSM and transgender community globally","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/October/viiv-healthcare-employee-named-top-marketer-in-healthcare-industry-by-medical-marketing-media/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare employee named top marketer in healthcare industry, by Medical Marketing & Media","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/September/new-phase-iiibiv-data-show-switching-to-once-daily-triumeq-maintains-hiv-viral-suppression/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"New Phase IIIb/IV data show switching to once-daily Triumeq® maintains HIV viral suppression","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/July/viiv-healthcare-and-desano-pharmaceuticals-manufacturing-agreement-will-allow-competitive-supply-of-dolutegravir-in-china-and-several-developing-countries/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare and Desano Pharmaceuticals’ manufacturing agreement will allow competitive supply of dolutegravir in China and several developing countries","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/June/viiv-healthcare-announces-new-positive-action-project-in-us-for-msm-youth-calls-for-proposals/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare Announces New Positive Action Project in US for MSM Youth, Calls for Proposals","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/May/press-release/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"Press Release","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/May/european-patient-advocacy-groups-awarded-grants-from-positive-action-europe/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"European Patient Advocacy Groups Awarded Grants from Positive Action Europe","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/May/viiv-healthcare-begins-phase-iii-programme-with-dolutegravirrilpivirine-combination-for-hiv-maintenance-therapy/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare begins phase III programme with dolutegravir/rilpivirine combination for HIV maintenance therapy","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/March/viiv-healthcare-launches-new-global-positive-action-programme-focused-on-msm-and-transgender-populations/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare Launches New Global Positive Action Programme Focused on MSM and Transgender Populations","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/March/viiv-healthcare-announces-the-approval-in-japan-of-triumeq-dolutegravir-abacavir-and-lamivudine-a-new-single-pill-regimen-for-the-treatment-of-hiv-infection/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces the approval in Japan of Triumeq® (dolutegravir, abacavir and lamivudine), a new single-pill regimen for the treatment of HIV infection","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/february/viiv-healthcare-announces--10-million-initiative-to-accelerate-r/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare Announces $10 Million Initiative to Accelerate Response to HIV/AIDS Among Black Gay and Bisexual Men","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/december/viiv-healthcare-announces-regulatory-submission-in-japan-for-sin/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces regulatory submission in Japan for single-pill regimen combining dolutegravir, abacavir and lamivudine for the treatment of HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/december/mylans-tentative-fda-approval-for-paeds-formulations-of-abacavir/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"Mylan's tentative FDA approval for paeds formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and CHAI","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/november/viiv-healthcare-announces-new-grants-in-support-of-ending-mother/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces new grants in support of ending mother to child transmission of HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/november/hiv-testing-week/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"HIV Testing Week","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/november/gsk-ranked-top-of-the-2014-access-to-medicines-atm-index-for-the/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"GSK ranked top of the 2014 Access to Medicines (ATM) Index for the fourth consecutive time","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/october/viiv-healthcare-expands-program-to-reduce-hiv-disparities-in-sou/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare Expands Program to Reduce HIV Disparities in Southern US","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/august/viiv-healthcare-receives-fda-approval-for-triumeq/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare receives FDA approval for Triumeq","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/july/viiv-healthcare-presents-phase-iii-data-comparing-once-daily-mar/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare presents phase III data comparing once-daily maraviroc","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/june/viiv-healthcare-announces-new-collaboration-with-janssen/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces new collaboration with Janssen","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/april/viiv-healthcare-announces-new-initiatives-to-improve-access-to-d/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/march/viiv-healthcare-announces-next-round-of-the-positive-action-sout/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare Announces Next Round of the Positive Action Southern Initiative to Support Linkages to HIV/AIDS Care and Treatment Adherence","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/january/viiv-healthcare-s-new-hiv-medicine-tivicay-dolutegravir-is-appro/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare’s new HIV medicine Tivicay™ (dolutegravir) is approved in Europe","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/january/viiv-healthcare-to-make-available-anonymised-patient-level-data-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare to Make Available Anonymised Patient-Level Data from its Clinical Trials","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/december/update-on-patent-ruling-on-viiv-healthcare-s-epzicom-and-trizivi/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"Update on patent ruling on ViiV Healthcare’s Epzicom® and Trizivir®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/december/viiv-healthcare-commits-34m-in-positive-action-for-children-fund/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare commits £3.4M in Positive Action for Children Fund grants for programmes focused on prevention of mother-to-child transmission of HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/october/viiv-healthcare-announces-european-regulatory-submission-for-sin/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces European regulatory submission for single-tablet regimen","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/october/viiv-healthcare-announces-us-regulatory-submission-for-a-single-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces US regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/september/viiv-healthcare-presents-positive-data-from-phase-iiibiv-study-o/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naïve Adults with HIV-1","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/september/viiv-healthcare-expands-hivaids-community-support-in-hard-hit-so/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare Expands HIV/AIDS Community Support in Hard-Hit Southern US","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/august/viiv-healthcare-announces-us-approval-of-tivicay-dolutegravir-fo/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces US approval of Tivicay® (dolutegravir) for the treatment of HIV-1","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/march/viiv-healthcare-presents-data-from-phase-iii-study-of-dolutegrav/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare presents data from Phase III study of dolutegravir vs raltegravir in treatment-experienced adults with HIV-1","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/february0/viiv-healthcare-announces-a-voluntary-licence-agreement-with-the/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces a voluntary licence agreement with the Medicines Patent Pool to increase access to HIV medicines for children","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/february0/viiv-healthcare-announces-fda-priority-review-designation-for-do/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces FDA priority review designation for dolutegravir as a potential treatment for HIV infection","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/february0/viiv-healthcare-expands-positive-action-southern-initiative-to-f/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare expands Positive Action Southern Initiative to fight HIV/AIDS and support community action","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/december/viiv-healthcare-announces-regulatory-submissions-for-dolutegravi/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces regulatory submissions for dolutegravir in the EU, US and Canada","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/November/viiv-healthcare-presents-phase-iii-data-from-viking-3-study-of-d/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare presents phase III data from VIKING-3 study of dolutegravir in HIV-1 infected integrase inhibitor-resistant adults","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/November/viiv-healthcare-commits-nearly-4m-in-positive-action-for-children-fund-grants-for-programmes-focused-on-alleviating-burden-of-hiv-on-women-and-children/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare commits nearly £4M in Positive Action for Children Fund grants for programmes focused on alleviating burden of HIV on women and children","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/october/shionogi-and-viiv-healthcare-announce-new-agreement-to-commercia/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/october/shionogi-viiv-healthcare-announces-completion-of-initial-clinica/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"Shionogi-ViiV Healthcare announces completion of initial clinical registration package for dolutegravir in HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/July/-viiv-healthcare-expands-support-for-hiv-prevention-and-educatio/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare Expands Support for HIV Prevention and Education in Hard-Hit US Region","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/July/once-daily-dolutegravir-is-non-inferior-to-twice-daily-raltegrav/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"Once-Daily Dolutegravir is Non-Inferior to Twice-Daily Raltegravir in Treatment-Naïve Adults with HIV-1","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/July/ViiV%20Healthcare%20Expands%20Commitment%20to%20Addressing%20Gaps%20in%20Paediatric%20HIV%20Research%20Care%20and%20Treatment/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare Expands Commitment to Addressing Gaps in Paediatric HIV Research, Care and Treatment","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/July/shionogi-viiv-healthcare-announces-positive-initial-data-from-ph/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"Shionogi – ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/april/shionogi-viiv-healthcare-announces-initial-data-from-pivotal-pha/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"Shionogi – ViiV Healthcare announces initial data from Pivotal Phase III study of dolutegravir in HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/october/media-alert-viiv-healthcare-s-positive-action-for-children-fund-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"Media Alert: ViiV Healthcare’s Positive Action for Children Fund announces 16 new grantees for the year 2011/2012","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/october/viiv-healthcare-starts-phase-iii-programme-of-celsentri-selzentr/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare starts phase III programme of Celsentri-Selzentry versus Truvada in combination with a protease inhibitor in people living with HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/september/viiv-healthcare-reaffirms-commitment-to-us-regions-hardest-hit-b/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare Reaffirms Commitment to US Regions Hardest Hit by HIV/AIDS","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/september/regulatory-update-celsentriselzentry-maraviroc/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"Regulatory Update – Celsentri/Selzentry® (maraviroc)","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/june/-viiv-healthcare-awards-small-grants-from-positive-action-for-ch/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare Awards Small Grants from Positive Action for Children Fund to 82 Charitable Organisations Globally","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/april/viiv-healthcare-expands-positive-action-us-southern-initiative-t/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare Expands Positive Action US Southern Initiative to Fight HIV/AIDS in Hard-hit Region","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/march/-regulatory-update-celsentriselzentry-maraviroc/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"Regulatory Update – Celsentri/Selzentry® (maraviroc)","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/february/david-redfern-appointed-as-chairman-of-the-board-for-viiv-health/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"David Redfern appointed as Chairman of the Board for ViiV Healthcare","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/february/positive-action-and-vida-digna-further-information/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"Positive Action and Vida Digna - further information","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/february/viiv-healthcare-s-positive-action-and-the-international-hivaids-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare’s Positive Action and the International HIV/AIDS Alliance Tackle HIV Stigma in Six Central American Countries","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/december/global-agenda-for-elimination-of-mother-to-child-transmission-of/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"Global Agenda for Elimination of Mother to Child Transmission of HIV: Positive Action for Children Fund Calls for Proposals to Fill the Gaps","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/october/shionogi-viiv-healthcare-llc-initiates-phase-iii-clinical-progra/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/october/ViiV%20Healthcare%20acts%20to%20improve%20access%20to%20HIV%20Medicines%20in%20United%20States%20for%20those%20most%20in%20need/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare acts to improve access to HIV Medicines in United States for those most in need","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/september/viiv-healthcare-awards-southern-initiative-grants-to-reduce-hiv-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare Awards Southern Initiative Grants to Reduce HIV Disparities Among African Americans and Latinos","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/july/shionogi-viiv-healthcare-announces-commitment-to-phase-iii-devel/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"Shionogi - ViiV Healthcare Announces Commitment to Phase III Development Programme for Investigational Once-Daily HIV Integrase Inhibitor","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/july/positive-phase-iib-data-on-investigational-once-daily-integrase-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"Positive Phase IIb Data on Investigational Once-Daily Integrase Inhibitor, 572, presented at International AIDS Conference","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/july/viiv-healthcare-announces-further-initiatives-to-improve-access-0/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces further initiatives to improve access to HIV medications for people living in the least developed countries","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/july/viiv-healthcare-announces-positive-action-us-southern-initiative/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare Announces Positive Action US Southern Initiative, an Innovative Community Support Program to Fight HIV/AIDS","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/june/viiv-healthcare-awards-grants-from-the-positive-action-for-child/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare Awards Grants from the Positive Action for Children Fund of £3.6m","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/june/viiv-healthcare-and-amfar-partner-to-optimize-hiv-treatment-for-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare and amfAR Partner to Optimize HIV Treatment for Infants and Children in Asia","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/june/viiv-healthcare-and-elizabeth-glaser-pediatric-aids-foundation-p/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare and Elizabeth Glaser Pediatric AIDS Foundation Partner to Expedite Access to ARV Treatment for Infants and Children","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/march/viiv-healthcare-calls-for-initial-grant-proposals-to-the-positiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare Calls for Initial Grant Proposals to the Positive Action for Children Fund","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2009/november/fda-approves-expanded-use-of-selzentry--for-appropriate-patients/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"FDA Approves Expanded Use of Selzentry® for Appropriate Patients Starting HIV Antiretroviral Therapy for the First Time","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2009/november/viiv-healthcare-launches/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare Launches","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2009/april/glaxosmithkline-and-pfizer-announce-innovative-agreement-to-crea/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"GlaxoSmithKline and Pfizer announce innovative agreement to create a new world-leading, specialist HIV company","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/june/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"June","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/september/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"September","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/march/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"March","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/october/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"October","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/february/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"February","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/april/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"April","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"2011","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2009/november/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"November","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2009/april/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"April","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2009/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"2009","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/january/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"January","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/march/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"March","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/april/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"April","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/june/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"June","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/july/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"July","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/august/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"August","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/october/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"October","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/november/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"November","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/december/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"December","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"2014","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/september/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"September","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/march/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"March","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/june/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"June","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/december/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"December","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/july/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"july","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/october/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"october","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"2010","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/february0/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"february","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/march/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"march","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/august/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"august","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/september/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"september","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/october/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"october","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/november/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"november","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/december/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"december","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/february/ViiV%20Healthcare%20announces%20a%20voluntary%20licence%20agreement%20with%20the%20Medicines%20Patent%20Pool%20to%20increase%20access%20to%20HIV%20medicines%20for%20children/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"ViiV Healthcare announces a voluntary licence agreement with the Medicines Patent Pool to increase access to HIV medicines for children","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/february/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"february","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"2013","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/february/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"February","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/March/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"March","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/May/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"May","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/June/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"June","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/July/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"July","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/September/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"September","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/October/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"October","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/November/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"November","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/December/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"December","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"2015","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/January/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"January","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/February/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"February","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/April/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"April","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/May/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"May","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/June/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"June","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/July/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"July","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/August/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"August","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/September/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"September","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/October/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"October","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/November/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"November","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/December/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"December","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"2016","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/January/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"January","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/February/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"February","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/March/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"March","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/June/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"June","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/July/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"July","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/October/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"October","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/November/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"November","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"2017","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/december/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"December","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/october/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"October","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/april/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"April","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/November/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"November","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/July/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"July","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"2012","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/october/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"October","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/august/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"August","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/February/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"February","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/March/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"March","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/May/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"May","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/June/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"June","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/July/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"July","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/","txt":"2018","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/our-people/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/what-we-do/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/","txt":"What we do","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/","txt":"Our medicines","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/","txt":"ViiV News","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/","txt":"Community Partnerships","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/contact-us/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/","txt":"Contact us","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/community-partnerships-grants/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/privacy-policy/":{"redirectedFrom":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/site-services/privacy/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/website-terms-of-use/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/","txt":"Website Terms of Use","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/report-an-adverse-event/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/","txt":"Report an adverse event","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/transparency-reporting/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/","txt":"Transparency Reporting","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/bienvenido/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/","txt":"Bienvenido  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/spanish-articles/por-que-menos-es-mas/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/","txt":"¿Por qué Menos es Más?  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/spanish-articles/conoce-a-los-protagonistas/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/","txt":"- Conoce a los protagonistas  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/spanish-articles/sumate-a-conmenosesposiblemas/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/","txt":" - SÚMATE a #conMenosEsposibleMas  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/","txt":"- Consejos Menos es Más  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/quienes-somos/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/","txt":"Quiénes somos  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/content/cf-viiv/viiv-healthcare/en_GB/sitemap.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/","txt":"Sitemap","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/contenuti-ita/i-nostri-valori/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/","txt":"I \n              \n              \n                nostri \n               \n              Valori","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/viiv-brochure/":{"status":"redirected","redirectedTo":"https://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Italy/Original_PDF's/viiv_brochure_bassa.pdf"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/","txt":"Sala Stampa - l’area delle nostre news per i giornalisti e i media","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/novembre/viiv-healthcare-ha-ricevuto-lopinione-positiva-del-chmp-in-europ/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/","txt":"ViiV Healthcare ha ricevuto l’opinione positiva del CHMP in Europa per l’aggiornamento del foglietto illustrativo di dolutegravir con i dati dello studio GEMINI per il regime a due farmaci di dolutegravir + lamivudina","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-annuncia-i-risultati-positivi-di-fase-3-dello-st/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/","txt":"ViiV Healthcare annuncia i risultati positivi di Fase 3 dello studio Brighte su fostemsavir nei pazienti con HIV HTE (Heavily Treatment-Experienced)","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-presenta-i-risultati-positivi-a-48-settimane-del/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/","txt":"ViiV Healthcare presenta i risultati positivi a 48 settimane del secondo studio di fase III per un innovativo trattamento iniettabile","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/contenuti-ita/il-nostro-obiettivo/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/contenuti-ita/la-nostra-ricerca/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/contenuti-ita/il-nostro-essere-responsabili/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/informativa-sulla-privacy/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/","txt":"Informativa sulla Privacy","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/content/cf-viiv/viiv-healthcare/master/sitemap.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/","txt":"Sitemap","status":"done","statusCode":404},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/lactualite-en-direct/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/","txt":" \n              \n               L'actualité en direct  \n              ViiV Healthcare communique ! Retrouvez nos dernières communications et actualités \n               ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/","txt":" \n              \n               Nos engagements, nos services en France  \n               ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/","txt":"Bienvenue  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/politique-qualite-en-matiere-dinformation-promotionnelle/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/","txt":"Politique qualité en matière d'information promotionnelle  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/viiv-healthcare-en-bref/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/","txt":"ViiV Healthcare en bref  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/mieux-nous-connaitre/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/","txt":"Mieux nous connaître  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/viiv-healthcare-en-france/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/","txt":"ViiV Healthcare en France  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/","txt":"Nos médicaments en France  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/mentions-legales/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/","txt":"Mentions Légales","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/","txt":"Politique de protection des données personnelles","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/politique-de-cookies/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/","txt":"Politique de cookies","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/conditions-dutilisation/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/","txt":"Conditions d'utilisation","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/","txt":" \n              \n                \n               ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/herzlich-willkommen/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/","txt":"Herzlich Willkommen  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/","txt":"Aktuelles  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/","txt":"Unser Engagement weltweit  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/","txt":"Unser Engagement in Deutschland  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/fuer-eine-hiv-freie-zukunft/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/","txt":"Für eine HIV-freie Zukunft  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/forschung-und-innovation/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/","txt":"Forschung und Innovation  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/90-90-90/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/","txt":"90-90-90  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/","txt":"Kalender  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/viiv-foerderpreis/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/","txt":"ViiV Förderpreis  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/test-auf-hiv-und-geschlechtskrankheiten-per-post/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/","txt":"  Jul 19  \n       \n        \n       \n       \n       Pilotprojekt in Bayern: Per Abo soll der diskrete und regelmäßige Check einfacher werden.  \n       ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/rote-hand-brief-zu-dolutegravir/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/","txt":"  Jun 01  \n       \n        \n       \n       \n       Rote-Hand-Brief zu Tivicay (Dolutegravir), Triumeq (Dolutegravir/Abacavir/Lamivudin), Juluca (Dolutegravir/Rilpivirin): Berichte über Neuralrohrdefekte bei Neugeborenen von Frauen, die zur Zeit der Konzeption Dolutegravir eingenommen haben  \n       ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/viiv-ist-1-im-patientview-report/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/","txt":"  Mai 16  \n       \n        \n       \n       \n       In dem von PatientView kürzlich veröffentlichten Bericht über „Das Ansehen von Pharmaunternehmen für das Jahr 2017“ belegt ViiV Healthcare erneut den ersten Platz. Es ist das fünfte Jahr in Folge, dass ViiV Healthcare bei der Umfrage das Feld anführt, diesmal in 11 der 12 Kategorien.  \n       ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/solidaritaet-mit-hivplus-frauen-zeigen-undsichtbar/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/","txt":"  Mrz 08  \n       \n        \n       \n       \n       Solidarität mit HIV+ Frauen zeigen #UNDSICHTBAR  \n       ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/artikel/positive-action/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/datenschutzerklaerung/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/","txt":"Datenschutzerklärung","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/nutzungsbedingungen/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/","txt":"Nutzungsbedingungen","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/cookie-richtlinie/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/","txt":"Cookie-Richtlinie","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/","txt":"FR","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/healthcare-professionals/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/","txt":"Healthcare professionals","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/about-us/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/","txt":"About us","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/careers/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/","txt":"Careers","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/contact-us/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/","txt":"Contact us","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/about-hivaids/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/","txt":"About HIV/AIDS","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/","txt":"Our medicines","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/","txt":"Community Partnerships","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/media/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/","txt":"Media","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/about-us/our-values/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/","txt":" \n           \n            Our core values run deep    \n           Our values lead to action. See what drives our commitment to deliver innovative new options for the care and treatment of people living with HIV/AIDS. \n            ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/","txt":"  \n       \n         Community grants \n        ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/healthcare-professionals/research-development/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/healthcare-professionals/independent-grants-and-support-programs/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/juluca/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/","txt":"ViiV Healthcare is proud to announce that Juluca is now available in Canada!","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/accessibility/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/","txt":"Accessibility","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/privacy-statement/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/","txt":"Privacy Code","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/privacy-code/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/terms-of-use/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/","txt":"Terms of Use","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/cookie-policy/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/","txt":"Cookie Policy","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/welkom/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/","txt":"Welkom  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/","txt":"RETHiNK+ verhalen  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/viiv-positive-survey-8-1/":{"status":"redirected","redirectedTo":"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Netherlands/Original_PDFs/Welkom/1711063-viiv-positive-perspective-survey-report-8-1.pdf"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/leven-met-het-hiv-label/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/","txt":"hier","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/-ik-had-meer-last-van-het-leven-met-een-geheim-dan-van-hiv-zelf-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/","txt":"interview met Gino","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/happi-app/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/","txt":"Lees hier het artikel","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/privacy-verklaring/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/","txt":"Privacy Verklaring","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/","txt":"DE","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/","txt":"FR","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/latest-news/2017/september/flashcards/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/","txt":" \n              \n               HIV Flashcards Learn the most important facts about HIV in an entertaining way  \n               ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/welcome-switzerland/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/","txt":"Welcome Switzerland  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/swiss-viiv-team/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/latest-news/2018/june-1/hiv-knowledge-builds-trust/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/","txt":"  Jun 30  \n       \n        \n       \n       \n       YES! Let's talk about sex!  \n       ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/privacy-notice/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/","txt":"Privacy notice","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/our-culture-and-values/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/who-we-are/","txt":"Our culture and values  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/our-board/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/who-we-are/","txt":"Our Board  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/our-executive-team/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/who-we-are/","txt":"Our Executive Team  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/who-we-are/","txt":"Corporate ethics and compliance  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/careers/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/who-we-are/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/we-partner-with-the-hiv-community/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/what-we-do/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-community-led-hiv-aids-prevention-project-kenya/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/what-we-do/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/contact-us/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":"Contact Us","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/about-us/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":"About us","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/who-we-are/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":"Who We Are","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/how-we-work/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":"How We Work","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/where-we-work/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":"Where we work","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/standing-together/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":"Standing Together","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/community-giving/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":"Community Giving","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-community-grants/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":"Positive Action Community Grants","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-southern-initiative/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":"Positive Action Southern Initiative","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-for-women/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":"Positive Action for Women","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-for-youth/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":"Positive Action for Youth","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/accelerate--initiative/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":"ACCELERATE! Initiative","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/community-youth-summits/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":"Community & Youth Summits","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/advancing-science/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":"Advancing Science","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-medicines/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":"Our Medicines","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/medicines-in-development/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":"Medicines in Development","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/educating-healthcare-professionals/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":"Educating Healthcare Professionals","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/as-much-as-i-can-wins-excellence-in-patient-engagement-award/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":" \n           \n            \"As Much as I Can\" Wins Excellence in Patient Engagement Award    \n           Click here to learn more. \n            ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":" \n           \n            \"As Much as I Can\" Received With Open Arms    \n           The immersive theater experience captivated sold-out crowds during its run in NYC. \n            ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":"News","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-positive-phase-3-results-from-the-brig0/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":"ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":"ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-presents-three-year-data-for-investigational-lon/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":"ViiV Healthcare presents three-year data for investigational long-acting injectable, two-drug HIV regimen","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/redirects/report-a-possible-side-effect/":{"status":"redirected","redirectedTo":"https://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/terms-of-use/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":"Terms of use","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/accessibility/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":"Accessibility","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/privacy-policy/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":"Privacy policy","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/terms-and-conditions/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":"Terms and conditions","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/juluca/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/","txt":"Juluca®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/triumeq/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/","txt":"Triumeq®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/tivicay/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/","txt":"Tivicay®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/selzentry-celsentri/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/","txt":"Selzentry/ Celsentri®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/epzicom-kivexa/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/","txt":"Epzicom/ Kivexa®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/ziagen/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/","txt":"Ziagen®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/trizivir/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/","txt":"Trizivir®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/combivir/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/","txt":"Combivir®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/epivir-3tc/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/","txt":"Epivir/ 3TC®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/retrovir-azt/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/","txt":"Retrovir/ AZT®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/lexiva-telzir/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/","txt":"Lexiva/ Telzir®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/viracept/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/","txt":"Viracept®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/rescriptor/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/","txt":"Rescriptor®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/external/gsk-com-en-gb-contact-us-report-a-possible-side-effect-/":{"status":"redirected","redirectedTo":"https://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/hiv-treatment-and-care/european-network-of-young-hiv-experts/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/medical-education-events/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-research-and-develop-new-hiv-medicines/","txt":"Explore our stories","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-research-and-develop-new-hiv-medicines/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-research-and-develop-new-hiv-medicines/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/towards-a-cure--exploring-cure-and-remission-in-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-collaborate-to-innovate/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/how-we-are-collaborating-to-seek-remission-strategies-in-paediat/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-collaborate-to-innovate/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/how-our-innovation-unit-is-addressing-new-areas-of-need-in-hiv-c/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-collaborate-to-innovate/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/facing-the-challenges-of-getting-old-with-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-collaborate-to-innovate/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/external/hivimplementationscience-com-/":{"status":"redirected","redirectedTo":"https://hivimplementationscience.com/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/working-towards-90-90-90/fast-track-cities/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/working-towards-90-90-90/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/working-towards-90-90-90/positive-pathways/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/working-towards-90-90-90/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/working-towards-90-90-90/positive-partnerships/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/working-towards-90-90-90/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/implementation-science/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/policy-papers/","txt":"Implementation Science  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/dolutegravir-expanded-access-program/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/policy-papers/","txt":"Dolutegravir Expanded Access Program  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/paediatric-hiv-care/","txt":"Positive Action for Children Fund","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-adolescents/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/paediatric-hiv-care/","txt":"Positive Action for Adolescents","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-girls-and-women/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/paediatric-hiv-care/","txt":"Positive Action for Girls & Women","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/paediatric-hiv-care/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/spark--igniting-change/":{"redirectedFrom":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/inspiring-the-next-generation-of-hiv-leaders/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/the-fight-to-end-mother-to-child-transmission-of-hiv/":{"redirectedFrom":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/the-fight-to-end-mother-to-child-transmission-of-hiv/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/canada/hiv-environment-in-saskatchewan/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/argentina/hiv-environment-in-buenos-aires/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/uruguay/hiv-environment-in-montevideo/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/brazil/hiv-environment-in-brazil/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/uk/hiv-environment-in-london/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/estonia/hiv-environment-in-estonia/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/spain/hiv-environment-in-spain/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/italy/hiv-environment-in-italy/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/germany/hiv-environment-in-bochum/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/germany-ii/hiv-environment-in-berlin/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/switzerland/hiv-environment-in-switzerland/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/we-improve-access-to-our-medicines/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/we-improve-access-to-our-medicines/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/striking-the-right-balance/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/we-improve-access-to-our-medicines/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/helping-botswana-treat-all-people-living-with-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/we-improve-access-to-our-medicines/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/hiv--a-virus-that-thrives-on-inequality/":{"redirectedFrom":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/focusing-on-communities-affected-by-hiv/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-msm-transgender-people/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-southern-initiative/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/local-partnerships/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/external/www-positiveactionchallenges-com-/":{"status":"redirected","redirectedTo":"https://www.positiveactionchallenges.com/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-shuga/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kaiser-family-foundation/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-centre-for-sexual-health-and-hivaids-research-ceshhar-zimbab/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amplifychange/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kenya-council-of-imams-and-ulamaa-kcui/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/czech-aids-help-association/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/iskorak/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/national-aids-trust-nat/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/diapluslogs/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/global-forum-on-msm-and-hiv-speaking-out/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-action-europe/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vida-digna-life-with-dignity/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/adolescents-count-today-kenya/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-2012-global-village/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-dudes--club/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/hiv-young-leaders-fund/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vitu-newala--newala-youth-can-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/ubuntu-education-fund-living-positively/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-msm-initiative/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-initiative/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-staying-alive-initiative/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/partners-in-health-lesotho-project/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/save-the-children-drc/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/beats-for-life/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/elizabeth-glaser-pediatric-aids-foundation-partnership/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/iskorak-croatia/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":"Iskorak, Croatia","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-czech-aids-help-society-czech-republic/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positivo-grupos-de-apoio-e-autoajuda-portugal/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-aidsmap/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/our-approach/","txt":"Find out more","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/hiv--a-virus-that-thrives-on-inequality/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/our-approach/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/hiv-treatment-and-care/the-positive-perspectives-survey/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/understanding-hiv-stigma-and-discrimination/","txt":"Positive Perspectives","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/u-u--undetectable-equals-untransmittable/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/understanding-hiv-stigma-and-discrimination/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/international-day-against-homophobia--transphobia---biphobia/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/understanding-hiv-stigma-and-discrimination/","txt":"International Day Against Homophobia, Transphobia & Biphobia","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/pride-around-the-world/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/understanding-hiv-stigma-and-discrimination/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/branford--the-worlds-only-hiv-dedicated-research-facility/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/","txt":" ","status":"redirected","statusCode":"200,302","redirectedTo":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/welcome-to-branford--the-worlds-only-hiv-dedicated-research-faci/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/accelerating-the-pace-of-innovation/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/","txt":" ","status":"redirected","statusCode":"200,302","redirectedTo":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/accelerating-the-pace-of-innovation/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/working-towards-unaids--90-90-90-targets-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/","txt":" ","status":"redirected","statusCode":"200,302","redirectedTo":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/working-towards-90-90-90/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/the-state-of-hiv-implementation-science--do-we-need-more-science/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/","txt":" ","status":"redirected","statusCode":"200,302","redirectedTo":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/the-state-of-hiv-implementation-science--do-we-need-more-science/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/how-the-unity-tool-can-help-conversations-between-plhiv-and-thei/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/","txt":" ","status":"redirected","statusCode":"200,302","redirectedTo":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/how-the-unity-tool-can-help-conversations-between-plhiv-and-thei/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/focusing-on-communities-affected-by-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/","txt":" ","status":"redirected","statusCode":"200,302","redirectedTo":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/hiv--a-virus-that-thrives-on-inequality/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/inspiring-the-next-generation-of-hiv-leaders/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/","txt":" ","status":"redirected","statusCode":"200,302","redirectedTo":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/spark--igniting-change/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/the-fight-to-end-mother-to-child-transmission-of-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/","txt":" ","status":"redirected","statusCode":"200,302","redirectedTo":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/the-fight-to-end-mother-to-child-transmission-of-hiv/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/accelerating-the-pace-of-innovation/":{"redirectedFrom":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/accelerating-the-pace-of-innovation/","statusCode":200,"status":"done"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/welcome-to-branford--the-worlds-only-hiv-dedicated-research-faci/":{"redirectedFrom":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/branford--the-worlds-only-hiv-dedicated-research-facility/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/championing-effective-hiv-care-for-plhiv/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/championing-effective-hiv-care-for-plhiv/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/the-state-of-hiv-implementation-science--do-we-need-more-science/":{"redirectedFrom":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/the-state-of-hiv-implementation-science--do-we-need-more-science/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/accelerating-city-hiv-aids-responses-through-collaboration/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/championing-effective-hiv-care-for-plhiv/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/viiv-healthcare_s-commitment-to-implementation-science/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/championing-effective-hiv-care-for-plhiv/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/understanding-the-concerns-of-people-living-with-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/championing-effective-hiv-care-for-plhiv/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/driving-change-through-implementation-science/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/championing-effective-hiv-care-for-plhiv/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/juluca-the-first-single-pill-2-drug-regimen-for-the-maintenance-/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/juluca-the-first-single-pill-2-drug-regimen-for-the-maintenance-/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/viiv-healthcare-receives-chmp-positive-opinion-for-tivicay-eu-la/#bottom":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/viiv-healthcare-receives-chmp-positive-opinion-for-tivicay-eu-la/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/privacy-notice/#whatpersonalinformationwecollectaboutyou":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/privacy-notice/","txt":"what personal information we collect about you;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/privacy-notice/#howdoweuseyourpersonalinformation":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/privacy-notice/","txt":"how do we use your personal information?","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/privacy-notice/#onwhatbasisweuseyourpersonalinformation":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/privacy-notice/","txt":"on what basis we use your personal information;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/privacy-notice/#howlongwekeepyourpersonalinformation":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/privacy-notice/","txt":"how long we keep your personal information;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/privacy-notice/#wemayshareyourpersonalinformationwithothersandtransferitinternationally":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/privacy-notice/","txt":"we may share your personal information with others and transfer it internationally;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/privacy-notice/#howweprotectyourpersonalinformation":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/privacy-notice/","txt":"how we protect your personal information;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/privacy-notice/#yourrightsregardingyourpersonalinformation":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/privacy-notice/","txt":"your rights regarding your personal information;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/privacy-notice/#whattodoifyoudontwanttoprovideuswithyourpersonalinformation":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/privacy-notice/","txt":"what to do if you don’t want to provide us with your personal information; and","status":"done","statusCode":":("},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/privacy-notice/#howweusecookiesandwheretofindfurtherinformation":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/privacy-notice/","txt":"how we use cookies and where to find further information.","status":"done","statusCode":":("},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/privacy-notice/#Contactus":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/privacy-notice/","txt":"Contact us","status":"done","statusCode":":("},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/viiv-healthcare-presents-three-year-data-for-investigational-lon/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/viiv-healthcare-presents-three-year-data-for-investigational-lon/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/viiv-healthcare-presents-three-year-data-for-investigational-lon/ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/viiv-healthcare-presents-three-year-data-for-investigational-lon/","txt":"","status":"redirected","statusCode":"404,301","redirectedTo":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/viiv-healthcare-presents-three-year-data-for-investigational-lon/ref/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/october/viiv-healthcare-reports-positive-48-week-results-for-second-phas/#bottom":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/october/viiv-healthcare-reports-positive-48-week-results-for-second-phas/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/viiv-healthcare-reports-positive-48-week-results-for-first-pivotal-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/#1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/viiv-healthcare-reports-positive-48-week-results-for-first-pivotal-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/July/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen-has-similar-efficacy-to-a-three-drug-regimen-in-treatment-na%C3%AFve-hiv-patients-with-no-resistance/#1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/July/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen-has-similar-efficacy-to-a-three-drug-regimen-in-treatment-na%C3%AFve-hiv-patients-with-no-resistance/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/July/viiv-healthcare-announces-sword-100-week-data-for-juluca-dolutegravirrilpivirine-at-aids-2018/#1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/July/viiv-healthcare-announces-sword-100-week-data-for-juluca-dolutegravirrilpivirine-at-aids-2018/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/July/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-at-aids-2018/#1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/July/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-at-aids-2018/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/May/viiv-healthcare-reports-positive-results-for-landmark-phase-iii-studies-for-dolutegravir-and-lamivudine/#1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/May/viiv-healthcare-reports-positive-results-for-landmark-phase-iii-studies-for-dolutegravir-and-lamivudine/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/March/viiv-healthcare-gains-chmp-positive-opinion-for-juluca-dolutegravirrilpivirine-in-europe/#1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/March/viiv-healthcare-gains-chmp-positive-opinion-for-juluca-dolutegravirrilpivirine-in-europe/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/February/viiv-healthcare-launches-eighth-phase-iii-study-in-two-drug-regimen-programme-for-hiv-1-treatment/#1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/February/viiv-healthcare-launches-eighth-phase-iii-study-in-two-drug-regimen-programme-for-hiv-1-treatment/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/February/viiv-healthcare-launches-eighth-phase-iii-study-in-two-drug-regimen-programme-for-hiv-1-treatment/_callto_+442080473763":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/February/viiv-healthcare-launches-eighth-phase-iii-study-in-two-drug-regimen-programme-for-hiv-1-treatment/","txt":"+44 (0) 20 8047 5502","status":"redirected","statusCode":"404,301","redirectedTo":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/February/viiv-healthcare-launches-eighth-phase-iii-study-in-two-drug-regimen-programme-for-hiv-1-treatment/_callto_+442080473763/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/March/viiv-healthcare-announces-positive-new-dolutegravir-data-for-the-treatment-of-people-living-with-hiv-co-infected-with-tuberculosis/#1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/March/viiv-healthcare-announces-positive-new-dolutegravir-data-for-the-treatment-of-people-living-with-hiv-co-infected-with-tuberculosis/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/March/viiv-healthcare-announces-positive-new-dolutegravir-data-for-the-treatment-of-people-living-with-hiv-co-infected-with-tuberculosis/#2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/March/viiv-healthcare-announces-positive-new-dolutegravir-data-for-the-treatment-of-people-living-with-hiv-co-infected-with-tuberculosis/","txt":"[2]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/November/viiv-healthcare-announces-start-of-phase-iii-study-of-long-acting-cabotegravir-for-hiv-prevention-in-women/#Bottom":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/November/viiv-healthcare-announces-start-of-phase-iii-study-of-long-acting-cabotegravir-for-hiv-prevention-in-women/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/November/viiv-healthcare-starts-third-phase-iii-hiv-treatment-study-investigating-long-acting-two-drug-regimen-of-cabotegravir-plus-rilpivirine/#Bottom":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/November/viiv-healthcare-starts-third-phase-iii-hiv-treatment-study-investigating-long-acting-two-drug-regimen-of-cabotegravir-plus-rilpivirine/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/November/viiv-healthcare-starts-third-phase-iii-hiv-treatment-study-investigating-long-acting-two-drug-regimen-of-cabotegravir-plus-rilpivirine/#+442080473763":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/November/viiv-healthcare-starts-third-phase-iii-hiv-treatment-study-investigating-long-acting-two-drug-regimen-of-cabotegravir-plus-rilpivirine/","txt":"+44 (0) 20 8047 3763","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/October/new-results-from-the-positive-perspectives-global-survey-provide-insights-into-the-attitudes-and-perceptions-of-people-living-with-hiv/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/October/new-results-from-the-positive-perspectives-global-survey-provide-insights-into-the-attitudes-and-perceptions-of-people-living-with-hiv/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/tivicay-and-celsentri-now-included-in-the-essential-drug-list-in-russia/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/tivicay-and-celsentri-now-included-in-the-essential-drug-list-in-russia/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/July/viiv-healthcare-and-neat-id-announce-results-from-the-neat-022-study-at-the-international-aids-society-meeting-in-paris/#Bottom":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/July/viiv-healthcare-and-neat-id-announce-results-from-the-neat-022-study-at-the-international-aids-society-meeting-in-paris/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/July/phase-ii-study-results-showed-comparable-viral-suppression-rates-at-96-weeks-for-a-two-drug-regimen/#Bottom":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/July/phase-ii-study-results-showed-comparable-viral-suppression-rates-at-96-weeks-for-a-two-drug-regimen/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/July/viiv-healthcare-shares-data-from-its-innovative-portfolio-with-hiv-community-at-ias-2017/#Bottom":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/July/viiv-healthcare-shares-data-from-its-innovative-portfolio-with-hiv-community-at-ias-2017/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/February/viiv-healthcare-welcomes-european-commission-approval-of-dolutegravir-paediatric-type-ii-variation-and-extension-applications/#Bottom":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/February/viiv-healthcare-welcomes-european-commission-approval-of-dolutegravir-paediatric-type-ii-variation-and-extension-applications/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/January/viiv-healthcare-awards-grants-to-msm-and-transgender-hiv-programmes-led-by-the-community-for-the-community/#Bottom":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/January/viiv-healthcare-awards-grants-to-msm-and-transgender-hiv-programmes-led-by-the-community-for-the-community/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/January/viiv-healthcare-re-affirms-its-continued-commitment-to-ending-mother-to-child-transmission-of-hiv-with-35-new-community-grants/#Bottom":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/January/viiv-healthcare-re-affirms-its-continued-commitment-to-ending-mother-to-child-transmission-of-hiv-with-35-new-community-grants/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/December/viiv-healthcare-announces-start-of-phase-iii-study-evaluating-long-acting-cabotegravir-for-hiv-prevention/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/December/viiv-healthcare-announces-start-of-phase-iii-study-evaluating-long-acting-cabotegravir-for-hiv-prevention/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/December/viiv-healthcare-announces-chmp-positive-opinion-to-lower-the-age-and-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv-in-europe/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/December/viiv-healthcare-announces-chmp-positive-opinion-to-lower-the-age-and-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv-in-europe/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/December/new-agreement-with-ministry-of-health-will-enable-access-to-dolutegravir-for-the-treatment-of-hiv-under-the-national-health-programme-in-brazil/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/December/new-agreement-with-ministry-of-health-will-enable-access-to-dolutegravir-for-the-treatment-of-hiv-under-the-national-health-programme-in-brazil/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/December/new-agreement-with-ministry-of-health-will-enable-access-to-dolutegravir-for-the-treatment-of-hiv-under-the-national-health-programme-in-brazil/#+44%20(0)%2020%208047%203763":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/December/new-agreement-with-ministry-of-health-will-enable-access-to-dolutegravir-for-the-treatment-of-hiv-under-the-national-health-programme-in-brazil/","txt":"+44 (0) 20 8047 3763","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/November/viiv-healthcare-launches-phase-iii-programme-to-evaluate-a-long-acting-injectable-hiv-treatment-regimen/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/November/viiv-healthcare-launches-phase-iii-programme-to-evaluate-a-long-acting-injectable-hiv-treatment-regimen/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/October/viiv-healthcare-announces-fda-approval-of-selzentry-maraviroc-for-use-in-children-and-adolescents-living-with-hiv/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/October/viiv-healthcare-announces-fda-approval-of-selzentry-maraviroc-for-use-in-children-and-adolescents-living-with-hiv/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/October/viiv-healthcare-s-positive-action-europe-invites-applications-for-2017-grants-scheme/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/October/viiv-healthcare-s-positive-action-europe-invites-applications-for-2017-grants-scheme/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/October/viiv-healthcare-s-positive-action-europe-invites-applications-for-2017-grants-scheme/#+44%20(0)%2020%208047%203763":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/October/viiv-healthcare-s-positive-action-europe-invites-applications-for-2017-grants-scheme/","txt":"+44 (0) 20 8047 3763","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/September/viiv-healthcare-welcomes-the-fda-s-tentative-approval-of-the-first-generic-dolutegravir-from-aurobindo-pharma/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/September/viiv-healthcare-welcomes-the-fda-s-tentative-approval-of-the-first-generic-dolutegravir-from-aurobindo-pharma/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/August/viiv-healthcare-launches-phase-iii-programme-evaluating-a-two-drug-regimen-combining-dolutegravir-and-lamivudine-for-hiv-1-treatment/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/August/viiv-healthcare-launches-phase-iii-programme-evaluating-a-two-drug-regimen-combining-dolutegravir-and-lamivudine-for-hiv-1-treatment/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/July/aria-study-shows-superior-efficacy-of-triumeq-for-treatment-na%C3%AFve-women-living-with-hiv/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/July/aria-study-shows-superior-efficacy-of-triumeq-for-treatment-na%C3%AFve-women-living-with-hiv/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/June/viiv-healthcare-joins-penta-foundation-in-search-for-strategies-to-achieve-remission-in-children-living-with-hiv/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/June/viiv-healthcare-joins-penta-foundation-in-search-for-strategies-to-achieve-remission-in-children-living-with-hiv/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/June/viiv-healthcare-announces-fda-approval-to-lower-the-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/June/viiv-healthcare-announces-fda-approval-to-lower-the-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/June/viiv-healthcare-announces-public-tender-agreement-with-botswana-ministry-of-health-for-dolutegravir/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/June/viiv-healthcare-announces-public-tender-agreement-with-botswana-ministry-of-health-for-dolutegravir/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/June/viiv-healthcare-announces-public-tender-agreement-with-botswana-ministry-of-health-for-dolutegravir/#+44%20(0)%2020%208047%203763":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/June/viiv-healthcare-announces-public-tender-agreement-with-botswana-ministry-of-health-for-dolutegravir/","txt":"+44 (0) 20 8047 3763","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/May/viiv-healthcare-and-the-international-association-of-providers-of-aids-care-to-collaborate-on-fast-track-cities/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/May/viiv-healthcare-and-the-international-association-of-providers-of-aids-care-to-collaborate-on-fast-track-cities/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/April/global-partnership-launches-new-programme-with-goal-to-save-the-lives-of-thousands-of-children-affected-by-hiv-in-lesotho/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/April/global-partnership-launches-new-programme-with-goal-to-save-the-lives-of-thousands-of-children-affected-by-hiv-in-lesotho/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/February/viiv-healthcare-announces-first-phase-ii-hiv-prevention-study-results-for-investigational-long-acting-injectable-cabotegravir/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/February/viiv-healthcare-announces-first-phase-ii-hiv-prevention-study-results-for-investigational-long-acting-injectable-cabotegravir/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/April/viiv-healthcare-extends-medicines-patent-pool-licence-agreement-for-dolutegravir-to-cover-all-lower-middle-income-countries/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/April/viiv-healthcare-extends-medicines-patent-pool-licence-agreement-for-dolutegravir-to-cover-all-lower-middle-income-countries/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/November/viiv-healthcare-awards-additional-round-of-grants-to-support-innovative-hiv-programs-aimed-at-reducing-disparities-in-the-southern-us/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/November/viiv-healthcare-awards-additional-round-of-grants-to-support-innovative-hiv-programs-aimed-at-reducing-disparities-in-the-southern-us/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/November/viiv-healthcare-announces-positive-headline-results-from-a-study-of-two-drug-injectable-regimen-for-hiv-maintenance-therapy/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/November/viiv-healthcare-announces-positive-headline-results-from-a-study-of-two-drug-injectable-regimen-for-hiv-maintenance-therapy/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/October/viiv-healthcare-awards-23-small-grants-to-help-alleviate-the-stigma-of-hiv-and-aids-in-the-msm-and-transgender-community-globally/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/October/viiv-healthcare-awards-23-small-grants-to-help-alleviate-the-stigma-of-hiv-and-aids-in-the-msm-and-transgender-community-globally/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/September/new-phase-iiibiv-data-show-switching-to-once-daily-triumeq-maintains-hiv-viral-suppression/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/September/new-phase-iiibiv-data-show-switching-to-once-daily-triumeq-maintains-hiv-viral-suppression/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/July/viiv-healthcare-and-desano-pharmaceuticals-manufacturing-agreement-will-allow-competitive-supply-of-dolutegravir-in-china-and-several-developing-countries/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/July/viiv-healthcare-and-desano-pharmaceuticals-manufacturing-agreement-will-allow-competitive-supply-of-dolutegravir-in-china-and-several-developing-countries/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/June/viiv-healthcare-announces-new-positive-action-project-in-us-for-msm-youth-calls-for-proposals/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/June/viiv-healthcare-announces-new-positive-action-project-in-us-for-msm-youth-calls-for-proposals/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/May/european-patient-advocacy-groups-awarded-grants-from-positive-action-europe/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/May/european-patient-advocacy-groups-awarded-grants-from-positive-action-europe/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/May/viiv-healthcare-begins-phase-iii-programme-with-dolutegravirrilpivirine-combination-for-hiv-maintenance-therapy/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/May/viiv-healthcare-begins-phase-iii-programme-with-dolutegravirrilpivirine-combination-for-hiv-maintenance-therapy/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/March/viiv-healthcare-launches-new-global-positive-action-programme-focused-on-msm-and-transgender-populations/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/March/viiv-healthcare-launches-new-global-positive-action-programme-focused-on-msm-and-transgender-populations/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/March/viiv-healthcare-announces-the-approval-in-japan-of-triumeq-dolutegravir-abacavir-and-lamivudine-a-new-single-pill-regimen-for-the-treatment-of-hiv-infection/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/March/viiv-healthcare-announces-the-approval-in-japan-of-triumeq-dolutegravir-abacavir-and-lamivudine-a-new-single-pill-regimen-for-the-treatment-of-hiv-infection/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/february/viiv-healthcare-announces--10-million-initiative-to-accelerate-r/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/february/viiv-healthcare-announces--10-million-initiative-to-accelerate-r/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/december/viiv-healthcare-announces-regulatory-submission-in-japan-for-sin/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/december/viiv-healthcare-announces-regulatory-submission-in-japan-for-sin/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/december/mylans-tentative-fda-approval-for-paeds-formulations-of-abacavir/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/december/mylans-tentative-fda-approval-for-paeds-formulations-of-abacavir/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/november/gsk-ranked-top-of-the-2014-access-to-medicines-atm-index-for-the/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/november/gsk-ranked-top-of-the-2014-access-to-medicines-atm-index-for-the/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/paediatric-innovation-seed-fund/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/november/gsk-ranked-top-of-the-2014-access-to-medicines-atm-index-for-the/","txt":"Paediatric Innovation Seed Fund","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/october/viiv-healthcare-expands-program-to-reduce-hiv-disparities-in-sou/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/october/viiv-healthcare-expands-program-to-reduce-hiv-disparities-in-sou/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/august/viiv-healthcare-receives-fda-approval-for-triumeq/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/august/viiv-healthcare-receives-fda-approval-for-triumeq/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/june/viiv-healthcare-announces-new-collaboration-with-janssen/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/june/viiv-healthcare-announces-new-collaboration-with-janssen/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/april/viiv-healthcare-announces-new-initiatives-to-improve-access-to-d/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/april/viiv-healthcare-announces-new-initiatives-to-improve-access-to-d/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/march/viiv-healthcare-announces-next-round-of-the-positive-action-sout/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/march/viiv-healthcare-announces-next-round-of-the-positive-action-sout/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/january/viiv-healthcare-s-new-hiv-medicine-tivicay-dolutegravir-is-appro/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/january/viiv-healthcare-s-new-hiv-medicine-tivicay-dolutegravir-is-appro/","txt":"[1-4]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/december/viiv-healthcare-commits-34m-in-positive-action-for-children-fund/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/december/viiv-healthcare-commits-34m-in-positive-action-for-children-fund/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/october/viiv-healthcare-announces-european-regulatory-submission-for-sin/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/october/viiv-healthcare-announces-european-regulatory-submission-for-sin/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/october/viiv-healthcare-announces-us-regulatory-submission-for-a-single-/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/october/viiv-healthcare-announces-us-regulatory-submission-for-a-single-/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/september/viiv-healthcare-presents-positive-data-from-phase-iiibiv-study-o/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/september/viiv-healthcare-presents-positive-data-from-phase-iiibiv-study-o/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/september/viiv-healthcare-expands-hivaids-community-support-in-hard-hit-so/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/september/viiv-healthcare-expands-hivaids-community-support-in-hard-hit-so/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/august/viiv-healthcare-announces-us-approval-of-tivicay-dolutegravir-fo/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/august/viiv-healthcare-announces-us-approval-of-tivicay-dolutegravir-fo/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/february0/viiv-healthcare-expands-positive-action-southern-initiative-to-f/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/february0/viiv-healthcare-expands-positive-action-southern-initiative-to-f/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/November/viiv-healthcare-commits-nearly-4m-in-positive-action-for-children-fund-grants-for-programmes-focused-on-alleviating-burden-of-hiv-on-women-and-children/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/November/viiv-healthcare-commits-nearly-4m-in-positive-action-for-children-fund-grants-for-programmes-focused-on-alleviating-burden-of-hiv-on-women-and-children/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/July/-viiv-healthcare-expands-support-for-hiv-prevention-and-educatio/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/July/-viiv-healthcare-expands-support-for-hiv-prevention-and-educatio/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/July/ViiV%20Healthcare%20Expands%20Commitment%20to%20Addressing%20Gaps%20in%20Paediatric%20HIV%20Research%20Care%20and%20Treatment/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/July/ViiV%20Healthcare%20Expands%20Commitment%20to%20Addressing%20Gaps%20in%20Paediatric%20HIV%20Research%20Care%20and%20Treatment/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/september/viiv-healthcare-reaffirms-commitment-to-us-regions-hardest-hit-b/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/september/viiv-healthcare-reaffirms-commitment-to-us-regions-hardest-hit-b/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/april/viiv-healthcare-expands-positive-action-us-southern-initiative-t/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/april/viiv-healthcare-expands-positive-action-us-southern-initiative-t/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/february/positive-action-and-vida-digna-further-information/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/february/positive-action-and-vida-digna-further-information/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/october/ViiV%20Healthcare%20acts%20to%20improve%20access%20to%20HIV%20Medicines%20in%20United%20States%20for%20those%20most%20in%20need/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/october/ViiV%20Healthcare%20acts%20to%20improve%20access%20to%20HIV%20Medicines%20in%20United%20States%20for%20those%20most%20in%20need/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/september/viiv-healthcare-awards-southern-initiative-grants-to-reduce-hiv-/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/september/viiv-healthcare-awards-southern-initiative-grants-to-reduce-hiv-/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/july/viiv-healthcare-announces-further-initiatives-to-improve-access-0/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/july/viiv-healthcare-announces-further-initiatives-to-improve-access-0/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/july/viiv-healthcare-announces-positive-action-us-southern-initiative/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/july/viiv-healthcare-announces-positive-action-us-southern-initiative/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/advancing-hiv-science-through-collaboration/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/","txt":"  \n    \n      Advancing HIV science through collaboration \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/metrics-matter--measuring-impact-in-hiv-implementation/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/","txt":"  \n    \n      Metrics matter: measuring impact in HIV implementation \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/overcoming-the-challenges-for-partners-of-people-living-with-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/","txt":"  \n    \n      Overcoming the challenges for partners of people living with HIV \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/how-the-unity-tool-can-help-conversations-between-plhiv-and-thei/":{"redirectedFrom":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/how-the-unity-tool-can-help-conversations-between-plhiv-and-thei/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/preliminary-positive-perspectives-survey-data-released-at-9th-in/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/","txt":"  \n    \n      Preliminary Positive Perspectives Survey Data Released at 9th International AIDS Society Conference \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/hiv-is-a-global-issue-that-needs-an-ongoing--collaborative-respo/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/","txt":"  \n    \n      HIV is a global issue that needs an ongoing, collaborative response. \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/addressing-the-challenges-of-the-hiv-epidemic-in-africa/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/","txt":"  \n    \n      Addressing the challenges of the HIV epidemic in Africa \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/viiv-healthcare_s-positive-partnerships-accelerates-progress-tow1/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/","txt":"  \n    \n      ViiV Healthcare’s Positive Partnerships Accelerates Progress Towards 90-90-90 Goals in Estonia \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/fighting-hiv-together--collaboration-is-driving-progress-with-th/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/","txt":"  \n    \n      Fighting HIV Together: Collaboration is driving progress with the launch of new Fast-Track City dashboards \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/positive-partnerships-initiative-launches-in-estonia1/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/","txt":"  \n    \n      Positive Partnerships initiative launches in Estonia \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/see-you-in-paris--viiv-healthcare---the-international-aids-socie/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/","txt":"  \n    \n      See you in Paris! ViiV Healthcare @ the International AIDS Society conference \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/viiv-healthcare-to-host-inaugural-implementation-science-network/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/","txt":"  \n    \n      ViiV Healthcare to host inaugural Implementation Science Network Meeting in Paris \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/hiv-behind-bars--supporting-hiv-research--education-and-testing-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/","txt":"  \n    \n      HIV Behind Bars: Supporting HIV research, education and testing in Italian prisons \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/celebrating-the-25th-year-of-community-partnerships-and-collabor/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/","txt":"  \n    \n      Celebrating the 25th year of community partnerships and collaborations through Positive Action \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/facing-the-challenges-of-getting-old-with-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/","txt":"  \n    \n      Facing the Challenges of getting old with HIV \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/addressing-hiv-in-adolescents/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/","txt":"  \n    \n      Addressing HIV in Adolescents \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/understanding-hiv-in-women--spotlight-on-the-gender-gap-in-hiv-r/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/","txt":"  \n    \n      Understanding HIV in women: Spotlight on the gender gap in HIV research \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/young-britons-break-down-hiv-stigma---isolation-to-be-the--genen/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/","txt":"  \n    \n      Young Britons break down HIV stigma & isolation to be the #GenEndIt \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/new-online-platform-for-positive-action-challenges-launched/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/","txt":"  \n    \n      New Online Platform for Positive Action Challenges Launched \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/our-people/one-million-positive-faces/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/our-people/","txt":"  \n    \n      One Million Positive Faces \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/our-people/find-out-about-industrial-placement-opportunities-at-viiv-health/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/our-people/","txt":"  \n    \n      Find out about Industrial Placement opportunities at ViiV Healthcare \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/our-people/treating-hiv--building-on-30-years-of-innovation--ingenuity-and-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/our-people/","txt":"  \n    \n      Treating HIV: building on 30 years of innovation, ingenuity and passion \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/our-people/sabena-solomon-pursues-diverse-career-opportunities-at-viiv-heal/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/our-people/","txt":"  \n    \n      Sabena Solomon pursues diverse career opportunities at ViiV Healthcare \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/our-people/from-classroom-to-congress-hall-my-year-at-viiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/our-people/","txt":"  \n    \n      From classroom to congress hall: my year at ViiV \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/3tc-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/","txt":"3TC®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/celsentri-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/","txt":"Celsentri®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/combivir-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/","txt":"Combivir®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/juluca-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/","txt":"Juluca®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/kivexa-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/","txt":"Kivexa®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/retrovir-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/","txt":"Retrovir®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/telzir-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/","txt":"Telzir®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/tivicay-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/","txt":"Tivicay®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/triumeq-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/","txt":"Triumeq®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/trizivir-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/","txt":"Trizivir®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/ziagen-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/","txt":"Ziagen®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/first-two-drug-pill-now-available-for-australians-with-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/","txt":"First two drug pill now available for Australians with HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/first-two-drug-single-pill-for-hiv-now-approved-for-use-in-austr/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/","txt":"First two drug single pill for HIV now approved for use in Australia","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/october/viiv-healthcare-awards-new-grants-to-accelerate-community-led-so/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/","txt":"ViiV Healthcare awards new grants to accelerate community led solutions to HIV challenges","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/september/critical-steps-towards-addressing-hiv-in-australia-a-report-from/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/","txt":"Critical Steps Towards Addressing HIV in Australia a report from ViiV Healthcare Australia","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/march/oonagh-makes-a-difference-for-people-affected-by-hiv-through-pos/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/","txt":"Oonagh makes a difference for people affected by HIV through Positive Action programmes","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2016/viiv-healthcare-to-progress-collaboration-with-janssen-to-develo/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/","txt":"ViiV Healthcare to progress collaboration with Janssen to develop the first long-acting two drug injectable regimen for treatment of HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2016/grassroots-hiv-organisations-receive-140-000-funding-boost/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/","txt":"Grassroots HIV organisations receive 140 000 funding boost","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2016/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/","txt":"2016","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/march/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/","txt":"March","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/september/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/","txt":"September","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/october/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/","txt":"October","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/","txt":"2017","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/about-positive-action/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/","txt":"  \n    \n      About Positive Action \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-action-grant-projects/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/","txt":"  \n    \n      Positive Action Grant Projects \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/other-community-partnership-projects/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/","txt":"  \n    \n      Other Community Partnership Projects \n     ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/global-community-partnerships/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/","txt":"  \n    \n      Global Community Partnerships \n     ","status":"redirected","statusCode":"200,302","redirectedTo":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/external/au-viivexchange-com--utmcampaign-viivcorporate-utmsource-whatwed/":{"status":"redirected","redirectedTo":"https://au.viivexchange.com/?utm_campaign=viivcorporate&utm_source=whatwedo&utm_medium=web&utm_content=vxbtn"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/acon-healthy-ageing-with-hiv---self-management-groups/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/community-partnerships-grants/","txt":"ACON- Healthy Ageing with HIV - Self Management Groups  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/bgf-online-group-counselling-for-isolated-people-living-with-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/community-partnerships-grants/","txt":"BGF - Online Group Counselling for Isolated People Living with HIV  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/napwha-linkage-to-care-project-lkcp-identifying-the-barriers-and/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/community-partnerships-grants/","txt":"NAPWHA - Linkage to Care Project (LKCP): Identifying the Barriers and Facilitators for Maintaining Linkage to HIV Care  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-women-victoria-needs-of-women-from-african-diaspora-com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/community-partnerships-grants/","txt":"Positive women Victoria needs of women from African diaspora communities in Victoria Australia who are living with HIV  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/qpp-plhiv-peer-testernavigator-pilot-project-townsville-queensla/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/community-partnerships-grants/","txt":"QPP - PLHIV Peer Tester/Navigator Pilot Project (Townsville, Queensland)  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/qpp-queensland-positive-speakers-bureau-neutralising-the-health-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/community-partnerships-grants/","txt":"QPP - Queensland Positive Speakers Bureau. Neutralising the health impact of HIV related stigma  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/tascahrd-rural-tasmanian-council-on-aids-hepatitis-and-related-d/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/community-partnerships-grants/","txt":"TasCAHRD Rural - Tasmanian Council on AIDS, Hepatitis and Related Diseases  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/the-western-suburbs-haven-young-and-moving-forward/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/community-partnerships-grants/","txt":"The Western Suburbs Haven - Young and Moving Forward  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/site-services/privacy/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/website-terms-of-use/","txt":"VHCA Privacy Policy","status":"redirected","statusCode":"200,302","redirectedTo":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/privacy-policy/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/spanish-articles/conoce-a-los-protagonistas/#tab-0146898285-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/spanish-articles/conoce-a-los-protagonistas/","txt":" \n          \n           \n           Victor \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/spanish-articles/conoce-a-los-protagonistas/#tab-0146898285-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/spanish-articles/conoce-a-los-protagonistas/","txt":" \n          \n           \n           Graciela \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/spanish-articles/conoce-a-los-protagonistas/#tab-0146898285-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/spanish-articles/conoce-a-los-protagonistas/","txt":" \n          \n           \n           Jorge Garrido \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/en-el-deporte-como-en-la-vida-menos-es-mas/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/trabajando-en-positivo/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/menos-es-mas-en-nuestra-cocina-y-en-nuestro-paladar/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/imagina-mas/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/consigue-mas-salud-con-menos-esfuerzo-en-10-pasos/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/contenuti-ita/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/contenuti-ita/i-nostri-valori/","txt":"Contenuti ITA  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/febbraio/viiv-healthcare-annuncia-la-partenza-dellottavo-studio-di-fase-i/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/","txt":"ViiV Healthcare annuncia la partenza dell’ottavo studio di fase III nell’ambito del programma di sviluppo di regimi a due farmaci per il trattamento dell’HIV-1  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/marzo/marzo/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/","txt":"ViiV Healthcare ha ricevuto l’opinione positiva del CHMP in Europa per la combinazione dolutegravir/rilpivirina  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/maggio/viiv-healthcare-riceve-lapprovazione-in-europa-per-la-combinazio/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/","txt":"ViiV Healthcare riceve l’approvazione in Europa per la combinazione dolutegravir-rilpivirina  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/giugno/viiv-healthcare-annuncia-importanti-studi-di-fase-iii-per-dolute/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/","txt":"ViiV Healthcare annuncia importanti studi di fase III per dolutegravir e lamivudina  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/luglio/viiv-healthcare-presenta-ad-aids-2018-i-dati-di-fase-iii-per-gli/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/","txt":"ViiV Healthcare presenta ad AIDS 2018 i dati di fase III per gli importanti studi GEMINI  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/hiv--da-parma-innovazione--industria-e-cure-per-i-pazienti-di-tu/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/","txt":"HIV: da Parma innovazione, industria e cure per i pazienti di tutto il mondo  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-presenta-i-dati-relativi-a-tre-anni-di-trattamen/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/","txt":"ViiV Healthcare presenta i dati relativi a tre anni di trattamento con il regime sperimentale iniettabile a due farmaci HIV a lunga durata di azione  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2017/giugno/sottoposta-la-richiesta-di-autorizzazione-regolatoria-per-il-pri/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/","txt":"Sottoposta la richiesta di autorizzazione regolatoria per il primo regime di mantenimento per il trattamento dell’HIV con due soli farmaci  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2017/settembre/l_hiv-in-carcere--un-progetto-svela-la-ricetta-per-combatterlo/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/","txt":"L’HIV in carcere, un progetto svela la ricetta per combatterlo  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2017/ottobre/viiv-healthcare-annuncia-i-risultati-positivi-dello-studio-di-fa/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/","txt":"ViiV Healthcare annuncia i risultati positivi dello studio di fase 3 BRIGHTE su fostemsavir in pazienti con HIV multitrattati  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2017/novembre/viiv-healthcare-annuncia-la-partenza-dello-studio-di-fase-iii-co/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/","txt":"ViiV Healthcare annuncia la partenza dello studio di fase III con cabotegravir a lunga durata d’azione per la prevenzione dell’HIV nella donna  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/novembre/viiv-healthcare-ha-ricevuto-lopinione-positiva-del-chmp-in-europ/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/novembre/viiv-healthcare-ha-ricevuto-lopinione-positiva-del-chmp-in-europ/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-presenta-i-risultati-positivi-a-48-settimane-del/#bottom":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-presenta-i-risultati-positivi-a-48-settimane-del/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/italia/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/informativa-sulla-privacy/","txt":"Italia  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/#tab-01425121435-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/","txt":" \n          \n           \n           Patients \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/#tab-01425121435-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/","txt":" \n          \n           \n           Professionnels de santé \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/#tab-01425121435-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/","txt":" \n          \n           \n           Pour tous \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/mieux-nous-connaitre/#tab-0544765655-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/mieux-nous-connaitre/","txt":" \n          \n           \n           L’expertise en héritage \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/mieux-nous-connaitre/#tab-0544765655-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/mieux-nous-connaitre/","txt":" \n          \n           \n           Engagé pour l’innovation \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/mieux-nous-connaitre/#tab-0544765655-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/mieux-nous-connaitre/","txt":" \n          \n           \n           Un modèle R&D novateur \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/mieux-nous-connaitre/#tab-0544765655-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/mieux-nous-connaitre/","txt":" \n          \n           \n           Notre empreinte RSE \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/mieux-nous-connaitre/#tab-0544765655-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/mieux-nous-connaitre/","txt":" \n          \n           \n           Santé maternelle \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/mieux-nous-connaitre/#tab-0544765655-5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/mieux-nous-connaitre/","txt":" \n          \n           \n           Accès aux médicaments \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles/#n1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles/","txt":"Quelles données personnelles nous recueillons à votre sujet ;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles/#n2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles/","txt":"Comment nous utilisons vos données personnelles ;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles/#n3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles/","txt":"Sur quelle base nous utilisons vos données personnelles ;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles/#n4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles/","txt":"Combien de temps nous conservons vos données personnelles ;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles/#n5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles/","txt":"Dans quel cas vos données personnelles peuvent être partagées avec des tierces parties et transférées à l’international ;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles/#n6":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles/","txt":"Comment sont protégées vos données personnelles ;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles/#n7":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles/","txt":"Vos droits en vertu de la Politique de protection des données personnelles ;","status":"done","statusCode":":("},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles/#n8":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles/","txt":"Que faire si vous ne souhaitez pas nous communiquer vos données personnelles","status":"done","statusCode":":("},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles/#n9":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles/","txt":"Comment nous utilisons les cookies et où trouver des informations supplémentaires","status":"done","statusCode":":("},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/content/cf-viiv/viiv-healthcare/master/home/contact-us.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles/","txt":"ici","status":"done","statusCode":404},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/bundesweites-treffen-fuer-hiv-positive-jugendliche/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/","txt":"Bundesweites Treffen für HIV-positive Jugendliche  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/deutsch-oesterreichischer-aids-kongress/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/","txt":"Deutsch-Österreichischer AIDS-Kongress  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/schulung-und-selbstmanagement-koennen-die-adhaerenz-verbessern/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/","txt":"Schulung und Selbstmanagement können die Adhärenz verbessern  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/deutsche-aids-hilfe-startet-die-informationskampagne-zum-welt-ai/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/","txt":"Deutsche AIDS-Hilfe startet die Informationskampagne zum Welt-AIDS-Tag  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/auf-dem-weg-zu-90-90-90-wie-sieht-es-in-europa-aus/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/","txt":"Auf dem Weg zu 90-90-90: Wie sieht es in Europa aus?  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/antiretrovirale-kombinationstherapie-eine-erfolgsgeschichte/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/","txt":"Antiretrovirale Kombinationstherapie – eine Erfolgsgeschichte  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/art-erreicht-mehr-als-20-mio-menschen/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/","txt":"ART erreicht mehr als 20 Mio Menschen  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/geringes-resistenzrisiko-auch-bei-sofortigem-art-beginn/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/","txt":"Geringes Resistenzrisiko auch bei sofortigem ART-Beginn  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/uebertragene-hiv-resistenzen-seltener/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/","txt":"Übertragene HIV-Resistenzen seltener  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/patienten-mit-hohen-cd4-zellzahlen-wer-profitiert-am-meisten-von/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/","txt":"Patienten mit hohen CD4-Zellzahlen: wer profitiert am meisten von sofortigem Therapiebeginn?  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/frueher-therapiebeginn-kann-resistenzentwicklung-verhindern/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/","txt":"Früher Therapiebeginn kann Resistenzentwicklung verhindern  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/therapie-als-praevention-tasp-wie-gross-ist-das-wissen-bei-msm/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/","txt":"Therapie als Prävention (TasP): wie groß ist das Wissen bei MSM?  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/begleiterkrankungen-bei-hiv-patienten-daten-aus-den-usa/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/","txt":"Begleiterkrankungen bei HIV-Patienten – Daten aus den USA  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/artikel/weltweiter-zugang-zu-medikamenten/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/artikel/kinder-und-jugendliche-im-fokus/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/hiv-und-sti-test-leicht-er-gemacht-self-sampling-in-muenchen/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/let-s-talk-about-sex-and-drugs-in-berlin/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/das-innovative-zentrum-fuer-sexuelle-gesundheit-und-medizin-wir-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/let-s-talk-about-sex/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/spickzettel-unterstuetzung-bei-der-fruehen-diagnose-informatione/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/90-90-90/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/90-90-90/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/datenschutzerklaerung/#1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/datenschutzerklaerung/","txt":"Welche personenbezogenen Daten erheben wir","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/datenschutzerklaerung/#2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/datenschutzerklaerung/","txt":"Wie verwenden wir Ihre personenbezogenen Daten","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/datenschutzerklaerung/#3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/datenschutzerklaerung/","txt":"Auf welcher Grundlage verwenden wir Ihre personenbezogenen Daten","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/datenschutzerklaerung/#4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/datenschutzerklaerung/","txt":"Wie lange speichern wir Ihre personenbezogenen Daten","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/datenschutzerklaerung/#5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/datenschutzerklaerung/","txt":"Wir geben Ihre personenbezogenen Daten gelegentlich an Dritte weiter und übertragen Sie ins Ausland","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/datenschutzerklaerung/#6":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/datenschutzerklaerung/","txt":"Wie schützen wir geben Ihre personenbezogenen Daten","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/datenschutzerklaerung/#7":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/datenschutzerklaerung/","txt":"Websites, die uns nicht gehören und die sich unserer Kontrolle entziehen","status":"done","statusCode":":("},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/datenschutzerklaerung/#8":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/datenschutzerklaerung/","txt":"Ihre Rechte in Bezug auf Ihren personenbezogenen Daten","status":"done","statusCode":":("},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/datenschutzerklaerung/#9":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/datenschutzerklaerung/","txt":"Wenn Sie uns Ihre personenbezogenen Daten nicht überlassen wollen","status":"done","statusCode":":("},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/datenschutzerklaerung/#10":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/datenschutzerklaerung/","txt":"Wie setzen wir Cookies ein und wo finden Sie weitere Informationen","status":"done","statusCode":":("},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/datenschutzerklaerung/#11":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/datenschutzerklaerung/","txt":"Kontaktangaben","status":"done","statusCode":":("},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/healthcare-professionals/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/healthcare-professionals/","txt":"FR","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/healthcare-professionals/viiv-healthcare-clinical-study-register/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/healthcare-professionals/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/medicines-in-development/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/healthcare-professionals/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/healthcare-professionals/voluntary-disclosure-of-viiv-healthcare-canada-payments-to-hcps-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/healthcare-professionals/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/about-us/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/","txt":"À notre sujet","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/careers/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/","txt":"Carrières","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/contact-us/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/","txt":"Pour nous joindre","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/about-hivaids/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/","txt":"À propos du VIH/sida","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/","txt":"Nos médicaments","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/","txt":"Partenariats communautaires","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/search/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/","txt":"Médias","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/about-us/our-values/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/","txt":" \n           \n            Nos valeurs fondamentales sont profondément ancrées    \n           Nos valeurs mènent à l'action. Voyez ce qui motive notre engagement à offrir de nouvelles options novatrices pour les soins et le traitement des personnes vivant avec le VIH/sida.  \n            ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-grants-subventions-communautaires/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/","txt":"  \n          \n            Subventions communautaires \n           ","status":"redirected","statusCode":"200,302","redirectedTo":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/healthcare-professionals/research-development/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/healthcare-professionals/independent-grants-and-support-programs/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/redirects/max-ottawa-et-viiv-healthcare-lancent-la-campagne-innovante-spil/":{"status":"redirected","redirectedTo":"https://www.fugues.com/251957-article-max-ottawa-et-viiv-healthcare-lancent-la-campagne-innovante-spill-the-tea.html"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/juluca/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/","txt":"ViiV Soins de santé est fière d’annoncer la disponibilité de Juluca au Canada","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/content/cf-viiv/viiv-healthcare/fr_CA/home/redirects/viiv-fr":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/","txt":"Renseignements importants en matière d’innocuité au sujet de TIVICAY, TRIUMEQ et JULUCA","status":"redirected","statusCode":"403,302","redirectedTo":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/content/cf-viiv/viiv-healthcare/fr_CA/home/redirects/viiv-fr/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/","txt":"Lire toutes les nouvelles","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/accessibility/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/","txt":"Accessibilité","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/privacy-code/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/","txt":"Code de protection des renseignements personnels","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/terms-of-use/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/","txt":"Conditions d'utilisation","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/privacy-statement/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/","txt":"Énoncé de confidentialité","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/cookie-policy/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/","txt":"Politique relative aux cookies","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/about-hivaids/about-hivaids-in-canada/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/about-hivaids/","txt":" \n      \n      About HIV/Aids in Canada \n      Find out more about HIV/AIDS in Canada. \n      Read more \n      ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/about-hivaids/canadian-resources/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/about-hivaids/","txt":" \n      \n      Canadian resources  Find out what ViiV Healthcare in Canada is doing to support populations at risk, people living with HIV/AIDS, their caregivers and healthcare providers  \n      Read more \n      ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/contact-us/#1-450-680-4810":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/contact-us/","txt":"(450) 680-4810","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/contact-us/#1-877-335-2186":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/contact-us/","txt":"1-877-335-2186","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/contact-us/#1-450-680-4801":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/contact-us/","txt":"(450) 680-4801","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/contact-us/#1-877-393-8448":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/contact-us/","txt":" 1-877-393-8448","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/contact-us/#1-905-819-3363":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/contact-us/","txt":"1-905-819-3363","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/":{"redirectedFrom":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-grants-subventions-communautaires/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/#1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/","txt":"Community Education and Services Grants","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/#2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/","txt":"Positive Action Canada HIV/AIDS Innovation Program","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/#3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/","txt":"Positive Action Canada Indigenous HIV/AIDS Initiative.","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/in-the-community/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/","txt":"In the community  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/positive-action/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/","txt":"Positive Action  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/3tc/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/","txt":"3TC®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/celsentri/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/","txt":"Celsentri®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/combivir/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/","txt":"Combivir®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/kivexa/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/","txt":"Kivexa®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/rescriptor/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/","txt":"Rescriptor®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/retrovirazt/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/","txt":"Retrovir/AZT®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/telzir/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/","txt":"Telzir®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/tivicay/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/","txt":"Tivicay®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/triumeq/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/","txt":"Triumeq®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/trizivir/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/","txt":"Trizivir®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/viracept/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/","txt":"Viracept®*","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/ziagen/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/","txt":"Ziagen®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/the-viiv-healthcare-effect/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/","txt":" \n      \n      The ViiV Healthcare Effect  \n      The ViiV Healthcare Effect showcases our partners’ projects across Canada and around the world using an Interactive Map and in-depth Project Tours.  \n      Read more \n      ","status":"done","statusCode":404},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/about-us/our-mission/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/about-us/who-we-are/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/about-us/","txt":" \n      \n      Who we are  \n      ViiV Healthcare Canada works to provide treatment, research and support to people affected by HIV/AIDS.  \n      Read more \n      ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/about-us/our-team/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/about-us/","txt":" \n      \n      Our team  \n      Find out more about ViiV Healthcare's leadership team who work closely with our CEO to set our strategy and run the company according to our values of innovation, passion, trust, resilience and integrity.  \n      Read more \n      ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/media/press-releases/2017/viiv-healthcare-ranks-1-in-patientview-corporate-reputation-surv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/media/","txt":" ViiV Healthcare ranks #1 in PatientView corporate reputation survey","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/media/press-releases/2017/inspiring-voices-in-hiv-lead-the-way-on-international-women-s-da/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/media/","txt":"Inspiring voices in HIV lead the way on International Women’s Day 2017","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/media/press-releases/2014/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/media/","txt":"2014","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/media/press-releases/2018/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/media/","txt":"2018","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/media/press-releases/2013/january/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/media/","txt":"January","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/press-releases/2017/viiv-healthcare-ranks-1-in-patientview-corporate-reputation-surv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/media/","txt":"ViiV Soins de santé se classe première dans le sondage PatientView sur la réputation d’entreprise","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/press-releases/2017/inspiring-voices-in-hiv-lead-the-way-on-international-women-s-da/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/media/","txt":"Des témoignages inspirants sur le VIH donnent le ton à la Journée internationale des femmes 2017","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/press-releases/2014/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/media/","txt":"2014","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/press-releases/2013/january/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/media/","txt":"January","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/rethink--volgens-viiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/amsterdam-op-weg-naar-een-toekomst-zonder-nieuwe-hiv-infecties/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/brenda--leven-met-hiv-in-oeganda/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/hiv-uit-de-kast-campagne/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/stigma-ervaring--john/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/positieve-krachten-bundelen/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/matchen-van-maatjes/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/therapietrouw-bij-migranten/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/mijn-maatje-heeft-mijn-leven-gered/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/de-mensen-van-de-hiv-vereniging/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-pieter-brokx--directeur-hiv-vereniging/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-reina/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-corina/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-eliane/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-jorgen--vrijwilliger-voor-poz-proud/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-tim/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/jongvolwassenen-hebben-speciale-aandacht-nodig/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/als-een-kind-tegen-hiv-blijft-vechten--dan-wordt-het-een-groot-d/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/veel-pubers-worstelen-met-het-aangaan-van-intieme-relaties/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/knap-als-een-tiener-de-pillen-goed-slikt/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/de-leukste-dag-van-het-jaar-om-hiv-te-hebben/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/privacy-verklaring/#welke":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/privacy-verklaring/","txt":"Welke persoonlijke informatie we over u verzamelen;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/privacy-verklaring/#gebruiken":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/privacy-verklaring/","txt":"hoe we uw persoonlijke informatie gebruiken;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/privacy-verklaring/#informatie":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/privacy-verklaring/","txt":"op welke basis we uw persoonlijke informatie gebruiken;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/privacy-verklaring/#bewaren":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/privacy-verklaring/","txt":"hoelang we uw persoonlijke informatie bewaren;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/privacy-verklaring/#door":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/privacy-verklaring/","txt":"dat we uw persoonlijke informatie kunnen delen met anderen en internationaal kunnen doorgeven;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/privacy-verklaring/#bescherming":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/privacy-verklaring/","txt":"hoe we uw persoonlijke informatie beschermen;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/privacy-verklaring/#uw":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/privacy-verklaring/","txt":"wat uw rechten zijn met betrekking tot uw persoonlijke informatie;","status":"done","statusCode":":("},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/privacy-verklaring/#cookies":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/privacy-verklaring/","txt":"hoe we gebruikmaken van cookies en waar u nadere informatie kunt vinden.","status":"done","statusCode":":("},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/privacy-verklaring/#co":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/privacy-verklaring/","txt":"Contact","status":"done","statusCode":":("},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/latest-news/2017/september/flashcards/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/latest-news/2017/september/flashcards/","txt":"DE","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/latest-news/2017/september/flashcards/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/latest-news/2017/september/flashcards/","txt":"FR","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/welcome-switzerland/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/welcome-switzerland/","txt":"DE","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/welcome-switzerland/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/welcome-switzerland/","txt":"FR","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/swiss-viiv-team/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/latest-news/2018/june-1/hiv-knowledge-builds-trust/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/","txt":"  Jun 30  \n       \n        \n       \n       \n       JA! Let's talk about Sex!  \n       ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-states/us-healthcare-professional-fee-disclosures/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/","txt":"US healthcare professional fee disclosures","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-states/research-and-development-payments-in-the-us/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/","txt":"Research and Development payments in the US","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-kingdom/viiv-healthcare---disclosure-of-payments-to-uk-based-healthcare-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/","txt":"ViiV Healthcare - Disclosure of payments to UK based healthcare professionals and healthcare organisations and patient organisations","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/","txt":"The NGOs & patient advocacy groups we fund","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/swiss-viiv-team/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/content/cf-viiv/viiv-healthcare/fr_CH/home/latest-news/2018/june-1/hiv-knowledge-builds-trust":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/","txt":"  juin 30  \n       \n        \n       \n       \n       OUI! Let's talk about Sex!  \n       ","status":"redirected","statusCode":"403,302","redirectedTo":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/content/cf-viiv/viiv-healthcare/fr_CH/home/latest-news/2018/june-1/hiv-knowledge-builds-trust/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/privacy-notice/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/","txt":"Privacy notice","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/careers/why-join-us/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/careers/","txt":" \n      \n      Why join us? \n      If you are passionate about making a difference to people living with HIV we'd love to meet you. \n      Read more \n      ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/careers/how-to-apply/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/careers/","txt":" \n      \n      How to apply \n      A step-by-step guide to our recruitment process and how to set up an email notification of vacancies that match your requirements. \n      Read more \n      ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/careers/job-search/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/careers/","txt":" \n      \n      Job search \n      Find out about current vacancies in the ViiV Healthcare team \n      Read more \n      ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/careers/frequently-asked-questions/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/careers/","txt":" \n      \n      Frequently asked questions \n      Read more \n      ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/latest-news/2018/june-1/hiv-knowledge-builds-trust/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/latest-news/2018/june-1/hiv-knowledge-builds-trust/","txt":"FR","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/privacy-notice/","txt":"DE","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/privacy-notice/#1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/privacy-notice/","txt":"what personal information we collect about you;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/privacy-notice/#2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/privacy-notice/","txt":"how we use your personal information;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/privacy-notice/#3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/privacy-notice/","txt":"on what basis we use your personal information;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/privacy-notice/#4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/privacy-notice/","txt":"how long we keep your personal information;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/privacy-notice/#5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/privacy-notice/","txt":"we may share your personal information with others and transfer it internationally;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/privacy-notice/#6":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/privacy-notice/","txt":"how we protect your personal information;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/privacy-notice/#7":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/privacy-notice/","txt":"your rights regarding your personal information;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/privacy-notice/#8":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/privacy-notice/","txt":"what to do if you don’t want to provide us with your personal information; and","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/privacy-notice/#9":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/privacy-notice/","txt":"how we use cookies and where to find further information.","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/privacy-notice/#contact":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/privacy-notice/","txt":"Contact us","status":"done","statusCode":":("},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-community-led-hiv-aids-prevention-project-kenya/#keyfacts":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-community-led-hiv-aids-prevention-project-kenya/","txt":"Project key facts","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-community-led-hiv-aids-prevention-project-kenya/#tab-206278409-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-community-led-hiv-aids-prevention-project-kenya/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-community-led-hiv-aids-prevention-project-kenya/#tab-206278409-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-community-led-hiv-aids-prevention-project-kenya/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-community-led-hiv-aids-prevention-project-kenya/#tab-206278409-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-community-led-hiv-aids-prevention-project-kenya/","txt":" \n          \n           \n           The project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-community-led-hiv-aids-prevention-project-kenya/#tab-206278409-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-community-led-hiv-aids-prevention-project-kenya/","txt":" \n          \n           \n           What we do \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-community-led-hiv-aids-prevention-project-kenya/#tab-206278409-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-community-led-hiv-aids-prevention-project-kenya/","txt":" \n          \n           \n           Impact so far \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-community-led-hiv-aids-prevention-project-kenya/#tab-206278409-5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-community-led-hiv-aids-prevention-project-kenya/","txt":" \n          \n           \n           Lessons learned \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/standing-together/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/standing-together/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-community-grants/","txt":"ACCELERATE! Initiative Resources  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-southern-initiative-resources/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-southern-initiative/","txt":"Positive Action Southern Initiative Resources  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-for-youth/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-for-youth/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-expands-u-s--commitment-to-youth-living-with-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-for-youth/","txt":"click here","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/redirects/accelerate-research-fact-sheet-pdf/":{"status":"redirected","redirectedTo":"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/US/accelerate-research-fact-sheet.pdf"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Juluca/pdf/JULUCA-PI-PIL.PDF":{"status":"redirected","redirectedTo":"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Juluca/pdf/JULUCA-PI-PIL.PDF"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Triumeq/pdf/TRIUMEQ-PI-MG.PDF":{"status":"redirected","redirectedTo":"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Triumeq/pdf/TRIUMEQ-PI-MG.PDF"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Tivicay/pdf/TIVICAY-PI-PIL.PDF":{"status":"redirected","redirectedTo":"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Tivicay/pdf/TIVICAY-PI-PIL.PDF"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Selzentry/pdf/SELZENTRY-PI-MG-IFU.PDF":{"status":"redirected","redirectedTo":"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Selzentry/pdf/SELZENTRY-PI-MG-IFU.PDF"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Ziagen/pdf/ZIAGEN-PI-MG.PDF":{"status":"redirected","redirectedTo":"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Ziagen/pdf/ZIAGEN-PI-MG.PDF"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Trizivir/pdf/TRIZIVIR-PI-MG.PDF":{"status":"redirected","redirectedTo":"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Trizivir/pdf/TRIZIVIR-PI-MG.PDF"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Epivir/pdf/EPIVIR-PI-PIL.PDF":{"status":"redirected","redirectedTo":"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Epivir/pdf/EPIVIR-PI-PIL.PDF"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Lexiva/pdf/LEXIVA-PI-PIL.PDF":{"status":"redirected","redirectedTo":"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Lexiva/pdf/LEXIVA-PI-PIL.PDF"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Rescriptor/pdf/RESCRIPTOR-PI-PIL.PDF":{"status":"redirected","redirectedTo":"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Rescriptor/pdf/RESCRIPTOR-PI-PIL.PDF"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/redirects/compassionate-use--expanded-access-/":{"status":"redirected","redirectedTo":"https://viiv-cu-portal.idea-point.com/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/redirects/compassionate-use--expanded-access-0/":{"status":"redirected","redirectedTo":"https://viiv-cu-portal.idea-point.com/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/redirects/report-a-side-effect/":{"status":"redirected","redirectedTo":"https://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/as-much-as-i-can/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/as-much-as-i-can-wins-excellence-in-patient-engagement-award/","txt":"\"As Much as I Can\"  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-reports-positive-48-week-results-for-first-pivot/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/","txt":"ViiV Healthcare reports positive 48-week results for first pivotal, phase III study for novel, long-acting, injectable HIV-treatment regimen","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-sword-100-week-data-for-juluca-dolute/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/","txt":"ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/","txt":"ViiV Healthcare presents phase III data showing two drug regimen has similar efficacy to a three-drug regimen in treatment naïve HIV patients, with no resistance","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/","txt":"ViiV Healthcare shares data from landmark 2-drug regimen trials at AIDS 2018","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-positive-new-dolutegravir-data-for-the/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/","txt":"ViiV Healthcare announces positive new dolutegravir data for the treatment of people living with HIV co-infected with tuberculosis","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-files-patent-infringement-litigation-against-gil/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/","txt":"ViiV Healthcare files patent infringement litigation against Gilead Sciences Inc. over bictegravir","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-launches-eighth-phase-iii-study-in-two--drug-reg/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/","txt":"ViiV Healthcare launches eighth phase III study in two- drug regimen programme for HIV-1 treatment","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-start-of-phase-iii-study-of-long-actin/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/","txt":"ViiV Healthcare announces start of phase III study of long-acting cabotegravir for HIV prevention in women","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/iiv-healthcare-starts-third-phase-iii-hiv-treatment-study-invest/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/","txt":"ViiV Healthcare starts third phase III HIV treatment study investigating long-acting two-drug regimen of cabotegravir plus rilpivirine","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-us-fda-approval-for-juluca/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/","txt":"ViiV Healthcare announces US FDA approval for Juluca®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-positive-phase-3-results-from-the-brig/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/","txt":"ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/new-results-from-the-positive-perspectives-global-survey-provide/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/","txt":"New results from the Positive Perspectives global survey provide insights into the attitudes and perceptions of people living with HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-awards--1-million-in-grants-for-positive-action-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/","txt":"ViiV Healthcare Awards $1 Million In Grants For Positive Action For Women In The U.S.","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-and-neat-id-announce-results-from-the-neat-022-s/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/","txt":"ViiV Healthcare and NEAT-ID announce results from the NEAT 022 study at the International AIDS Society meeting in Paris","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-superior-efficacy-of-dolutegravir-vers/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/","txt":"ViiV Healthcare announces superior efficacy of dolutegravir versus lopinavir/ritonavir in second-line HIV treatment in resource-limited settings","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/phase-ii-study-results-showed-comparable-viral-suppression-rates/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/","txt":"Phase II study results showed comparable viral suppression rates at 96 weeks for a two-drug regimen","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-shares-data-from-its-innovative-portfolio-with-h/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/","txt":"ViiV Healthcare shares data from its innovative portfolio with HIV community at IAS 2017","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-submits-regulatory-applications-for-the-first-hi/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/","txt":"ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-fda-approval-of-selzentry-maraviroc/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/","txt":"ViiV Healthcare Announces FDA Approval of SELZENTRY® (maraviroc) for Use in Children and Adolescents Living With HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-extends-medicines-patent-pool-licence-agreement/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/","txt":"ViiV Healthcare extends Medicines Patent Pool licence agreement for dolutegravir to cover all lower middle-income countries","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-first-phase-ii-hiv-prevention-study-re/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/","txt":"ViiV Healthcare announces first phase II HIV prevention study results for investigational long-acting injectable cabotegravir","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-phase-ii-study-results-for-first-two-d/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/","txt":"ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-to-progress-collaboration-with-janssen-to-develo/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/","txt":"ViiV Healthcare to progress collaboration with Janssen to develop the first long-acting, two drug injectable regimen for treatment of HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/articles-sidebar-navigation/other-local-stories/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-positive-phase-3-results-from-the-brig0/","txt":"Other Local Stories  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-presents-three-year-data-for-investigational-lon/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-presents-three-year-data-for-investigational-lon/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/cookie-policy/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/terms-of-use/","txt":"Other Local Stories  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-commitment-to-latinx-communities-living-with-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/terms-of-use/","txt":"Our commitment to Latinx communities living with HIV  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/report-a-side-effect/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/juluca/","txt":"Report a side effect","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-at-hiv-glasgow/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/towards-a-cure--exploring-cure-and-remission-in-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/ageing-with-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/accelerating-the-pace-of-innovation/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-reports-positive-48-week-results-for-second-phas/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/external/infographic/":{"status":"redirected","redirectedTo":"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/hiv-tb_infographic-final.pdf"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/branford-the-world-s-only-hiv-dedicated-research-facility/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/positive-perspectives-looking-into-the-lives-of-people-living-wi/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-exchange/":{"status":"redirected","redirectedTo":"https://www.viivexchange.com/routing"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/our-medicines/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/our-approach-to-r-d0/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/","txt":" ","status":"redirected","statusCode":"200,302","redirectedTo":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-collaborate-to-innovate/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/medicines-in-development/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/committed-to-data-transparency/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/more-press-releases-from-viiv-healthcare/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/towards-a-cure--exploring-cure-and-remission-in-hiv/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/towards-a-cure--exploring-cure-and-remission-in-hiv/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/how-we-are-collaborating-to-seek-remission-strategies-in-paediat/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/how-we-are-collaborating-to-seek-remission-strategies-in-paediat/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/q-a-with-heather-brogan--piloting-a-new-mentoring-app-for-hiv-pa/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/how-our-innovation-unit-is-addressing-new-areas-of-need-in-hiv-c/","txt":"Q&A with Heather Brogan: piloting a new mentoring app for HIV patients","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/ViiV%20Healthcare's%20Innovation%20Unit%20Offers%20Fresh%20Approach%20to%20Solving%20Important%20Challenges%20in%20HIV/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/how-our-innovation-unit-is-addressing-new-areas-of-need-in-hiv-c/","txt":"ViiV Healthcare's Innovation Unit offers fresh approach to solving important challenges in HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/viiv-healthcare-s-the-hive-and-positive-action-community-challenge-seek-outside-collaborations-in-order-to-innovate-for-people-living-with-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/how-our-innovation-unit-is-addressing-new-areas-of-need-in-hiv-c/","txt":"ViiV Healthcare's 'the hive' and Positive Action Community Challenge seek outside collaborations in order to innovate for people living with HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/towards-a-cure--exploring-cure-and-remission-in-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/how-our-innovation-unit-is-addressing-new-areas-of-need-in-hiv-c/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/facing-the-challenges-of-getting-old-with-hiv/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/facing-the-challenges-of-getting-old-with-hiv/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/dolutegravir-expanded-access-program/#tab-02006000839-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/dolutegravir-expanded-access-program/","txt":" \n       \n        \n        EN \n        \n       ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/dolutegravir-expanded-access-program/#tab-02006000839-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/dolutegravir-expanded-access-program/","txt":" \n       \n        \n        DE \n        \n       ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/dolutegravir-expanded-access-program/#tab-02006000839-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/dolutegravir-expanded-access-program/","txt":" \n       \n        \n        ES \n        \n       ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/dolutegravir-expanded-access-program/#tab-02006000839-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/dolutegravir-expanded-access-program/","txt":" \n       \n        \n        FR \n        \n       ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/dolutegravir-expanded-access-program/#tab-02006000839-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/dolutegravir-expanded-access-program/","txt":" \n       \n        \n        IT \n        \n       ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/dolutegravir-expanded-access-program/#tab-02006000839-5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/dolutegravir-expanded-access-program/","txt":" \n       \n        \n        PT \n        \n       ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund-french/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/","txt":"  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/#tab-01360423428-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/","txt":" \n          \n           \n           About \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/#tab-01360423428-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/","txt":" \n          \n           \n           Grant Applications \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/#tab-01360423428-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/","txt":" \n          \n           \n           Grantees \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/#tab-01360423428-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/","txt":" \n          \n           \n           PA Online Community \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/#tab-01360423428-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/","txt":" \n          \n           \n           Every Footstep Counts \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/#bottom":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-adolescents/#tab-01871778870-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-adolescents/","txt":" \n          \n           \n           About \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-adolescents/#tab-01871778870-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-adolescents/","txt":" \n          \n           \n           Younth-Led Grants \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-adolescents/#Bottom":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-adolescents/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-girls-and-women/#tab-01175805323-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-girls-and-women/","txt":" \n          \n           \n           About \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-girls-and-women/#tab-01175805323-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-girls-and-women/","txt":" \n          \n           \n           Call For Proposals \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-girls-and-women/#tab-01175805323-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-girls-and-women/","txt":" \n          \n           \n           DREAMS Innovation \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-girls-and-women/#tab-01175805323-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-girls-and-women/","txt":" \n          \n           \n           Small Grantees \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-girls-and-women/#Bottom":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-girls-and-women/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/spark--igniting-change/#tab-01043701642-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/spark--igniting-change/","txt":" \n          \n           \n           HIV in adolescents \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/spark--igniting-change/#tab-01043701642-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/spark--igniting-change/","txt":" \n          \n           \n           About SPARK \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/spark--igniting-change/#tab-01043701642-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/spark--igniting-change/","txt":" \n          \n           \n           Skills development \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/spark--igniting-change/#Access":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/spark--igniting-change/","txt":"three modules","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/canada/hiv-environment-in-saskatchewan/#keyfacts":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/canada/hiv-environment-in-saskatchewan/","txt":"Project key facts","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/canada/hiv-environment-in-saskatchewan/#tab-1277232558-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/canada/hiv-environment-in-saskatchewan/","txt":" \n          \n           \n           HIV Environment in Saskatchewan \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/canada/hiv-environment-in-saskatchewan/#tab-1277232558-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/canada/hiv-environment-in-saskatchewan/","txt":" \n          \n           \n           Key Challenges \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/canada/hiv-environment-in-saskatchewan/#tab-1277232558-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/canada/hiv-environment-in-saskatchewan/","txt":" \n          \n           \n           Aim \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/argentina/hiv-environment-in-buenos-aires/#keyfacts":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/argentina/hiv-environment-in-buenos-aires/","txt":"Project key facts","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/argentina/hiv-environment-in-buenos-aires/#tab-206797231-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/argentina/hiv-environment-in-buenos-aires/","txt":" \n          \n           \n           HIV Environment in Buenos Aires \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/argentina/hiv-environment-in-buenos-aires/#tab-206797231-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/argentina/hiv-environment-in-buenos-aires/","txt":" \n          \n           \n           Key Challenges \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/argentina/hiv-environment-in-buenos-aires/#tab-206797231-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/argentina/hiv-environment-in-buenos-aires/","txt":" \n          \n           \n           Aim \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/uruguay/hiv-environment-in-montevideo/#keyfacts":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/uruguay/hiv-environment-in-montevideo/","txt":"Project key facts","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/uruguay/hiv-environment-in-montevideo/#tab-01021270811-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/uruguay/hiv-environment-in-montevideo/","txt":" \n          \n           \n           HIV Environment in Montevideo \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/uruguay/hiv-environment-in-montevideo/#tab-01021270811-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/uruguay/hiv-environment-in-montevideo/","txt":" \n          \n           \n           Key Challenges \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/uruguay/hiv-environment-in-montevideo/#tab-01021270811-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/uruguay/hiv-environment-in-montevideo/","txt":" \n          \n           \n           Aim \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/#tab-1917279609-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/#tab-1917279609-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/#tab-1917279609-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/","txt":" \n          \n           \n           The project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/#tab-1917279609-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/","txt":" \n          \n           \n           What we do \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/#tab-1917279609-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/","txt":" \n          \n           \n           Impact so far \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/#tab-1917279609-5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/","txt":" \n          \n           \n           Lessons learned \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/brazil/hiv-environment-in-brazil/#keyfacts":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/brazil/hiv-environment-in-brazil/","txt":"Project key facts","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/brazil/hiv-environment-in-brazil/#tab-02222111-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/brazil/hiv-environment-in-brazil/","txt":" \n          \n           \n           HIV Environment in Brazil \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/brazil/hiv-environment-in-brazil/#tab-02222111-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/brazil/hiv-environment-in-brazil/","txt":" \n          \n           \n           Key Challenges \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/brazil/hiv-environment-in-brazil/#tab-02222111-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/brazil/hiv-environment-in-brazil/","txt":" \n          \n           \n           Aim \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/estonia/hiv-environment-in-estonia/#keyfacts":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/estonia/hiv-environment-in-estonia/","txt":"Project key facts","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/estonia/hiv-environment-in-estonia/#tab-212236295-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/estonia/hiv-environment-in-estonia/","txt":" \n          \n           \n           HIV Environment in Estonia \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/estonia/hiv-environment-in-estonia/#tab-212236295-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/estonia/hiv-environment-in-estonia/","txt":" \n          \n           \n           Key Challenges \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/estonia/hiv-environment-in-estonia/#tab-212236295-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/estonia/hiv-environment-in-estonia/","txt":" \n          \n           \n           Aim \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/uk/hiv-environment-in-london/#keyfacts":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/uk/hiv-environment-in-london/","txt":"Project key facts","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/uk/hiv-environment-in-london/#tab-0489481653-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/uk/hiv-environment-in-london/","txt":" \n          \n           \n           HIV Environment in London \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/uk/hiv-environment-in-london/#tab-0489481653-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/uk/hiv-environment-in-london/","txt":" \n          \n           \n           Key Challenges \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/uk/hiv-environment-in-london/#tab-0489481653-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/uk/hiv-environment-in-london/","txt":" \n          \n           \n           Aim \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/spain/hiv-environment-in-spain/#keyfacts":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/spain/hiv-environment-in-spain/","txt":"Project key facts","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/spain/hiv-environment-in-spain/#tab-2051887495-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/spain/hiv-environment-in-spain/","txt":" \n          \n           \n           HIV Environment in Spain \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/spain/hiv-environment-in-spain/#tab-2051887495-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/spain/hiv-environment-in-spain/","txt":" \n          \n           \n           Key Challenges \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/spain/hiv-environment-in-spain/#tab-2051887495-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/spain/hiv-environment-in-spain/","txt":" \n          \n           \n           Aim \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/italy/hiv-environment-in-italy/#keyfacts":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/italy/hiv-environment-in-italy/","txt":"Project key facts","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/italy/hiv-environment-in-italy/#tab-0236548025-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/italy/hiv-environment-in-italy/","txt":" \n          \n           \n           HIV Environment in Italy \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/italy/hiv-environment-in-italy/#tab-0236548025-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/italy/hiv-environment-in-italy/","txt":" \n          \n           \n           Key Challenges \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/italy/hiv-environment-in-italy/#tab-0236548025-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/italy/hiv-environment-in-italy/","txt":" \n          \n           \n           Aim \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/germany/hiv-environment-in-bochum/#keyfacts":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/germany/hiv-environment-in-bochum/","txt":"Project key facts","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/germany/hiv-environment-in-bochum/#tab-865792324-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/germany/hiv-environment-in-bochum/","txt":" \n          \n           \n           HIV Environment in Bochum \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/germany/hiv-environment-in-bochum/#tab-865792324-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/germany/hiv-environment-in-bochum/","txt":" \n          \n           \n           Key Challenges \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/germany/hiv-environment-in-bochum/#tab-865792324-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/germany/hiv-environment-in-bochum/","txt":" \n          \n           \n           Aim \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/germany-ii/hiv-environment-in-berlin/#keyfacts":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/germany-ii/hiv-environment-in-berlin/","txt":"Project key facts","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/germany-ii/hiv-environment-in-berlin/#tab-1551001501-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/germany-ii/hiv-environment-in-berlin/","txt":" \n          \n           \n           HIV Environment in Berlin \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/germany-ii/hiv-environment-in-berlin/#tab-1551001501-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/germany-ii/hiv-environment-in-berlin/","txt":" \n          \n           \n           Key Challenges \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/germany-ii/hiv-environment-in-berlin/#tab-1551001501-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/germany-ii/hiv-environment-in-berlin/","txt":" \n          \n           \n           Aim \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/switzerland/hiv-environment-in-switzerland/#keyfacts":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/switzerland/hiv-environment-in-switzerland/","txt":"Project key facts","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/switzerland/hiv-environment-in-switzerland/#tab-2141511367-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/switzerland/hiv-environment-in-switzerland/","txt":" \n          \n           \n           HIV Environment in Switzerland \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/switzerland/hiv-environment-in-switzerland/#tab-2141511367-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/switzerland/hiv-environment-in-switzerland/","txt":" \n          \n           \n           Key Challenges \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/switzerland/hiv-environment-in-switzerland/#tab-2141511367-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/switzerland/hiv-environment-in-switzerland/","txt":" \n          \n           \n           Aim \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/striking-the-right-balance/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/striking-the-right-balance/","txt":"[1]","status":"done","statusCode":200},"https://www.avert.org/professionals/hiv-around-world/latin-america/brazil":{"status":"redirected","redirectedTo":"https://www.avert.org/professionals/hiv-around-world/latin-america/brazil"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/helping-botswana-treat-all-people-living-with-hiv/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/helping-botswana-treat-all-people-living-with-hiv/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/hiv--a-virus-that-thrives-on-inequality/#unaids":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/hiv--a-virus-that-thrives-on-inequality/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-msm-transgender-people/#tab-02071038744-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-msm-transgender-people/","txt":" \n          \n           \n           About \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-msm-transgender-people/#tab-02071038744-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-msm-transgender-people/","txt":" \n          \n           \n           Grant Applications \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-msm-transgender-people/#tab-02071038744-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-msm-transgender-people/","txt":" \n          \n           \n           Contact Us \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/#tab-0962092961-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/","txt":" \n          \n           \n           2019 Grants \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/#tab-0962092961-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/","txt":" \n          \n           \n           2018 Grants \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/#tab-0962092961-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/","txt":" \n          \n           \n           2017 Awards \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/#tab-0962092961-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/","txt":" \n          \n           \n           2016 Awards \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/#tab-0962092961-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/","txt":" \n          \n           \n           About PAE \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/#pae":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/","txt":"Iskorak, Croatia","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-shuga/#tab-1414086804-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-shuga/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-shuga/#tab-1414086804-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-shuga/","txt":" \n          \n           \n           The Need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-shuga/#tab-1414086804-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-shuga/","txt":" \n          \n           \n           The Project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-shuga/#tab-1414086804-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-shuga/","txt":" \n          \n           \n           What we do \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-shuga/#tab-1414086804-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-shuga/","txt":" \n          \n           \n           Impact so far \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kaiser-family-foundation/#tab-0203130052-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kaiser-family-foundation/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kaiser-family-foundation/#tab-0203130052-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kaiser-family-foundation/","txt":" \n          \n           \n           The Need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kaiser-family-foundation/#tab-0203130052-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kaiser-family-foundation/","txt":" \n          \n           \n           The Project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kaiser-family-foundation/#tab-0203130052-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kaiser-family-foundation/","txt":" \n          \n           \n           What we do \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kaiser-family-foundation/#tab-0203130052-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kaiser-family-foundation/","txt":" \n          \n           \n           Impact so far \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-centre-for-sexual-health-and-hivaids-research-ceshhar-zimbab/#tab-0285113211-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-centre-for-sexual-health-and-hivaids-research-ceshhar-zimbab/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-centre-for-sexual-health-and-hivaids-research-ceshhar-zimbab/#tab-0285113211-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-centre-for-sexual-health-and-hivaids-research-ceshhar-zimbab/","txt":" \n          \n           \n           The Need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-centre-for-sexual-health-and-hivaids-research-ceshhar-zimbab/#tab-0285113211-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-centre-for-sexual-health-and-hivaids-research-ceshhar-zimbab/","txt":" \n          \n           \n           The Project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-centre-for-sexual-health-and-hivaids-research-ceshhar-zimbab/#tab-0285113211-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-centre-for-sexual-health-and-hivaids-research-ceshhar-zimbab/","txt":" \n          \n           \n           What we do \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-centre-for-sexual-health-and-hivaids-research-ceshhar-zimbab/#tab-0285113211-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-centre-for-sexual-health-and-hivaids-research-ceshhar-zimbab/","txt":" \n          \n           \n           Impact so far \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amplifychange/#tab-01060490740-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amplifychange/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amplifychange/#tab-01060490740-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amplifychange/","txt":" \n          \n           \n           The Need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amplifychange/#tab-01060490740-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amplifychange/","txt":" \n          \n           \n           The Project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amplifychange/#tab-01060490740-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amplifychange/","txt":" \n          \n           \n           What we do \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amplifychange/#tab-01060490740-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amplifychange/","txt":" \n          \n           \n           Impact so far \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kenya-council-of-imams-and-ulamaa-kcui/#tab-235718523-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kenya-council-of-imams-and-ulamaa-kcui/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kenya-council-of-imams-and-ulamaa-kcui/#tab-235718523-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kenya-council-of-imams-and-ulamaa-kcui/","txt":" \n          \n           \n           The Need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kenya-council-of-imams-and-ulamaa-kcui/#tab-235718523-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kenya-council-of-imams-and-ulamaa-kcui/","txt":" \n          \n           \n           The Project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kenya-council-of-imams-and-ulamaa-kcui/#tab-235718523-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kenya-council-of-imams-and-ulamaa-kcui/","txt":" \n          \n           \n           What we do \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kenya-council-of-imams-and-ulamaa-kcui/#tab-235718523-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kenya-council-of-imams-and-ulamaa-kcui/","txt":" \n          \n           \n           Impact so far \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/czech-aids-help-association/#tab-0659845762-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/czech-aids-help-association/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/czech-aids-help-association/#tab-0659845762-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/czech-aids-help-association/","txt":" \n          \n           \n           The Need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/czech-aids-help-association/#tab-0659845762-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/czech-aids-help-association/","txt":" \n          \n           \n           The Project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/czech-aids-help-association/#tab-0659845762-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/czech-aids-help-association/","txt":" \n          \n           \n           What we do \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/czech-aids-help-association/#tab-0659845762-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/czech-aids-help-association/","txt":" \n          \n           \n           Impact so far \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/iskorak/#tab-0789333118-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/iskorak/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/iskorak/#tab-0789333118-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/iskorak/","txt":" \n          \n           \n           The Need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/iskorak/#tab-0789333118-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/iskorak/","txt":" \n          \n           \n           The Project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/iskorak/#tab-0789333118-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/iskorak/","txt":" \n          \n           \n           What we do \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/iskorak/#tab-0789333118-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/iskorak/","txt":" \n          \n           \n           Impact so far \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/iskorak/#Bottom":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/iskorak/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/national-aids-trust-nat/#tab-01974929249-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/national-aids-trust-nat/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/national-aids-trust-nat/#tab-01974929249-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/national-aids-trust-nat/","txt":" \n          \n           \n           The Need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/national-aids-trust-nat/#tab-01974929249-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/national-aids-trust-nat/","txt":" \n          \n           \n           The Project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/national-aids-trust-nat/#tab-01974929249-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/national-aids-trust-nat/","txt":" \n          \n           \n           What we do \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/national-aids-trust-nat/#tab-01974929249-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/national-aids-trust-nat/","txt":" \n          \n           \n           Impact so far \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/diapluslogs/#tab-337664619-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/diapluslogs/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/diapluslogs/#tab-337664619-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/diapluslogs/","txt":" \n          \n           \n           The Need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/diapluslogs/#tab-337664619-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/diapluslogs/","txt":" \n          \n           \n           The project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/diapluslogs/#tab-337664619-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/diapluslogs/","txt":" \n          \n           \n           What we do \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/diapluslogs/#tab-337664619-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/diapluslogs/","txt":" \n          \n           \n           Impact so far \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vida-digna-life-with-dignity/#keyfacts":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vida-digna-life-with-dignity/","txt":"Project key facts","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vida-digna-life-with-dignity/#tab-01793913599-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vida-digna-life-with-dignity/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vida-digna-life-with-dignity/#tab-01793913599-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vida-digna-life-with-dignity/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vida-digna-life-with-dignity/#tab-01793913599-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vida-digna-life-with-dignity/","txt":" \n          \n           \n           The project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vida-digna-life-with-dignity/#tab-01793913599-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vida-digna-life-with-dignity/","txt":" \n          \n           \n           What we do \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vida-digna-life-with-dignity/#tab-01793913599-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vida-digna-life-with-dignity/","txt":" \n          \n           \n           The impact \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vida-digna-life-with-dignity/#tab-01793913599-5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vida-digna-life-with-dignity/","txt":" \n          \n           \n           Lessons learned \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/adolescents-count-today-kenya/#tab-1884591214-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/adolescents-count-today-kenya/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/adolescents-count-today-kenya/#tab-1884591214-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/adolescents-count-today-kenya/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/adolescents-count-today-kenya/#tab-1884591214-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/adolescents-count-today-kenya/","txt":" \n          \n           \n           Project overview \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/adolescents-count-today-kenya/#tab-1884591214-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/adolescents-count-today-kenya/","txt":" \n          \n           \n           What we do \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/adolescents-count-today-kenya/#tab-1884591214-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/adolescents-count-today-kenya/","txt":" \n          \n           \n           The impact \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/adolescents-count-today-kenya/#tab-1884591214-5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/adolescents-count-today-kenya/","txt":" \n          \n           \n           Lessons \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/#tab-0252253153-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/#tab-0252253153-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/#tab-0252253153-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/","txt":" \n          \n           \n           The project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/#tab-0252253153-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/","txt":" \n          \n           \n           What we do \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/#tab-0252253153-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/","txt":" \n          \n           \n           The impact \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/#tab-0252253153-5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/","txt":" \n          \n           \n           Lessons learned \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-dudes--club/#tab-01470568235-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-dudes--club/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-dudes--club/#tab-01470568235-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-dudes--club/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-dudes--club/#tab-01470568235-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-dudes--club/","txt":" \n          \n           \n           The project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-dudes--club/#tab-01470568235-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-dudes--club/","txt":" \n          \n           \n           The impact \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-dudes--club/#tab-01470568235-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-dudes--club/","txt":" \n          \n           \n           Next step & lessons \n           \n          ","status":"done","statusCode":":("},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-dudes--club/#tab-01470568235-5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-dudes--club/","txt":" \n          \n           \n           Our stories \n           \n          ","status":"done","statusCode":":("},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/global-forum-on-msm-and-hiv-speaking-out/#tab-01630504229-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/global-forum-on-msm-and-hiv-speaking-out/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/global-forum-on-msm-and-hiv-speaking-out/#tab-01630504229-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/global-forum-on-msm-and-hiv-speaking-out/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/global-forum-on-msm-and-hiv-speaking-out/#tab-01630504229-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/global-forum-on-msm-and-hiv-speaking-out/","txt":" \n          \n           \n           What we do \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/global-forum-on-msm-and-hiv-speaking-out/#tab-01630504229-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/global-forum-on-msm-and-hiv-speaking-out/","txt":" \n          \n           \n           The impact \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/global-forum-on-msm-and-hiv-speaking-out/#tab-01630504229-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/global-forum-on-msm-and-hiv-speaking-out/","txt":" \n          \n           \n           Lessons learned \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/global-forum-on-msm-and-hiv-speaking-out/#tab-01630504229-5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/global-forum-on-msm-and-hiv-speaking-out/","txt":" \n          \n           \n           Our stories \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-action-europe/#keyfacts":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-action-europe/","txt":"Project key facts","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-action-europe/#tab-1079477429-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-action-europe/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-action-europe/#tab-1079477429-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-action-europe/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-action-europe/#tab-1079477429-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-action-europe/","txt":" \n          \n           \n           The project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-action-europe/#tab-1079477429-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-action-europe/","txt":" \n          \n           \n           What we do \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-action-europe/#tab-1079477429-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-action-europe/","txt":" \n          \n           \n           The impact \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-action-europe/#tab-1079477429-5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-action-europe/","txt":" \n          \n           \n           Lessons learned \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/#keyfacts":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/","txt":"Project key facts","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/#tab-0732943346-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/#tab-0732943346-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/#tab-0732943346-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/","txt":" \n          \n           \n           Project overview \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/#tab-0732943346-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/","txt":" \n          \n           \n           The impact so far \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/#tab-0732943346-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/","txt":" \n          \n           \n           Lessons learned \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/#tab-0732943346-5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/","txt":" \n          \n           \n           Webinars \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-2012-global-village/#tab-1122387326-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-2012-global-village/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-2012-global-village/#tab-1122387326-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-2012-global-village/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-2012-global-village/#tab-1122387326-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-2012-global-village/","txt":" \n          \n           \n           Global Village overview \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-2012-global-village/#tab-1122387326-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-2012-global-village/","txt":" \n          \n           \n           The impact \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vitu-newala--newala-youth-can-/#tab-1132099289-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vitu-newala--newala-youth-can-/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vitu-newala--newala-youth-can-/#tab-1132099289-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vitu-newala--newala-youth-can-/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vitu-newala--newala-youth-can-/#tab-1132099289-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vitu-newala--newala-youth-can-/","txt":" \n          \n           \n           Project overview \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vitu-newala--newala-youth-can-/#tab-1132099289-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vitu-newala--newala-youth-can-/","txt":" \n          \n           \n           What we did \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vitu-newala--newala-youth-can-/#tab-1132099289-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vitu-newala--newala-youth-can-/","txt":" \n          \n           \n           The impact \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vitu-newala--newala-youth-can-/#tab-1132099289-5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vitu-newala--newala-youth-can-/","txt":" \n          \n           \n           Lessons \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/hiv-young-leaders-fund/#tab-060819069-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/hiv-young-leaders-fund/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/hiv-young-leaders-fund/#tab-060819069-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/hiv-young-leaders-fund/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/hiv-young-leaders-fund/#tab-060819069-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/hiv-young-leaders-fund/","txt":" \n          \n           \n           The project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/hiv-young-leaders-fund/#tab-060819069-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/hiv-young-leaders-fund/","txt":" \n          \n           \n           The impact \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/hiv-young-leaders-fund/#tab-060819069-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/hiv-young-leaders-fund/","txt":" \n          \n           \n           Lessons learned \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/hiv-young-leaders-fund/#tab-060819069-5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/hiv-young-leaders-fund/","txt":" \n          \n           \n           Our stories \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/ubuntu-education-fund-living-positively/#tab-01130444701-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/ubuntu-education-fund-living-positively/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/ubuntu-education-fund-living-positively/#tab-01130444701-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/ubuntu-education-fund-living-positively/","txt":" \n          \n           \n           Project overview \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/ubuntu-education-fund-living-positively/#tab-01130444701-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/ubuntu-education-fund-living-positively/","txt":" \n          \n           \n           What we do \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/ubuntu-education-fund-living-positively/#tab-01130444701-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/ubuntu-education-fund-living-positively/","txt":" \n          \n           \n           The impact \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/ubuntu-education-fund-living-positively/#tab-01130444701-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/ubuntu-education-fund-living-positively/","txt":" \n          \n           \n           Our learnings \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/ubuntu-education-fund-living-positively/#tab-01130444701-5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/ubuntu-education-fund-living-positively/","txt":" \n          \n           \n           About us \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-msm-initiative/#tab-1363341348-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-msm-initiative/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-msm-initiative/#tab-1363341348-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-msm-initiative/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-msm-initiative/#tab-1363341348-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-msm-initiative/","txt":" \n          \n           \n           The project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-msm-initiative/#tab-1363341348-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-msm-initiative/","txt":" \n          \n           \n           What we do \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-msm-initiative/#tab-1363341348-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-msm-initiative/","txt":" \n          \n           \n           The impact \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-msm-initiative/#tab-1363341348-5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-msm-initiative/","txt":" \n          \n           \n           Lessons learned \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-initiative/#tab-0309376999-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-initiative/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-initiative/#tab-0309376999-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-initiative/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-initiative/#tab-0309376999-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-initiative/","txt":" \n          \n           \n           Our mission \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-initiative/#tab-0309376999-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-initiative/","txt":" \n          \n           \n           Supported initiatives \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-initiative/#tab-0309376999-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-initiative/","txt":" \n          \n           \n           The impact \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-initiative/#tab-0309376999-5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-initiative/","txt":" \n          \n           \n           Lessons \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/partners-in-health-lesotho-project/#tab-01747846173-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/partners-in-health-lesotho-project/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/partners-in-health-lesotho-project/#tab-01747846173-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/partners-in-health-lesotho-project/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/partners-in-health-lesotho-project/#tab-01747846173-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/partners-in-health-lesotho-project/","txt":" \n          \n           \n           Project overview \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/partners-in-health-lesotho-project/#tab-01747846173-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/partners-in-health-lesotho-project/","txt":" \n          \n           \n           What we do \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/partners-in-health-lesotho-project/#tab-01747846173-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/partners-in-health-lesotho-project/","txt":" \n          \n           \n           The impact \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/partners-in-health-lesotho-project/#tab-01747846173-5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/partners-in-health-lesotho-project/","txt":" \n          \n           \n           Learnings \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-staying-alive-initiative/#tab-1008080202-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-staying-alive-initiative/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-staying-alive-initiative/#tab-1008080202-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-staying-alive-initiative/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-staying-alive-initiative/#tab-1008080202-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-staying-alive-initiative/","txt":" \n          \n           \n           Overview \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-staying-alive-initiative/#tab-1008080202-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-staying-alive-initiative/","txt":" \n          \n           \n           What we do \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-staying-alive-initiative/#tab-1008080202-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-staying-alive-initiative/","txt":" \n          \n           \n           The impact \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-staying-alive-initiative/#tab-1008080202-5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-staying-alive-initiative/","txt":" \n          \n           \n           Lessons learned \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/elizabeth-glaser-pediatric-aids-foundation-partnership/#tab-217368194-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/elizabeth-glaser-pediatric-aids-foundation-partnership/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/elizabeth-glaser-pediatric-aids-foundation-partnership/#tab-217368194-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/elizabeth-glaser-pediatric-aids-foundation-partnership/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/elizabeth-glaser-pediatric-aids-foundation-partnership/#tab-217368194-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/elizabeth-glaser-pediatric-aids-foundation-partnership/","txt":" \n          \n           \n           Our goals \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/elizabeth-glaser-pediatric-aids-foundation-partnership/#tab-217368194-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/elizabeth-glaser-pediatric-aids-foundation-partnership/","txt":" \n          \n           \n           Supported initiatives \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/elizabeth-glaser-pediatric-aids-foundation-partnership/#tab-217368194-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/elizabeth-glaser-pediatric-aids-foundation-partnership/","txt":" \n          \n           \n           The partnership \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/iskorak-croatia/#tab-01285469532-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/iskorak-croatia/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/iskorak-croatia/#tab-01285469532-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/iskorak-croatia/","txt":" \n          \n           \n           Summery and project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/iskorak-croatia/#tab-01285469532-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/iskorak-croatia/","txt":" \n          \n           \n           Quotes \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-czech-aids-help-society-czech-republic/#tab-1492473105-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-czech-aids-help-society-czech-republic/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-czech-aids-help-society-czech-republic/#tab-1492473105-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-czech-aids-help-society-czech-republic/","txt":" \n          \n           \n           Summery and project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-czech-aids-help-society-czech-republic/#tab-1492473105-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-czech-aids-help-society-czech-republic/","txt":" \n          \n           \n           Quotes \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positivo-grupos-de-apoio-e-autoajuda-portugal/#tab-74846045-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positivo-grupos-de-apoio-e-autoajuda-portugal/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positivo-grupos-de-apoio-e-autoajuda-portugal/#tab-74846045-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positivo-grupos-de-apoio-e-autoajuda-portugal/","txt":" \n          \n           \n           Summery and project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positivo-grupos-de-apoio-e-autoajuda-portugal/#tab-74846045-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positivo-grupos-de-apoio-e-autoajuda-portugal/","txt":" \n          \n           \n           Quotes \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/save-the-children-drc/#tab-01368398217-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/save-the-children-drc/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/save-the-children-drc/#tab-01368398217-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/save-the-children-drc/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/save-the-children-drc/#tab-01368398217-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/save-the-children-drc/","txt":" \n          \n           \n           What we do \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/save-the-children-drc/#tab-01368398217-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/save-the-children-drc/","txt":" \n          \n           \n           Lessons learned \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/save-the-children-drc/#tab-01368398217-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/save-the-children-drc/","txt":" \n          \n           \n           The future \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-aidsmap/#tab-0640679082-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-aidsmap/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-aidsmap/#tab-0640679082-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-aidsmap/","txt":" \n          \n           \n           The Need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-aidsmap/#tab-0640679082-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-aidsmap/","txt":" \n          \n           \n           The Project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-aidsmap/#tab-0640679082-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-aidsmap/","txt":" \n          \n           \n           What we do \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-aidsmap/#tab-0640679082-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-aidsmap/","txt":" \n          \n           \n           The impact so far \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/beats-for-life/#tab-0926977016-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/beats-for-life/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/beats-for-life/#tab-0926977016-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/beats-for-life/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/beats-for-life/#tab-0926977016-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/beats-for-life/","txt":" \n          \n           \n           The project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/beats-for-life/#tab-0926977016-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/beats-for-life/","txt":" \n          \n           \n           Lina van de Mars \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/beats-for-life/#tab-0926977016-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/beats-for-life/","txt":" \n          \n           \n           Winner \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/beats-for-life/#tab-0926977016-5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/beats-for-life/","txt":" \n          \n           \n           Impact & lessons \n           \n          ","status":"done","statusCode":200},"http://www.facebook.com/":{"status":"redirected","redirectedTo":"https://www.facebook.com/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action/#tab-2018185174-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action/","txt":" \n          \n           \n           About \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action/#tab-2018185174-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action/","txt":" \n          \n           \n           Webinars \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/hiv--a-virus-that-thrives-on-inequality/#unaids":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/hiv--a-virus-that-thrives-on-inequality/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/preliminary-positive-perspectives-survey-data-released-at-9th-in/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/hiv-treatment-and-care/the-positive-perspectives-survey/","txt":"Exploring part one of our Positive Perspectives Survey","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/pride-around-the-world/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/pride-around-the-world/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/accelerating-the-pace-of-innovation/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/accelerating-the-pace-of-innovation/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/implementation-science0/":{"status":"redirected","redirectedTo":"https://hivimplementationscience.com/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/how-the-unity-tool-can-help-conversations-between-plhiv-and-thei/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/how-the-unity-tool-can-help-conversations-between-plhiv-and-thei/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/accelerating-city-hiv-aids-responses-through-collaboration/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/accelerating-city-hiv-aids-responses-through-collaboration/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/viiv-healthcare--aids-2016/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/accelerating-city-hiv-aids-responses-through-collaboration/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/announcing-the-2016-every-footsteps-counts-winners/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/accelerating-city-hiv-aids-responses-through-collaboration/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/how-we_re-addressing-the-challenges-of-the-hiv-epidemic-in-afric/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/accelerating-city-hiv-aids-responses-through-collaboration/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/addressing-hiv-in-adolescents/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/accelerating-city-hiv-aids-responses-through-collaboration/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/understanding-hiv-in-women--spotlight-on-the-gender-gap-in-hiv-r/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/accelerating-city-hiv-aids-responses-through-collaboration/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/a-look-back-at-aids-2016/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/accelerating-city-hiv-aids-responses-through-collaboration/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/viiv-healthcare_s-commitment-to-implementation-science/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/viiv-healthcare_s-commitment-to-implementation-science/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/viiv-healthcare-presents-three-year-data-for-investigational-lon/ref/":{"redirectedFrom":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/viiv-healthcare-presents-three-year-data-for-investigational-lon/ref"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/February/viiv-healthcare-launches-eighth-phase-iii-study-in-two-drug-regimen-programme-for-hiv-1-treatment/_callto_+442080473763/":{"redirectedFrom":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/February/viiv-healthcare-launches-eighth-phase-iii-study-in-two-drug-regimen-programme-for-hiv-1-treatment/_callto_+442080473763"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/advancing-hiv-science-through-collaboration/#reference":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/advancing-hiv-science-through-collaboration/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/treating-hiv--building-on-30-years-of-innovation--ingenuity-and-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/advancing-hiv-science-through-collaboration/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/overcoming-the-challenges-for-partners-of-people-living-with-hiv/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/overcoming-the-challenges-for-partners-of-people-living-with-hiv/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/positive-perspectives/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/overcoming-the-challenges-for-partners-of-people-living-with-hiv/","txt":"Positive Perspectives  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/preliminary-positive-perspectives-survey-data-released-at-9th-in/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/preliminary-positive-perspectives-survey-data-released-at-9th-in/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/addressing-the-challenges-of-the-hiv-epidemic-in-africa/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/addressing-the-challenges-of-the-hiv-epidemic-in-africa/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/fighting-hiv-together--collaboration-is-driving-progress-with-th/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/fighting-hiv-together--collaboration-is-driving-progress-with-th/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/positive-partnerships-initiative-launches-in-estonia1/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/positive-partnerships-initiative-launches-in-estonia1/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/viiv-healthcare-to-host-inaugural-implementation-science-network/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/viiv-healthcare-to-host-inaugural-implementation-science-network/","txt":"[1] ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/viiv-healthcare_s-commitment-to-implementation-science/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/viiv-healthcare-to-host-inaugural-implementation-science-network/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/celebrating-the-25th-year-of-community-partnerships-and-collabor/#Avert":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/celebrating-the-25th-year-of-community-partnerships-and-collabor/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/pride-around-the-world/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/celebrating-the-25th-year-of-community-partnerships-and-collabor/","txt":"Pride around the world","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/facing-the-challenges-of-getting-old-with-hiv/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/facing-the-challenges-of-getting-old-with-hiv/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/facing-the-challenges-of-getting-old-with-hiv/#References":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/facing-the-challenges-of-getting-old-with-hiv/","txt":"[4]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/addressing-hiv-in-adolescents/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/addressing-hiv-in-adolescents/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/understanding-hiv-in-women--spotlight-on-the-gender-gap-in-hiv-r/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/understanding-hiv-in-women--spotlight-on-the-gender-gap-in-hiv-r/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/first-two-drug-pill-now-available-for-australians-with-hiv/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/first-two-drug-pill-now-available-for-australians-with-hiv/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/first-two-drug-single-pill-for-hiv-now-approved-for-use-in-austr/#Bottom":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/first-two-drug-single-pill-for-hiv-now-approved-for-use-in-austr/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/october/viiv-healthcare-awards-new-grants-to-accelerate-community-led-so/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/october/viiv-healthcare-awards-new-grants-to-accelerate-community-led-so/","txt":"[i],[ii]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/acon-start-making-sense--online-workshops/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-action-grant-projects/","txt":"Healthy Ageing with HIV - Self Management Groups","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/afao-national-african-australian-hiv-network/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-action-grant-projects/","txt":"National African Australian HIV Network (2015)","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/wa-aids-council-ageing-and-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-action-grant-projects/","txt":"Ageing and HIV","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-women-victoria-community-camp/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-action-grant-projects/","txt":"Community Camp","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/qpp-peer-navigation-program--education-modules/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-action-grant-projects/","txt":"Peer Navigation Program: Education Modules","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-life-nsw-hiv-work-ready/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-action-grant-projects/","txt":"HIV Work Ready","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/inside-hiv-the-podcast-for-positive-people/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-action-grant-projects/","txt":"Inside HIV – The Podcast for Positive People","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/acon-healthy-ageing-with-hiv---self-management-groups/#tab-683725788-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/acon-healthy-ageing-with-hiv---self-management-groups/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/acon-healthy-ageing-with-hiv---self-management-groups/#tab-683725788-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/acon-healthy-ageing-with-hiv---self-management-groups/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/acon-healthy-ageing-with-hiv---self-management-groups/#tab-683725788-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/acon-healthy-ageing-with-hiv---self-management-groups/","txt":" \n          \n           \n           The project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/bgf-online-group-counselling-for-isolated-people-living-with-hiv/#tab-01651647920-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/bgf-online-group-counselling-for-isolated-people-living-with-hiv/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/bgf-online-group-counselling-for-isolated-people-living-with-hiv/#tab-01651647920-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/bgf-online-group-counselling-for-isolated-people-living-with-hiv/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/bgf-online-group-counselling-for-isolated-people-living-with-hiv/#tab-01651647920-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/bgf-online-group-counselling-for-isolated-people-living-with-hiv/","txt":" \n          \n           \n           The project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/napwha-linkage-to-care-project-lkcp-identifying-the-barriers-and/#tab-1483011428-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/napwha-linkage-to-care-project-lkcp-identifying-the-barriers-and/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/napwha-linkage-to-care-project-lkcp-identifying-the-barriers-and/#tab-1483011428-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/napwha-linkage-to-care-project-lkcp-identifying-the-barriers-and/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/napwha-linkage-to-care-project-lkcp-identifying-the-barriers-and/#tab-1483011428-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/napwha-linkage-to-care-project-lkcp-identifying-the-barriers-and/","txt":" \n          \n           \n           The project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-women-victoria-needs-of-women-from-african-diaspora-com/#tab-01831585323-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-women-victoria-needs-of-women-from-african-diaspora-com/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-women-victoria-needs-of-women-from-african-diaspora-com/#tab-01831585323-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-women-victoria-needs-of-women-from-african-diaspora-com/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-women-victoria-needs-of-women-from-african-diaspora-com/#tab-01831585323-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-women-victoria-needs-of-women-from-african-diaspora-com/","txt":" \n          \n           \n           The project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/qpp-plhiv-peer-testernavigator-pilot-project-townsville-queensla/#tab-320602159-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/qpp-plhiv-peer-testernavigator-pilot-project-townsville-queensla/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/qpp-plhiv-peer-testernavigator-pilot-project-townsville-queensla/#tab-320602159-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/qpp-plhiv-peer-testernavigator-pilot-project-townsville-queensla/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/qpp-plhiv-peer-testernavigator-pilot-project-townsville-queensla/#tab-320602159-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/qpp-plhiv-peer-testernavigator-pilot-project-townsville-queensla/","txt":" \n          \n           \n           The project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/qpp-queensland-positive-speakers-bureau-neutralising-the-health-/#tab-1693506522-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/qpp-queensland-positive-speakers-bureau-neutralising-the-health-/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/qpp-queensland-positive-speakers-bureau-neutralising-the-health-/#tab-1693506522-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/qpp-queensland-positive-speakers-bureau-neutralising-the-health-/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/qpp-queensland-positive-speakers-bureau-neutralising-the-health-/#tab-1693506522-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/qpp-queensland-positive-speakers-bureau-neutralising-the-health-/","txt":" \n          \n           \n           The project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/tascahrd-rural-tasmanian-council-on-aids-hepatitis-and-related-d/#tab-0531429989-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/tascahrd-rural-tasmanian-council-on-aids-hepatitis-and-related-d/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/tascahrd-rural-tasmanian-council-on-aids-hepatitis-and-related-d/#tab-0531429989-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/tascahrd-rural-tasmanian-council-on-aids-hepatitis-and-related-d/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/tascahrd-rural-tasmanian-council-on-aids-hepatitis-and-related-d/#tab-0531429989-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/tascahrd-rural-tasmanian-council-on-aids-hepatitis-and-related-d/","txt":" \n          \n           \n           The project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/the-western-suburbs-haven-young-and-moving-forward/#tab-01172419338-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/the-western-suburbs-haven-young-and-moving-forward/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/the-western-suburbs-haven-young-and-moving-forward/#tab-01172419338-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/the-western-suburbs-haven-young-and-moving-forward/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/the-western-suburbs-haven-young-and-moving-forward/#tab-01172419338-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/the-western-suburbs-haven-young-and-moving-forward/","txt":" \n          \n           \n           The project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/en-el-deporte-como-en-la-vida-menos-es-mas/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/en-el-deporte-como-en-la-vida-menos-es-mas/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/marzo/marzo/#bottom":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/marzo/marzo/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/maggio/viiv-healthcare-riceve-lapprovazione-in-europa-per-la-combinazio/#bottom":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/maggio/viiv-healthcare-riceve-lapprovazione-in-europa-per-la-combinazio/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/luglio/viiv-healthcare-presenta-ad-aids-2018-i-dati-di-fase-iii-per-gli/#bottom":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/luglio/viiv-healthcare-presenta-ad-aids-2018-i-dati-di-fase-iii-per-gli/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-presenta-i-dati-relativi-a-tre-anni-di-trattamen/#bottom":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-presenta-i-dati-relativi-a-tre-anni-di-trattamen/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/bundesweites-treffen-fuer-hiv-positive-jugendliche/$NewsURL_01":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/bundesweites-treffen-fuer-hiv-positive-jugendliche/","txt":"  Mai 25  \n       \n        \n       ","status":"redirected","statusCode":"404,301","redirectedTo":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/bundesweites-treffen-fuer-hiv-positive-jugendliche/$NewsURL_01/"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/schulung-und-selbstmanagement-koennen-die-adhaerenz-verbessern/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/schulung-und-selbstmanagement-koennen-die-adhaerenz-verbessern/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/deutsche-aids-hilfe-startet-die-informationskampagne-zum-welt-ai/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/deutsche-aids-hilfe-startet-die-informationskampagne-zum-welt-ai/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/auf-dem-weg-zu-90-90-90-wie-sieht-es-in-europa-aus/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/auf-dem-weg-zu-90-90-90-wie-sieht-es-in-europa-aus/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/antiretrovirale-kombinationstherapie-eine-erfolgsgeschichte/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/antiretrovirale-kombinationstherapie-eine-erfolgsgeschichte/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/artikel/weltweiter-zugang-zu-medikamenten/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/artikel/weltweiter-zugang-zu-medikamenten/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/spickzettel-unterstuetzung-bei-der-fruehen-diagnose-informatione/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/spickzettel-unterstuetzung-bei-der-fruehen-diagnose-informatione/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/healthcare-professionals/viiv-healthcare-clinical-study-register/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/healthcare-professionals/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/medicines-in-development/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/healthcare-professionals/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/healthcare-professionals/voluntary-disclosure-of-viiv-healthcare-canada-payments-to-hcps-/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/healthcare-professionals/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/contact-us/#1-450-680-4810":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/contact-us/","txt":"(450) 680-4810","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/contact-us/#1-877-335-2186":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/contact-us/","txt":"1-877-335-2186","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/contact-us/#1-450-680-4801":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/contact-us/","txt":"(450) 680-4801","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/contact-us/#1-877-393-8448":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/contact-us/","txt":" 1-877-393-8448","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/contact-us/#1-905-819-3363":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/contact-us/","txt":"1-905-819-3363","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/about-hivaids/about-hivaids-in-canada/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/about-hivaids/","txt":" \n      \n      À propos du VIH/sida au Canada \n      Pour en savoir plus à propos du VIH/sida au Canada \n      Lire la suite \n      ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/about-hivaids/canadian-resources/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/about-hivaids/","txt":" \n      \n      Ressources pour les Canadiens  Découvrez comment ViiV Soins de santé Canada soutient les populations à risque, les personnes atteintes du VIH/sida, leurs soignants et les professionnels de la santé. \n      Lire la suite \n      ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/about-us/who-we-are/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/about-us/","txt":" \n      \n      Qui sommes-nous?  \n      ViiV Soins de santé Canada se consacre à la recherche sur le VIH/sida et son traitement ainsi qu’au soutien des personnes touchées par le VIH/sida.  \n      Lire la suite \n      ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/about-us/our-team/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/about-us/","txt":" \n      \n      Notre équipe  \n      Faites plus ample connaissance avec l’équipe de leadership de ViiV Soins de santé Canada qui travaille étroitement avec notre directrice générale pour formuler notre stratégie et gérer notre entreprise conformément à nos valeurs d’innovation, de passion, de confiance, de résilience et d’intégrité.  \n      Lire la suite \n      ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/about-us/our-mission/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/about-us/","txt":" \n      \n      Notre mission  \n      Nous visons à être le meilleur partenaire qui soit dans le cadre d’une démarche favorisant la santé à long terme des patients vivant avec le VIH.  \n      Lire la suite \n      ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/3tc/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/","txt":"3TC®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/celsentri/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/","txt":"Celsentri®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/combivir/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/","txt":"Combivir®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/kivexa/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/","txt":"Kivexa®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/rescriptor/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/","txt":"Rescriptor®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/retrovirazt/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/","txt":"Retrovir/AZT®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/telzir/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/","txt":"Telzir®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/tivicay/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/","txt":"Tivicay®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/triumeq/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/","txt":"Triumeq®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/trizivir/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/","txt":"Trizivir®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/viracept/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/","txt":"Viracept®*","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/ziagen/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/","txt":"Ziagen®","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/search/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/search/","txt":"EN","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/","txt":"par nos Subventions communautaires à l’éducation et aux services,","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/","txt":"par notre Programme d’innovation VIH/sida Positive Action Canada, et","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/","txt":"par l'Initiative VIH/sida autochtone de Positive Action Canada.","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#1a":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/in-the-community/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/","txt":"Rôle social  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/positive-action/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/","txt":"Positive Action  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/content/cf-viiv/viiv-healthcare/fr_CA/home/redirects/viiv-fr/":{"redirectedFrom":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/content/cf-viiv/viiv-healthcare/fr_CA/home/redirects/viiv-fr"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/about-hivaids/about-hivaids-in-canada/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/about-hivaids/about-hivaids-in-canada/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/press-releases/2018/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/media/press-releases/2018/","txt":"FR","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/content/cf-viiv/viiv-healthcare/fr_CH/home/latest-news/2018/june-1/hiv-knowledge-builds-trust/":{"redirectedFrom":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/content/cf-viiv/viiv-healthcare/fr_CH/home/latest-news/2018/june-1/hiv-knowledge-builds-trust"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/latest-news/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/content/cf-viiv/viiv-healthcare/fr_CH/home/latest-news/2018/june-1/hiv-knowledge-builds-trust/","txt":"Latest News  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/privacy-notice/#1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/privacy-notice/","txt":"quelles données personnelles nous recueillons sur vous;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/privacy-notice/#2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/privacy-notice/","txt":"comment nous utilisons vos informations personnelles;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/privacy-notice/#3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/privacy-notice/","txt":"sur quelle base nous utilisons vos informations personnelles;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/privacy-notice/#4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/privacy-notice/","txt":"combien de temps nous conservons vos informations personnelles;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/privacy-notice/#5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/privacy-notice/","txt":"nous pouvons être amenés à partager vos informations personnelles avec des tiers et les transférer au niveau international;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/privacy-notice/#6":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/privacy-notice/","txt":"comment nous protégeons vos informations personnelles;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/privacy-notice/#7":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/privacy-notice/","txt":"vos droits relatifs à vos informations personnelles;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/privacy-notice/#8":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/privacy-notice/","txt":"Que faire si vous ne voulez pas nous fournir vos informations personnelles; et","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/privacy-notice/#9":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/privacy-notice/","txt":"comment nous utilisons des cookies et où trouver d’autres informations.","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/privacy-notice/#Contactus":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/privacy-notice/","txt":"contactez-nous","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/content/cf-viiv/viiv-healthcare/master/home/cookie-policy.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/privacy-notice/","txt":"politique sur les cookies","status":"done","statusCode":404},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/#1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/","txt":"welche personenbezogenen Informationen wir zu Ihrer Person erfassen;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/#2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/","txt":"wie wir Ihre personenbezogenen Informationen nutzen;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/#3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/","txt":"auf welcher Grundlage wir Ihre personenbezogenen Informationen nutzen;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/#4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/","txt":"wie lange wir Ihre personenbezogenen Informationen verwahren;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/#5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/","txt":"dass wir Ihre personenbezogenen Informationen unter Umständen an andere weitergeben und in andere Länder weiterleiten;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/#6":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/","txt":"wie wir Ihre personenbezogenen Informationen schützen;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/#7":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/","txt":"welche Rechte Sie in Bezug auf Ihre personenbezogenen Informationen besitzen;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/#8":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/","txt":"was zu tun ist, falls Sie uns Ihre personenbezogenen Informationen nicht zur Verfügung stellen möchten;","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/#9":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/","txt":"wie wir Cookies nutzen und wo Sie weitergehende Informationen erhalten können.","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/#1a":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/","txt":"Kontaktaufnahme","status":"done","statusCode":":("},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-expands-u-s--commitment-to-youth-living-with-hiv/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-expands-u-s--commitment-to-youth-living-with-hiv/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-reports-positive-48-week-results-for-first-pivot/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-reports-positive-48-week-results-for-first-pivot/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-sword-100-week-data-for-juluca-dolute/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-sword-100-week-data-for-juluca-dolute/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-positive-new-dolutegravir-data-for-the/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-positive-new-dolutegravir-data-for-the/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-launches-eighth-phase-iii-study-in-two--drug-reg/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-launches-eighth-phase-iii-study-in-two--drug-reg/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-start-of-phase-iii-study-of-long-actin/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-start-of-phase-iii-study-of-long-actin/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/iiv-healthcare-starts-third-phase-iii-hiv-treatment-study-invest/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/iiv-healthcare-starts-third-phase-iii-hiv-treatment-study-invest/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-us-fda-approval-for-juluca/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-us-fda-approval-for-juluca/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/new-results-from-the-positive-perspectives-global-survey-provide/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/new-results-from-the-positive-perspectives-global-survey-provide/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-and-neat-id-announce-results-from-the-neat-022-s/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-and-neat-id-announce-results-from-the-neat-022-s/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/phase-ii-study-results-showed-comparable-viral-suppression-rates/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/phase-ii-study-results-showed-comparable-viral-suppression-rates/","txt":"[2]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-shares-data-from-its-innovative-portfolio-with-h/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-shares-data-from-its-innovative-portfolio-with-h/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/content/cf-viiv/viiv-healthcare/master/home.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-shares-data-from-its-innovative-portfolio-with-h/","txt":"www.viivhealthcare.com","status":"done","statusCode":404},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-fda-approval-of-selzentry-maraviroc/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-fda-approval-of-selzentry-maraviroc/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-extends-medicines-patent-pool-licence-agreement/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-extends-medicines-patent-pool-licence-agreement/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-first-phase-ii-hiv-prevention-study-re/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-first-phase-ii-hiv-prevention-study-re/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-phase-ii-study-results-for-first-two-d/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-phase-ii-study-results-for-first-two-d/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/cierre-de-la-brecha-en-la-comunidad-latina/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-commitment-to-latinx-communities-living-with-hiv/","txt":"working to close the gap","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/closing-the-gap-in-the-latinx-community/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-commitment-to-latinx-communities-living-with-hiv/","txt":"Closing the Gap in the Latinx Community  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/nuestro-compromiso-con-la-poblacion-hispana-y-latina-que-vive-co/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-commitment-to-latinx-communities-living-with-hiv/","txt":"Nuestro compromiso con la población hispana y latina que vive con VIH  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/iconographic/":{"status":"redirected","redirectedTo":"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/hiv-tb_infographic-final.pdf"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/towards-a-cure--exploring-cure-and-remission-in-hiv/#Bottom":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/towards-a-cure--exploring-cure-and-remission-in-hiv/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/ageing-with-hiv/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/ageing-with-hiv/","txt":"1","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/ageing-with-hiv/#1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/ageing-with-hiv/","txt":"1","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/accelerating-the-pace-of-innovation/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/accelerating-the-pace-of-innovation/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-reports-positive-48-week-results-for-second-phas/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-reports-positive-48-week-results-for-second-phas/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/medicines-in-development/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/medicines-in-development/","txt":"1","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/towards-a-cure--exploring-cure-and-remission-in-hiv/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/towards-a-cure--exploring-cure-and-remission-in-hiv/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund-french/#tab-1615331907-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund-french/","txt":" \n          \n           \n           Contexte \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund-french/#tab-1615331907-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund-french/","txt":" \n          \n           \n           Demande de subventions \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund-french/#tab-1615331907-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund-french/","txt":" \n          \n           \n           Bénéficiaires \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund-french/#tab-1615331907-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund-french/","txt":" \n          \n           \n           Communauté en ligne PA \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund-french/#tab-1615331907-4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund-french/","txt":" \n          \n           \n           Every Footstep Counts \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/preliminary-positive-perspectives-survey-data-released-at-9th-in/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/preliminary-positive-perspectives-survey-data-released-at-9th-in/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/announcing-the-2016-every-footsteps-counts-winners/#bottom":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/announcing-the-2016-every-footsteps-counts-winners/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/how-we_re-addressing-the-challenges-of-the-hiv-epidemic-in-afric/#Bottom":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/how-we_re-addressing-the-challenges-of-the-hiv-epidemic-in-afric/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/addressing-hiv-in-adolescents/#References":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/addressing-hiv-in-adolescents/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-collaborathon-grants-announced/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/a-look-back-at-aids-2016/","txt":"Our PACF Collaborathon","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/understanding-hiv-in-women--spotlight-on-the-gender-gap-in-hiv-r/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/understanding-hiv-in-women--spotlight-on-the-gender-gap-in-hiv-r/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/understanding-hiv-in-women--spotlight-on-the-gender-gap-in-hiv-r/#societal":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/understanding-hiv-in-women--spotlight-on-the-gender-gap-in-hiv-r/","txt":"Societal considerations for HIV research in women","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/understanding-hiv-in-women--spotlight-on-the-gender-gap-in-hiv-r/#closing":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/understanding-hiv-in-women--spotlight-on-the-gender-gap-in-hiv-r/","txt":"Closing the research gap","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/understanding-hiv-in-women--spotlight-on-the-gender-gap-in-hiv-r/#our":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/understanding-hiv-in-women--spotlight-on-the-gender-gap-in-hiv-r/","txt":"Our commitment","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/viiv-healthcare_s-commitment-to-implementation-science/#Ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/viiv-healthcare_s-commitment-to-implementation-science/","txt":"[i]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/viiv-healthcare_s-commitment-to-implementation-science/#Top":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/viiv-healthcare_s-commitment-to-implementation-science/","txt":"Click here for more information on our Positive Pathways initiative","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/pride-around-the-world/#references":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/pride-around-the-world/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/acon-start-making-sense--online-workshops/#tab-01123138625-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/acon-start-making-sense--online-workshops/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/acon-start-making-sense--online-workshops/#tab-01123138625-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/acon-start-making-sense--online-workshops/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/acon-start-making-sense--online-workshops/#tab-01123138625-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/acon-start-making-sense--online-workshops/","txt":" \n          \n           \n           The project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/acon-start-making-sense--online-workshops/#tab-01123138625-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/acon-start-making-sense--online-workshops/","txt":" \n          \n           \n           Video \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/wa-aids-council-ageing-and-hiv/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/wa-aids-council-ageing-and-hiv/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-women-victoria-community-camp/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-women-victoria-community-camp/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/qpp-peer-navigation-program--education-modules/#tab-0964293614-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/qpp-peer-navigation-program--education-modules/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/qpp-peer-navigation-program--education-modules/#tab-0964293614-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/qpp-peer-navigation-program--education-modules/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/qpp-peer-navigation-program--education-modules/#tab-0964293614-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/qpp-peer-navigation-program--education-modules/","txt":" \n          \n           \n           The project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-life-nsw-hiv-work-ready/#tab-1323224673-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-life-nsw-hiv-work-ready/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-life-nsw-hiv-work-ready/#tab-1323224673-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-life-nsw-hiv-work-ready/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-life-nsw-hiv-work-ready/#tab-1323224673-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-life-nsw-hiv-work-ready/","txt":" \n          \n           \n           The project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-life-nsw-hiv-work-ready/#tab-1323224673-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-life-nsw-hiv-work-ready/","txt":" \n          \n           \n           Video \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/inside-hiv-the-podcast-for-positive-people/#tab-1775292383-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/inside-hiv-the-podcast-for-positive-people/","txt":" \n          \n           \n           Introduction \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/inside-hiv-the-podcast-for-positive-people/#tab-1775292383-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/inside-hiv-the-podcast-for-positive-people/","txt":" \n          \n           \n           The need \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/inside-hiv-the-podcast-for-positive-people/#tab-1775292383-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/inside-hiv-the-podcast-for-positive-people/","txt":" \n          \n           \n           The project \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/inside-hiv-the-podcast-for-positive-people/#tab-1775292383-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/inside-hiv-the-podcast-for-positive-people/","txt":" \n          \n           \n           Video \n           \n          ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/bundesweites-treffen-fuer-hiv-positive-jugendliche/$NewsURL_01/":{"redirectedFrom":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/bundesweites-treffen-fuer-hiv-positive-jugendliche/$NewsURL_01"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/about-hivaids/about-hivaids-in-canada/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/about-hivaids/about-hivaids-in-canada/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/latest-news/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/latest-news/","txt":"DE","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/latest-news/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/latest-news/","txt":"FR","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/latest-news/2018/may-1/new-insights-into-hiv-transmission/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/latest-news/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/latest-news/2018/combating-depression-by-telephone/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/latest-news/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/search/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/latest-news/","txt":"Search  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/nuestro-compromiso-con-la-poblacion-hispana-y-latina-que-vive-co/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/nuestro-compromiso-con-la-poblacion-hispana-y-latina-que-vive-co/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/es/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/nuestro-compromiso-con-la-poblacion-hispana-y-latina-que-vive-co/","txt":"Read More About  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/redirects/viiv_healthcare-narrativespanish/":{"status":"redirected","redirectedTo":"https://us.viivhealthcare.com/media/124445/viiv_healthcare-narrative_spanish.pdf"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/latest-news/2018/may-1/new-insights-into-hiv-transmission/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/latest-news/","txt":" ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/search/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/latest-news/","txt":"Search  ","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/latest-news/2018/may-1/new-insights-into-hiv-transmission/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/latest-news/2018/may-1/new-insights-into-hiv-transmission/","txt":"DE","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/es/#ref":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/es/","txt":"[1]","status":"done","statusCode":200},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/redirects/quienes-somos/":{"status":"redirected","redirectedTo":"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/viiv_healthcare-narrative_spanish.pdf"},"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/search/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/search/","txt":"DE","status":"done","statusCode":200}},"originMedia":{},"external":{},"other":{"":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/search/","txt":"","status":"new"},"http://www.viivexchange.com/routing":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/search/","txt":"Healthcare professionals","status":"new"},"https://www.livlife.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/search/","txt":"LiV Life Patient Site","status":"new"},"http://glaxosmithkline.co.jp/viiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/search/","txt":"Japan","status":"new"},"https://cu.viivhealthcare.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/search/","txt":"Compassionate Use","status":"new"},"https://hivimplementationscience.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/search/","txt":"Implementation Science","status":"new"},"https://everyfootstepcounts.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/search/","txt":"Every Footstep Counts","status":"new"},"http://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/report-a-side-effect/","txt":"Report a side effect","status":"new"},"https://www.facebook.com/ViiVHealthcare/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/search/","txt":"*** IMAGE WITHOUT ALT TEXT ***","status":"new"},"https://twitter.com/ViiVHC":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/search/","txt":"*** IMAGE WITHOUT ALT TEXT ***","status":"new"},"https://www.linkedin.com/company/viiv-healthcare":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/search/","txt":"*** IMAGE WITHOUT ALT TEXT ***","status":"new"},"https://www.youtube.com/user/viivhealthcare":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/search/","txt":"*** IMAGE WITHOUT ALT TEXT ***","status":"new"},"https://au.viivexchange.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/inside-hiv-the-podcast-for-positive-people/#tab-1775292383-3","txt":"ViiV Exchange for HCPs","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/critical-steps-towards-addressing-hiv-in-australia_viiv-australia-report.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/september/critical-steps-towards-addressing-hiv-in-australia-a-report-from/","txt":"To view the full interactive report click here.","status":"new"},"http://twitter.com/ViiVHC":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/inside-hiv-the-podcast-for-positive-people/#tab-1775292383-3","txt":"*** IMAGE WITHOUT ALT TEXT ***","status":"new"},"http://www.youtube.com/user/viivhealthcare":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/es/#ref","txt":"*** IMAGE WITHOUT ALT TEXT ***","status":"new"},"http://links.deepcrawl.com/wf/click?upn=2ivqYE4BVXDwXIen-2Bf2GGg7bVfbrP8T1PCq8GO-2Ff938LKEnw4ZTKisdrtTOwSZ-2Fn1ORrfiqQQ4S380Ke4njm52qRbww8jZxUk76vYUkGWgmkRxiVYw-2FHGwT3Sqy-2FXgFLMBkxvci11Z0TUmpRB4epaKrKumx4efNzPfJXmo36Hl1fOG1E3Kr3AqUYFto3Xibh8-2FvtU8EePh6cU9Y8nDsvgwFpQq8NJLbDju1m-2BX3Bp1Myc0QFiVKXWpUo-2F9ZzVSdL_ucayqdfMXlM8duOrxjJvzFWSV-2BB4NazG1NpTb-2B0j-2FLzmZKDYNp3YWdb1hxOX9aobRQf1-2F2BscGSnm22hFMLY85fdH0xNWrhTo66jq1R2UpJBcmKYJmTrV5IjlZRQ6V0FpAnGwwaDox5B82knCNNd2VtLnuizNb7N1e-2FYm3A0zF-2BQsTGyXwzn541kKgSUiDfj1p-2Fp9ad-2FMQasCsoQd6FfOhtl5QMKl8ISiqCa4HSSXas-3D":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/italia/","txt":"ViiV Healthcare presenta i dati relativi a tre anni di trattamento con il regime sperimentale iniettabile a due farmaci HIV a lunga durata di azione","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/France/Original_PDFs/bienvenue/acces-aux-traitements-infographique.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/","txt":"  oct. 03  \n       \n        \n       \n       \n       L’enjeu : Travailler ensemble pour un accès universel à l’échelle mondiale, 10 millions de personnes bénéficient d’un traitement ARV. Mais selon ses guidelines, l’OMS estime que 26 millions de personnes sont éligibles à ce traitement. \n       ","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/France/Original_PDFs/bienvenue/561487_viiv_ins_infodigit_girls-women_265x1005_exe.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/","txt":"  oct. 01  \n       \n        \n       \n       \n       Le VIH/SIDA chez les femmes âgées de 15 à 44 ans est la première cause de décès dans le monde. La prévalence du VIH est jusqu’à 8 fois plus élevée dans certains pays chez les adolescentes et les jeunes femmes que chez les hommes. \n       ","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/France/Original_PDFs/bienvenue/541784_viiv_ins_infodigit_femme-hiv_265x920_exe.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/","txt":"  sept. 28  \n       \n        \n       \n       \n       Dans le monde, la moitié des personnes vivant avec le VIH sont des femmes. Les taux d’infection chez les jeunes femmes (âgées de 15 à 24 ans) sont 2 fois plus élevés que chez les jeunes hommes. \n       ","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/France/Original_PDFs/bienvenue/journalistes-positive-action-community-grants-france-2018.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/","txt":"  avr. 10  \n       \n        \n       \n       \n       Programme Positive Action Community Grants de ViiV Healthcare France : lauréats de l’appel à projet destiné aux associations de lutte contre le sida pour améliorer l’accès au dépistage du VIH en 2018. \n       ","status":"new"},"https://www.gsk-kontakt.de/contact_viiv/index.html?contentarea=prof&referer=viivhealthcare.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/spickzettel-unterstuetzung-bei-der-fruehen-diagnose-informatione/#references","txt":"Nebenwirkung melden","status":"new"},"https://www.viivexchange.ca/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/","txt":"  ","status":"new"},"http://inmagazine.ca/2018/08/spilling-the-tea-on-guys-who-party-and-play/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"MAX Ottawa and ViiV Healthcare launches Spill the Tea campaign","status":"new"},"https://www.viivhealthcare.ca/media/209570/18211_viiv_en.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/","txt":"Important Safety Information on TIVICAY, TRIUMEQ and JULUCA","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Netherlands/Original_PDFs/Welkom/1711063-viiv-positive-perspective-survey-report-8-1.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/welkom/","txt":"Download hier het rapport","status":"new"},"http://www.gsk.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-reports-positive-48-week-results-for-second-phas/#ref","txt":"www.gsk.com","status":"new"},"http://pfizer.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/who-we-are/","txt":"Pfizer","status":"new"},"http://www.shionogi.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/april/shionogi-viiv-healthcare-announces-initial-data-from-pivotal-pha/","txt":"www.shionogi.com","status":"new"},"http://www.gsk.com/en-gb/investors/corporate-reporting/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/who-we-are/","txt":"£2.3 billion in 2015","status":"new"},"http://www.unaids.org/en/resources/campaigns/HowAIDSchangedeverything/factsheet":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/who-we-are/","txt":"36.9 million people living with the virus","status":"new"},"http://glaxosmithkline.co.jp/viiv/index.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/where-we-work/","txt":"http://glaxosmithkline.co.jp/viiv/index.html","status":"new"},"http://glaxosmithkline.co.jp/viiv/inquiry.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/where-we-work/","txt":"http://glaxosmithkline.co.jp/viiv/inquiry.html","status":"new"},"http://www.nmac.org/meet-the-2018-youth-initiative-scholars/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/","txt":" \n           \n            NMAC Announces 2018 Youth Initiative Scholars  \n           Learn more and meet the 2018 scholars here. \n            ","status":"new"},"https://en-gb.facebook.com/ViiVHealthcare/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/es/#ref","txt":"*** IMAGE WITHOUT ALT TEXT ***","status":"new"},"https://twitter.com/ViiVUS":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/es/#ref","txt":"*** IMAGE WITHOUT ALT TEXT ***","status":"new"},"https://www.linkedin.com/company/612511":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/es/#ref","txt":"*** IMAGE WITHOUT ALT TEXT ***","status":"new"},"https://www.viiv-clinicalstudyregister.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/committed-to-data-transparency/","txt":"clinical study register","status":"new"},"http://www.clinicaltrials.gov/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen/#ref","txt":"www.clinicaltrials.gov","status":"new"},"https://www.clinicaltrialsregister.eu/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/committed-to-data-transparency/","txt":"https://www.clinicaltrialsregister.eu","status":"new"},"https://clinicalstudydatarequest.com/Study-Sponsors-ViiV-Details.aspx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/committed-to-data-transparency/","txt":"https://clinicalstudydatarequest.com/Study-Sponsors-ViiV-Details.aspx","status":"new"},"http://www.unaids.org/en/resources/fact-sheet.%20Last%20accessed%20November%202018":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-research-and-develop-new-hiv-medicines/#references","txt":"http://www.unaids.org/en/resources/fact-sheet. Last accessed November 2018","status":"new"},"http://www.iasociety.org/Default.aspx?pageId=707":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-collaborate-to-innovate/","txt":"Towards an HIV Cure Industry Collaborative Group","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/CHAIT-Press-release.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-collaborate-to-innovate/","txt":"Collaboration for HIV/AIDS Immunological Therapy","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-healthcare_funding-and-investment-in-hiv-policy-position_final.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/policy-papers/","txt":"Funding and Investment in HIV","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-healthcare_continuous-innovation-in-prevention-testing-treatment-and-care-of-hiv-policy-position-final.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/policy-papers/","txt":"Continuous Innovation in Prevention, Testing, Treatment & Care of HIV","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-hc-universal-healthcoverage-for-plhiv-policy-2.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/policy-papers/","txt":"Universal Health Coverage (UHC) for PLHIV","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viivhc-stigma-and-discrimination-policy.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/policy-papers/","txt":"Stigma and Discrimination","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-healthcare_prevention-in-hiv-policy-position_final.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/policy-papers/","txt":"Prevention in HIV","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/vhc_access-to-medicine-public-policy_feb-2018_for-publication_corrections_june2018.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/we-improve-access-to-our-medicines/#references","txt":"Click to read our full Access to Medicine policy","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-healthcare_global-hiv-policy-position-summary_final.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/policy-papers/","txt":"Global HIV Policy","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-healthcare_hiv-testing-policy-position_final.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/policy-papers/","txt":"Position on HIV Testing","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-healthcare_retention-into-care-policy-position_final.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/policy-papers/","txt":"Retention into Care","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/positive-perspectives-survey-report-finalcompressed.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/first-two-drug-pill-now-available-for-australians-with-hiv/#references","txt":"https://www.viivhealthcare.com/media/125429/positive-perspectives-survey-report-finalcompressed.pdf","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/positiveperspectives_partner-report.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/positive-perspectives/","txt":"*** IMAGE WITHOUT ALT TEXT ***","status":"new"},"https://impaactnetwork.org/studies/p1093.asp":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/paediatric-hiv-care/","txt":"P1093 study","status":"new"},"https://penta-id.org/hiv/odyssey-penta-20/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/paediatric-hiv-care/","txt":"ODYSSEY clinical trial","status":"new"},"https://medicinespatentpool.org/licence-post/dolutegravir-paediatrics-dtg":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/paediatric-hiv-care/","txt":"Pool.","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/tivicay-paed-wwrs-11oct2018-for-external-use.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/we-improve-access-to-our-medicines/#references","txt":"regulatory filings and registration of paediatric Tivicay","status":"new"},"https://www.iasociety.org/CIPHER":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/paediatric-hiv-care/","txt":"IAS platform for Paediatric HIV","status":"new"},"http://www.unaids.org/en/resources/fact-sheet":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/addressing-hiv-in-adolescents/#References","txt":"http://www.unaids.org/en/resources/fact-sheet","status":"new"},"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978668/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/paediatric-hiv-care/","txt":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978668/","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/tivicay-adult-wwrs-11oct2018-for-external-use.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/we-improve-access-to-our-medicines/#references","txt":"Tivicay","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/triumeq-wwrs-11oct2018-for-external-use.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/we-improve-access-to-our-medicines/#references","txt":"Triumeq","status":"new"},"http://livlife.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/","txt":"Find out more","status":"new"},"http://www.positiveactionchallenges.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/celebrating-the-25th-year-of-community-partnerships-and-collabor/#Avert","txt":"Positive Action Challenges","status":"new"},"https://www.positiveactionchallenges.com/challenges.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-challenges/","txt":"challenge prizes to solve specific problems","status":"new"},"https://www.positiveactionchallenges.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/viiv-healthcare-s-the-hive-and-positive-action-community-challenge-seek-outside-collaborations-in-order-to-innovate-for-people-living-with-hiv/","txt":"Positive Action Community Challenge","status":"new"},"http://www.unaids.org/sites/default/files/media_asset/unaids-data-2018_en.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/understanding-hiv-stigma-and-discrimination/","txt":"http://www.unaids.org/sites/default/files/media_asset/unaids-data-2018_en.pdf","status":"new"},"https://twitter.com/hashtag/KnowYourStatus?src=hash":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/championing-effective-hiv-care-for-plhiv/#references","txt":"Knowing your status","status":"new"},"http://www.unaids.org/en/resources/909090":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/viiv-healthcare-to-host-inaugural-implementation-science-network/#references","txt":"UNAIDS 90-90-90 targets","status":"new"},"https://livlife.com/en-gb/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/championing-effective-hiv-care-for-plhiv/#references","txt":"LiVLife platform","status":"new"},"http://www.unaids.org/en/resources/documents/2017/90-90-90":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/world-aids-day/championing-effective-hiv-care-for-plhiv/#references","txt":"http://www.unaids.org/en/resources/documents/2017/90-90-90","status":"new"},"http://www.gsk.com/en-gb/investors/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/contact-us/","txt":"GlaxoSmithKline's Investor Relations","status":"new"},"http://www.viivhealthcare.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-collaborathon-grants-announced/","txt":"visit www.viivhealthcare.com","status":"new"},"https://clinicaltrials.gov/ct2/show/NCT02831673%20%20":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/viiv-healthcare-receives-chmp-positive-opinion-for-tivicay-eu-la/#bottom","txt":"https://clinicaltrials.gov/ct2/show/NCT02831673","status":"new"},"https://clinicaltrials.gov/ct2/show/NCT02831764%20":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/viiv-healthcare-receives-chmp-positive-opinion-for-tivicay-eu-la/#bottom","txt":"https://clinicaltrials.gov/ct2/show/NCT02831764","status":"new"},"https://www.w3.org/TR/WCAG20/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/accessibility/","txt":"World Wide Web Consortium Web Accessibility Initiative (WCAG WAI) 2.0 guidelines","status":"new"},"https://ec.europa.eu/info/law/law-topic/data-protection/data-transfers-outside-eu/model-contracts-transfer-personal-data-third-countries_en":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/#9","txt":"hier","status":"new"},"https://www.gsk.com/en-gb/contact-us/privacy-contact-information/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/#9","txt":"hier","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/General-conditions-of-sale-ViiV-Belgium-FR-NL-01-07-2012.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/terms-and-conditions/","txt":"Sales Terms & Conditions","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/General-conditions-of-purchase-ViiV-Belgium-FR-NL-01-07-2012.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/terms-and-conditions/","txt":"Purchase Order Terms & Conditions","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/CGA-ViiV-Cerps-Mai-2012-France.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/terms-and-conditions/","txt":"Purchase Order Terms & Conditions","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/AEB_VIIV.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/terms-and-conditions/","txt":"Purchase Order Terms & Conditions","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-acquistobeniservizicondizionigenerali_italiano.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/terms-and-conditions/","txt":"Purchase Order Terms & Condition (Italian)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-acquistobeniservizicondizionigenerali_inglese.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/terms-and-conditions/","txt":"Purchase Order Terms & Condition (English)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Netherlands-Algemene-Inkoop-voorwaarden-01-10-2010.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/terms-and-conditions/","txt":"Purchase Order Terms & Conditions","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/singapore-terms-and-conditions.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/terms-and-conditions/","txt":"Purchase Order Terms & Condition (English)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/t-and-c-spanish.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/terms-and-conditions/","txt":"Purchase Order Terms & Conditions (Spanish)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/t-and-c-english.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/terms-and-conditions/","txt":"Purchase Order Terms & Conditions (English)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/tc-po-viiv-june-english-2018-portugal.docx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/terms-and-conditions/","txt":"Purchase Order Terms & Conditions (English)","status":"new"},"http://www.edurant.com/hcp/prescribing-information":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-reports-positive-48-week-results-for-second-phas/#ref","txt":"Prescribing Information","status":"new"},"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002264/WC500118874.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-/#ref","txt":"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002264/WC500118874.pdf","status":"new"},"http://dx.doi.org/10.1016/S0140-6736(17)31917-7":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-reports-positive-48-week-results-for-second-phas/#ref","txt":"http://dx.doi.org/10.1016/S0140-6736(17)31917-7","status":"new"},"https://clinicaltrials.gov/ct2/show/NCT02938520?term=FLAIR&cond=HIV&rank=2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-presenta-i-dati-relativi-a-tre-anni-di-trattamen/#bottom","txt":"https://clinicaltrials.gov/ct2/show/NCT02938520?term=FLAIR&cond=HIV&rank=2","status":"new"},"https://clinicaltrials.gov/ct2/show/NCT02951052?term=ATLAS&cond=HIV&rank=3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-presenta-i-dati-relativi-a-tre-anni-di-trattamen/#bottom","txt":"https://clinicaltrials.gov/ct2/show/NCT02951052?term=ATLAS&cond=HIV&rank=3","status":"new"},"https://clinicaltrials.gov/ct2/show/NCT03299049?term=ATLAS-2M&rank=1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-presenta-i-dati-relativi-a-tre-anni-di-trattamen/#bottom","txt":"https://clinicaltrials.gov/ct2/show/NCT03299049?term=ATLAS-2M&rank=1","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Tivicay/pdf/TIVICAY-PI-PIL.PDF":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen/#ref","txt":"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Tivicay/pdf/TIVICAY-PI-PIL.PDF","status":"new"},"https://www.medicines.org.uk/emc/medicine/28545":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen/#ref","txt":"https://www.medicines.org.uk/emc/medicine/28545","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Epivir/pdf/EPIVIR-PI-PIL.PDF":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-launches-eighth-phase-iii-study-in-two--drug-reg/#ref","txt":"See full prescribing information for EPIVIR.","status":"new"},"https://www.medicines.org.uk/emc/product/943":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen/#ref","txt":"https://www.medicines.org.uk/emc/product/943","status":"new"},"https://clinicaltrials.gov/ct2/show/NCT02938520":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-reports-positive-48-week-results-for-second-phas/#ref","txt":"https://clinicaltrials.gov/ct2/show/NCT02938520","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Triumeq/pdf/TRIUMEQ-PI-MG.PDF":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-reports-positive-48-week-results-for-second-phas/#ref","txt":"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Triumeq/pdf/TRIUMEQ-PI-MG.PDF","status":"new"},"https://urldefense.proofpoint.com/v2/url?u=http-3A__www.janssenlabels.com_package-2Dinsert_product-2Dmonograph_prescribing-2Dinformation_EDURANT-2Dpi.pdf&d=DwMGaQ&c=9wxE0DgWbPxd1HCzjwN8Eaww1--ViDajIU4RXCxgSXE&r=J7wB1SLKWKA1gpwYoceY-y3xkhr4mhsieeIqcp-JNNE&m=CdcV4p0HxpVK7G7c7n0NMFDiNuHcQWwWSxPxU7Cs5NY&s=FembPrhrNjB2_SBd-TjvfGRbCi1XGave-2E-ZpDPeqU&e=":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-reports-positive-48-week-results-for-second-phas/#ref","txt":"http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/EDURANT-pi.pdf","status":"new"},"https://urldefense.proofpoint.com/v2/url?u=http-3A__www.ema.europa.eu_docs_en-5FGB_document-5Flibrary_EPAR-5F-2D-5FProduct-5FInformation_human_002264_WC500118874.pdf&d=DwMGaQ&c=9wxE0DgWbPxd1HCzjwN8Eaww1--ViDajIU4RXCxgSXE&r=J7wB1SLKWKA1gpwYoceY-y3xkhr4mhsieeIqcp-JNNE&m=CdcV4p0HxpVK7G7c7n0NMFDiNuHcQWwWSxPxU7Cs5NY&s=ra-RAn76KyzkyqsvXvDnUqQ7cNiiQ4g-hm0yMY_AhM8&e=":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-reports-positive-48-week-results-for-second-phas/#ref","txt":"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002264/WC500118874.pdf","status":"new"},"http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(15)00152-8/abstract":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-reports-positive-48-week-results-for-second-phas/#ref","txt":"http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(15)00152-8/abstract","status":"new"},"https://clinicaltrials.gov/ct2/show/NCT02951052":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-reports-positive-48-week-results-for-first-pivot/#ref","txt":"https://clinicaltrials.gov/ct2/show/NCT02951052","status":"new"},"http://www.fda.gov/medwatch":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-phase-ii-study-results-for-first-two-d/#ref","txt":"www.fda.gov/medwatch","status":"new"},"https://clinicaltrials.gov/ct2/show/NCT02938520?term=FLAIR+Cabotegravir&rank=1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/iiv-healthcare-starts-third-phase-iii-hiv-treatment-study-invest/#ref","txt":"https://clinicaltrials.gov/ct2/show/NCT02938520?term=FLAIR+Cabotegravir&rank=1","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Juluca/pdf/JULUCA-PI-PIL.PDF":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-us-fda-approval-for-juluca/#ref","txt":"See full prescribing information for JULUCA.","status":"new"},"https://www.medicines.org.uk/emc/product/9246":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-/#ref","txt":"https://www.medicines.org.uk/emc/product/9246","status":"new"},"http://www.ema.europa.eu/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-/#ref","txt":"www.ema.europa.eu","status":"new"},"https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2018-PI-01956-1&d=2018062916114622483":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-/#ref","txt":"https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2018-PI-01956-1&d=2018062916114622483","status":"new"},"http://apps.who.int/iris/bitstream/10665/128494/1/9789241507585_eng.pdf?ua=1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-phase-ii-study-results-for-first-two-d/#ref","txt":"http://apps.who.int/iris/bitstream/10665/128494/1/9789241507585_eng.pdf?ua=1","status":"new"},"http://www.who.int/mediacentre/factsheets/fs360/en/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/how-we_re-addressing-the-challenges-of-the-hiv-epidemic-in-afric/#Bottom","txt":"http://www.who.int/mediacentre/factsheets/fs360/en/","status":"new"},"http://www.euro.who.int/en/health-topics/communicable-diseases/hivaids/data-and-statistics/infographic-newly-diagnosed-hiv-infections-in-the-who-european-region,-2016":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-sword-100-week-data-for-juluca-dolute/#ref","txt":"http://www.euro.who.int/en/health-topics/communicable-diseases/hivaids/data-and-statistics/infographic-newly-diagnosed-hiv-infections-in-the-who-european-region,-2016","status":"new"},"https://clinicaltrials.gov/ct2/show/NCT02429791?term=dolutegravir+AND+sword&cond=HIV&rank=3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-sword-100-week-data-for-juluca-dolute/#ref","txt":"https://clinicaltrials.gov/ct2/show/NCT02429791?term=dolutegravir+AND+sword&cond=HIV&rank=3","status":"new"},"https://clinicaltrials.gov/ct2/show/NCT02422797?term=dolutegravir+AND+sword&cond=HIV&rank=1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-sword-100-week-data-for-juluca-dolute/#ref","txt":"https://clinicaltrials.gov/ct2/show/NCT02422797?term=dolutegravir+AND+sword&cond=HIV&rank=1","status":"new"},"http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/EDURANT-pi.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-/#ref","txt":"http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/EDURANT-pi.pdf","status":"new"},"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/03/news_detail_002925.jsp&mid=WC0b01ac058004d5c1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/May/viiv-healthcare-reports-positive-results-for-landmark-phase-iii-studies-for-dolutegravir-and-lamivudine/#1","txt":"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/03/news_detail_002925.jsp&mid=WC0b01ac058004d5c1","status":"new"},"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002753/human_med_001720.jsp&mid=WC0b01ac058001d124":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/March/viiv-healthcare-gains-chmp-positive-opinion-for-juluca-dolutegravirrilpivirine-in-europe/#1","txt":"dolutegravir","status":"new"},"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002264/human_med_001513.jsp&mid=WC0b01ac058001d124":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2018/March/viiv-healthcare-gains-chmp-positive-opinion-for-juluca-dolutegravirrilpivirine-in-europe/#1","txt":"rilpivirine","status":"new"},"http://www.aidsinfo.nih.gov/guidelines":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-launches-eighth-phase-iii-study-in-two--drug-reg/#ref","txt":"www.aidsinfo.nih.gov/guidelines","status":"new"},"http://www.who.int/hiv/pub/arv/arv-2016/en/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-launches-eighth-phase-iii-study-in-two--drug-reg/#ref","txt":"http://www.who.int/hiv/pub/arv/arv-2016/en/","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/hiv-tb_infographic-final.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-at-hiv-glasgow/","txt":"iconographic  ","status":"new"},"https://clinicaltrials.gov/ct2/show/NCT03164564":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-start-of-phase-iii-study-of-long-actin/#ref","txt":"https://clinicaltrials.gov/ct2/show/NCT03164564","status":"new"},"https://urldefense.proofpoint.com/v2/url?u=http-3A__www.edurant.com_hcp_prescribing-2Dinformation&d=DwMGaQ&c=9wxE0DgWbPxd1HCzjwN8Eaww1--ViDajIU4RXCxgSXE&r=6h7hpGyedwkht0DbYj72ha0FbipMPvCfJ2tYVxtfyu3hbmWWImBMDtaktZb3rIGv&m=Be0LwqZk7DeQS6_NEyv1pnwV8U17q2l4V2edmx_Hl74&s=sqVu2UeMq3pM_kQ6so4LxrtWvjaysQiPInjJGSuApN4&e=":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/iiv-healthcare-starts-third-phase-iii-hiv-treatment-study-invest/#ref","txt":"Prescribing Information","status":"new"},"https://clinicaltrials.gov/ct2/show/NCT02951052?term=ATLAS+cabotegravir&rank=1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/iiv-healthcare-starts-third-phase-iii-hiv-treatment-study-invest/#ref","txt":"https://clinicaltrials.gov/ct2/show/NCT02951052?term=ATLAS+cabotegravir&rank=1","status":"new"},"https://www.rosminzdrav.ru/news/2017/05/16/5440-informatsiya-minzdrava-rossii-otnositelno-sluchaev-vich-v-rossii-po-itogam-2016-goda":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/tivicay-and-celsentri-now-included-in-the-essential-drug-list-in-russia/#ref","txt":"https://www.rosminzdrav.ru/news/2017/05/16/5440-informatsiya-minzdrava-rossii-otnositelno-sluchaev-vich-v-rossii-po-itogam-2016-goda","status":"new"},"http://www.who.int/mediacentre/factsheets/fs317/en/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/July/viiv-healthcare-and-neat-id-announce-results-from-the-neat-022-study-at-the-international-aids-society-meeting-in-paris/#Bottom","txt":"http://www.who.int/mediacentre/factsheets/fs317/en/","status":"new"},"http://www.edurant.com/shared/prescribing-information-edurant.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/July/phase-ii-study-results-showed-comparable-viral-suppression-rates-at-96-weeks-for-a-two-drug-regimen/#Bottom","txt":"Product Information","status":"new"},"https://we.tl/LFu1QKB6OY":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/press-releases/2017/viiv-healthcare-ranks-1-in-patientview-corporate-reputation-surv/","txt":"Cliquez ici pour accéder au communiqué de presse complet de PatientView (en anglais). ","status":"new"},"http://www.medicines.org.uk/emc/medicine/28545":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/December/viiv-healthcare-announces-chmp-positive-opinion-to-lower-the-age-and-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv-in-europe/#ref","txt":"here","status":"new"},"http://www.btconferencing.com/globalaccess/?bid=54_attended":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2017/February/viiv-healthcare-announces-detailed-positive-phase-iii-results-for-investigational-two-drug-regimen-of-dolutegravir-and-rilpivirine-for-hiv-treatment/","txt":"http://www.btconferencing.com/globalaccess/?bid=54_attended","status":"new"},"http://siteresources.worldbank.org/INTHIVAIDS/Resources/375798-1103037153392/MSMReport.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/October/viiv-healthcare-awards-23-small-grants-to-help-alleviate-the-stigma-of-hiv-and-aids-in-the-msm-and-transgender-community-globally/#ref","txt":"http://siteresources.worldbank.org/INTHIVAIDS/Resources/375798-1103037153392/MSMReport.pdf","status":"new"},"http://www.hptn.org/research/studies/176":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/December/viiv-healthcare-announces-start-of-phase-iii-study-evaluating-long-acting-cabotegravir-for-hiv-prevention/#ref","txt":"www.hptn.org/research/studies/176","status":"new"},"http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/002753/WC500218158.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/December/viiv-healthcare-announces-chmp-positive-opinion-to-lower-the-age-and-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv-in-europe/#ref","txt":"http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/002753/WC500218158.pdf","status":"new"},"http://impaactnetwork.org/studies/P1093.asp":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/June/viiv-healthcare-announces-fda-approval-to-lower-the-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv/#ref","txt":"http://impaactnetwork.org/studies/P1093.asp","status":"new"},"https://translate.google.co.uk/translate?hl=en&sl=auto&tl=en&u=http%3A%2F%2Fportalsaude.saude.gov.br%2Findex.php%2Fcidadao%2Fprincipal%2Fagencia-saude%2F25857-saude-oferecera-melhor-tratamento-do-mundo-para-hiv-aids":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/December/new-agreement-with-ministry-of-health-will-enable-access-to-dolutegravir-for-the-treatment-of-hiv-under-the-national-health-programme-in-brazil/#+44%20(0)%2020%208047%203763","txt":"https://translate.google.co.uk/translate?hl=en&sl=auto&tl=en&u=http%3A%2F%2Fportalsaude.saude.gov.br%2Findex.php%2Fcidadao%2Fprincipal%2Fagencia-saude%2F25857-saude-oferecera-melhor-tratamento-do-mundo-para-hiv-aids","status":"new"},"http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/ageing-with-hiv/#1","txt":"http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf.","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Selzentry/pdf/SELZENTRY-PI-MG-IFU.PDF":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-fda-approval-of-selzentry-maraviroc/#ref","txt":"here","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Selzentry/pdf/SELZENTRY-PI-MG.PDF":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/October/viiv-healthcare-announces-fda-approval-of-selzentry-maraviroc-for-use-in-children-and-adolescents-living-with-hiv/#ref","txt":"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Selzentry/pdf/SELZENTRY-PI-MG.PDF","status":"new"},"http://www.cdc.gov/hiv/library/reports/surveillance/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-fda-approval-of-selzentry-maraviroc/#ref","txt":"http://www.cdc.gov/hiv/library/reports/surveillance/","status":"new"},"https://www.youtube.com/watch?v=U2kfgRl1M0w":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/October/viiv-healthcare-s-positive-action-europe-invites-applications-for-2017-grants-scheme/#+44%20(0)%2020%208047%203763","txt":"PAE Video","status":"new"},"http://www.unaids.org/sites/default/files/media_asset/MDG6Report_en.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/September/viiv-healthcare-welcomes-the-fda-s-tentative-approval-of-the-first-generic-dolutegravir-from-aurobindo-pharma/#ref","txt":"http://www.unaids.org/sites/default/files/media_asset/MDG6Report_en.pdf","status":"new"},"http://www.ayzh.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/September/every-woman-every-child-and-viiv-healthcare-announce-the-winner-of-empowering-girls-in-emergency-settings-challenge-prize/","txt":"Ayzh","status":"new"},"http://cohintl.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/September/every-woman-every-child-and-viiv-healthcare-announce-the-winner-of-empowering-girls-in-emergency-settings-challenge-prize/","txt":"Circle of Health International","status":"new"},"http://www.unaids.org/sites/default/files/media_asset/20151027_UNAIDS_PCB37_15_18_EN_rev1.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/July/aria-study-shows-superior-efficacy-of-triumeq-for-treatment-na%C3%AFve-women-living-with-hiv/#ref","txt":"http://www.unaids.org/sites/default/files/media_asset/20151027_UNAIDS_PCB37_15_18_EN_rev1.pdf","status":"new"},"http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/factsheet/2012/20120417_FS_adolescentsyoungpeoplehiv_en.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/July/aria-study-shows-superior-efficacy-of-triumeq-for-treatment-na%C3%AFve-women-living-with-hiv/#ref","txt":"http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/factsheet/2012/20120417_FS_adolescentsyoungpeoplehiv_en.pdf","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Triumeq/pdf/TRIUMEQ-PI-MG.PDF.":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/July/aria-study-shows-superior-efficacy-of-triumeq-for-treatment-na%C3%AFve-women-living-with-hiv/#ref","txt":"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Triumeq/pdf/TRIUMEQ-PI-MG.PDF.","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viivhc_penta-infographic-final-2.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/June/viiv-healthcare-joins-penta-foundation-in-search-for-strategies-to-achieve-remission-in-children-living-with-hiv/#ref","txt":"  ","status":"new"},"http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Global_Report_2013_en_1.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/June/viiv-healthcare-announces-fda-approval-to-lower-the-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv/#ref","txt":"http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Global_Report_2013_en_1.pdf","status":"new"},"http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/June/viiv-healthcare-announces-fda-approval-to-lower-the-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv/#ref","txt":"http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf","status":"new"},"http://www.who.int/gho/hiv/en/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/helping-botswana-treat-all-people-living-with-hiv/#references","txt":"http://www.who.int/gho/hiv/en/","status":"new"},"http://www.who.int/hiv/pub/arv/policy-brief-arv-2015/en/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/June/viiv-healthcare-announces-public-tender-agreement-with-botswana-ministry-of-health-for-dolutegravir/#+44%20(0)%2020%208047%203763","txt":"http://www.who.int/hiv/pub/arv/policy-brief-arv-2015/en/","status":"new"},"http://data.worldbank.org/income-level/LMC":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/June/viiv-healthcare-announces-public-tender-agreement-with-botswana-ministry-of-health-for-dolutegravir/#+44%20(0)%2020%208047%203763","txt":"http://data.worldbank.org/income-level/LMC","status":"new"},"http://www.iapac.org/fast-track-cities/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/accelerating-city-hiv-aids-responses-through-collaboration/#references","txt":"Fast-Track Cities","status":"new"},"http://www.unaids.org/en/resources/documents/2014/90-90-90":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/how-we_re-addressing-the-challenges-of-the-hiv-epidemic-in-afric/#Bottom","txt":"http://www.unaids.org/en/resources/documents/2014/90-90-90","status":"new"},"https://www.viivhealthcare.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/new-results-from-the-positive-perspectives-global-survey-provide/#ref","txt":"www.viivhealthcare.com","status":"new"},"http://www.iapac.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/May/viiv-healthcare-and-the-international-association-of-providers-of-aids-care-to-collaborate-on-fast-track-cities/#ref","txt":"www.iapac.org","status":"new"},"http://www.vodafone.com/content/index/about/foundation.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/April/global-partnership-launches-new-programme-with-goal-to-save-the-lives-of-thousands-of-children-affected-by-hiv-in-lesotho/#ref","txt":"http://www.vodafone.com/content/index/about/foundation.html","status":"new"},"http://www.vodacom.com/about-us/foundation/foundation-home":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/April/global-partnership-launches-new-programme-with-goal-to-save-the-lives-of-thousands-of-children-affected-by-hiv-in-lesotho/#ref","txt":"http://www.vodacom.com/about-us/foundation/foundation-home","status":"new"},"http://london.ejaf.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/April/global-partnership-launches-new-programme-with-goal-to-save-the-lives-of-thousands-of-children-affected-by-hiv-in-lesotho/#ref","txt":"london.ejaf.org","status":"new"},"http://www.vodafone.com/content/index/about/foundation/mobilising-maternal-health.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/April/global-partnership-launches-new-programme-with-goal-to-save-the-lives-of-thousands-of-children-affected-by-hiv-in-lesotho/#ref","txt":"http://www.vodafone.com/content/index/about/foundation/mobilising-maternal-health.html","status":"new"},"http://www.avert.org/professionals/hiv-around-world/sub-saharan-africa/lesotho":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/April/global-partnership-launches-new-programme-with-goal-to-save-the-lives-of-thousands-of-children-affected-by-hiv-in-lesotho/#ref","txt":"http://www.avert.org/professionals/hiv-around-world/sub-saharan-africa/lesotho","status":"new"},"http://www.unaids.org/en/regionscountries/countries/lesotho":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/April/global-partnership-launches-new-programme-with-goal-to-save-the-lives-of-thousands-of-children-affected-by-hiv-in-lesotho/#ref","txt":"http://www.unaids.org/en/regionscountries/countries/lesotho","status":"new"},"http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/April/global-partnership-launches-new-programme-with-goal-to-save-the-lives-of-thousands-of-children-affected-by-hiv-in-lesotho/#ref","txt":"http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/","status":"new"},"http://www.unaids.org/sites/default/files/country/documents/LSO_narrative_report_2015.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2016/April/global-partnership-launches-new-programme-with-goal-to-save-the-lives-of-thousands-of-children-affected-by-hiv-in-lesotho/#ref","txt":"http://www.unaids.org/sites/default/files/country/documents/LSO_narrative_report_2015.pdf","status":"new"},"http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf?ua=1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-first-phase-ii-hiv-prevention-study-re/#ref","txt":"http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf?ua=1","status":"new"},"http://apps.who.int/iris/bitstream/10665/198064/1/9789241509893_eng.pdf?ua=1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-first-phase-ii-hiv-prevention-study-re/#ref","txt":"http://apps.who.int/iris/bitstream/10665/198064/1/9789241509893_eng.pdf?ua=1","status":"new"},"http://aidsinfo.unaids.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-extends-medicines-patent-pool-licence-agreement/#ref","txt":"http://aidsinfo.unaids.org/","status":"new"},"http://www.unaids.org/en/regionscountries/countries/republicofmoldova":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-extends-medicines-patent-pool-licence-agreement/#ref","txt":"http://www.unaids.org/en/regionscountries/countries/republicofmoldova","status":"new"},"http://www.unaids.org/en/regionscountries/countries/armenia":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-extends-medicines-patent-pool-licence-agreement/#ref","txt":"http://www.unaids.org/en/regionscountries/countries/armenia","status":"new"},"http://www.unaids.org/en/regionscountries/countries/morocco":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-extends-medicines-patent-pool-licence-agreement/#ref","txt":"http://www.unaids.org/en/regionscountries/countries/morocco","status":"new"},"http://www.unaids.org/sites/default/files/country/documents/UKR_narrative_report_2015.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-extends-medicines-patent-pool-licence-agreement/#ref","txt":"http://www.unaids.org/sites/default/files/country/documents/UKR_narrative_report_2015.pdf","status":"new"},"http://www.who.int/hiv/topics/mtct/en/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/november/viiv-healthcare-announces-new-grants-in-support-of-ending-mother/","txt":"World Health Organisation’s prevention of mother to child transmission (PMTCT) Strategy","status":"new"},"http://www.unaids.org/believeitdoit/the-global-plan.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/november/viiv-healthcare-announces-new-grants-in-support-of-ending-mother/","txt":"UNAIDS' Global Plan","status":"new"},"http://www.unaids.org/sites/default/files/media_asset/JC2385_ProgressReportGlobalPlan_en_0.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/november/viiv-healthcare-announces-new-grants-in-support-of-ending-mother/","txt":"http://www.unaids.org/sites/default/files/media_asset/JC2385_ProgressReportGlobalPlan_en_0.pdf","status":"new"},"http://www.twitter.com/viivhc":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/viiv-healthcare--aids-2016/","txt":"@ViiVHC","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-healthcare-access-to-medicines-policy-final.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/November/viiv-healthcare-at-icasa-improving-access-to-hiv-treatment-and-care-for-people-everywhere/","txt":"https://www.viivhealthcare.com/media/112407/viiv-healthcare-access-to-medicines-policy-final.pdf","status":"new"},"http://www.aboundingprosperity.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-for-youth/#ref","txt":"Abounding Prosperity","status":"new"},"http://www.friendsforlifecorp.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/November/viiv-healthcare-awards-additional-round-of-grants-to-support-innovative-hiv-programs-aimed-at-reducing-disparities-in-the-southern-us/#ref","txt":"Friends for Life","status":"new"},"http://jasmyn.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/November/viiv-healthcare-awards-additional-round-of-grants-to-support-innovative-hiv-programs-aimed-at-reducing-disparities-in-the-southern-us/#ref","txt":"Jacksonville Area Sexual Minority Youth Network, Inc. (JASMYN)","status":"new"},"http://www.nashvillecares.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/November/viiv-healthcare-awards-additional-round-of-grants-to-support-innovative-hiv-programs-aimed-at-reducing-disparities-in-the-southern-us/#ref","txt":"Nashville CARES","status":"new"},"http://www.raininc.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/November/viiv-healthcare-awards-additional-round-of-grants-to-support-innovative-hiv-programs-aimed-at-reducing-disparities-in-the-southern-us/#ref","txt":"RAIN, Inc.","status":"new"},"http://www.rwhp.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/November/viiv-healthcare-awards-additional-round-of-grants-to-support-innovative-hiv-programs-aimed-at-reducing-disparities-in-the-southern-us/#ref","txt":"Rural Women’s Health Project","status":"new"},"http://wellflorida.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/November/viiv-healthcare-awards-additional-round-of-grants-to-support-innovative-hiv-programs-aimed-at-reducing-disparities-in-the-southern-us/#ref","txt":"WellFlorida Council, Inc.","status":"new"},"http://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-vol-25.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/November/viiv-healthcare-awards-additional-round-of-grants-to-support-innovative-hiv-programs-aimed-at-reducing-disparities-in-the-southern-us/#ref","txt":"http://www.cdc.gov/hiv/pdf/g-l/hiv_surveillance_report_vol_25.pdf","status":"new"},"http://www.who.int/hiv/pub/toolkits/YoungPeople_Techical_Guidance_GlobalFundR10_May2010.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/March/viiv-healthcare-launches-new-global-positive-action-programme-focused-on-msm-and-transgender-populations/#ref","txt":"http://www.who.int/hiv/pub/toolkits/YoungPeople_Techical_Guidance_GlobalFundR10_May2010.pdf","status":"new"},"http://www.mmm-online.com/mmm-awards/industry-marketer-of-the-year-2015/article/440218/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/October/viiv-healthcare-employee-named-top-marketer-in-healthcare-industry-by-medical-marketing-media/","txt":"Medical Marketing & Media","status":"new"},"http://www.cdc.gov/nchhstp/newsroom/docs/factsheets/cdc-msm-508.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/June/viiv-healthcare-announces-new-positive-action-project-in-us-for-msm-youth-calls-for-proposals/#ref","txt":"http://www.cdc.gov/hiv/pdf/HIV-MSM-english-508.pdf","status":"new"},"http://www.clintonhealthaccess.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/december/mylans-tentative-fda-approval-for-paeds-formulations-of-abacavir/#ref","txt":"www.clintonhealthaccess.org","status":"new"},"http://www.aurobindo.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/May/press-release/","txt":"www.aurobindo.com","status":"new"},"http://www.unaids.org/sites/default/files/media_asset/2014unaidsguidancenote_stigma_en.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/#pae","txt":"http://www.unaids.org/sites/default/files/media_asset/2014unaidsguidancenote_stigma_en.pdf","status":"new"},"http://www.edurant.com/sites/default/files/EDURANT-PI.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/june/viiv-healthcare-announces-new-collaboration-with-janssen/#ref","txt":"http://www.edurant.com/sites/default/files/EDURANT-PI.pdf","status":"new"},"http://www.gsk.com/en-gb/media/press-releases/2014/viiv-healthcare-receives-eu-marketing-authorisation-for-triumeq-dolutegravirabacavirlamivudine-a-new-once-daily-single-pill-regimen-for-the-treatment-of-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/december/viiv-healthcare-announces-regulatory-submission-in-japan-for-sin/#ref","txt":"the European Commission (EC) granted marketing authorisation in September 2014","status":"new"},"http://api-net.jfap.or.jp/status/2013/13nenpo/h25gaiyo.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/december/viiv-healthcare-announces-regulatory-submission-in-japan-for-sin/#ref","txt":"http://api-net.jfap.or.jp/status/2013/13nenpo/h25gaiyo.pdf","status":"new"},"http://www.hivtestingweek.eu/about-testing-week":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/november/hiv-testing-week/","txt":"http://www.hivtestingweek.eu/about-testing-week","status":"new"},"https://www.viivhealthcare.com/media/press-releases/2013/february/viiv-healthcare-announces-a-voluntary-licence-agreement-with-the-medicines-patent-pool-to-increase-access-to-hiv-medicines-for-children.aspx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/november/gsk-ranked-top-of-the-2014-access-to-medicines-atm-index-for-the/#ref","txt":"/media/press-releases/2013/february/viiv-healthcare-announces-a-voluntary-licence-agreement-with-the-medicines-patent-pool-to-increase-access-to-hiv-medicines-for-children.aspx","status":"new"},"https://www.viivhealthcare.com/media/press-releases/2014/april/viiv-healthcare-announces-new-initiatives-to-improve-access-to-dolutegravir-licence-to-the-medicines-patent-pool.aspx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/november/gsk-ranked-top-of-the-2014-access-to-medicines-atm-index-for-the/#ref","txt":"/media/press-releases/2014/april/viiv-healthcare-announces-new-initiatives-to-improve-access-to-dolutegravir-licence-to-the-medicines-patent-pool.aspx","status":"new"},"https://www.gsk.com/en-gb/media/press-releases/2014/gsk-leads-access-to-medicine-index-2014/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/november/gsk-ranked-top-of-the-2014-access-to-medicines-atm-index-for-the/#ref","txt":"http://www.gsk.com/en-gb/media/press-releases/2014/gsk-leads-access-to-medicine-index-2014/","status":"new"},"http://www.cdc.gov/hiv/resources/factsheets/geographic.htm":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/february0/viiv-healthcare-expands-positive-action-southern-initiative-to-f/#ref","txt":"http://www.cdc.gov/hiv/resources/factsheets/geographic.htm","status":"new"},"http://www.cdc.gov/hiv/pdf/statistics_surveillance_raceEthnicity.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/march/viiv-healthcare-announces-next-round-of-the-positive-action-sout/#ref","txt":"http://www.cdc.gov/hiv/pdf/statistics_surveillance_raceEthnicity.pdf","status":"new"},"http://quickfacts.census.gov/qfd/states/13000.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/october/viiv-healthcare-expands-program-to-reduce-hiv-disparities-in-sou/#ref","txt":"http://quickfacts.census.gov/qfd/states/13000.html","status":"new"},"http://www.dhh.louisiana.gov/assets/oph/HIVSTD/hiv-aids/2014/Second_Quarter2014.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/october/viiv-healthcare-expands-program-to-reduce-hiv-disparities-in-sou/#ref","txt":"http://www.dhh.louisiana.gov/assets/oph/HIVSTD/hiv-aids/2014/Second_Quarter2014.pdf","status":"new"},"http://msdh.ms.gov/msdhsite/_static/resources/5714.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/march/viiv-healthcare-announces-next-round-of-the-positive-action-sout/#ref","txt":"http://msdh.ms.gov/msdhsite/_static/resources/5070.pdf ","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/TRIUMEQ-PI-MG.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/august/viiv-healthcare-receives-fda-approval-for-triumeq/#ref","txt":"Triumeq US label","status":"new"},"http://journals.lww.com/jaids/Abstract/publishahead/Bioequivalence_of_a_Dolutegravir,_Abacavir_and.97920.aspx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/august/viiv-healthcare-receives-fda-approval-for-triumeq/#ref","txt":"http://journals.lww.com/jaids/Abstract/publishahead/Bioequivalence_of_a_Dolutegravir,_Abacavir_and.97920.aspx.","status":"new"},"http://www.cdc.gov/hiv/basics/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/august/viiv-healthcare-receives-fda-approval-for-triumeq/#ref","txt":"http://www.cdc.gov/hiv/basics/","status":"new"},"http://www.nhs.uk/conditions/HIV/Pages/Introduction.aspx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/august/viiv-healthcare-receives-fda-approval-for-triumeq/#ref","txt":"http://www.nhs.uk/conditions/HIV/Pages/Introduction.aspx.","status":"new"},"http://www.cdc.gov/hiv/pdf/research_mmp_StagesofCare.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/august/viiv-healthcare-receives-fda-approval-for-triumeq/#ref","txt":"http://www.cdc.gov/hiv/pdf/research_mmp_StagesofCare.pdf. Accessed July 28","status":"new"},"http://www.medicines.org.uk/EMC/medicine/20386/SPC/Celsentri+150mg+film-coated+tablets/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/july/viiv-healthcare-presents-phase-iii-data-comparing-once-daily-mar/","txt":"https://www.medicines.org.uk/emc/product/6159)","status":"new"},"http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/december/viiv-healthcare-commits-34m-in-positive-action-for-children-fund/#ref","txt":"http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf","status":"new"},"http://www.who.int/hiv/pub/guidelines/arv2013/arvs2013upplement_march2014/en/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/april/viiv-healthcare-announces-new-initiatives-to-improve-access-to-d/#ref","txt":"http://www.who.int/hiv/pub/guidelines/arv2013/arvs2013upplement_march2014/en/.","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Final-2014-Positive-Action-Southern-Initiative-LOI-Overview.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/#tab-0732943346-5","txt":"Round 6 LOI Overview","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Final-2014-Positive-Action-Southern-Initiative-LOI-Application-.docx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/#tab-0732943346-5","txt":"Round 6 LOI Application","status":"new"},"http://www.adph.org/aids/assets/Finalized_2012HIVSurveillance.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/march/viiv-healthcare-announces-next-round-of-the-positive-action-sout/#ref","txt":"http://www.adph.org/aids/assets/Finalized_2012HIVSurveillance.pdf","status":"new"},"https://dph.georgia.gov/sites/dph.georgia.gov/files/related_files/site_page/2011%20Georgia%20HIV%20AIDS%20Fact%20Sheet.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/march/viiv-healthcare-announces-next-round-of-the-positive-action-sout/#ref","txt":"https://dph.georgia.gov/sites/dph.georgia.gov/files/related_files/site_page/2011%20Georgia%20HIV%20AIDS%20Fact%20Sheet.pdf","status":"new"},"http://www.taepusa.org/Portals/0/Documents/Louisiana%20SHARP%20Report.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/march/viiv-healthcare-announces-next-round-of-the-positive-action-sout/#ref","txt":"http://www.taepusa.org/Portals/0/Documents/Louisiana%20SHARP%20Report.pdf","status":"new"},"http://www.clinicalstudydatarequest.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/january/viiv-healthcare-to-make-available-anonymised-patient-level-data-/","txt":"www.clinicalstudydatarequest.com","status":"new"},"http://www.viiv-clinicaltrialregister.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2014/january/viiv-healthcare-to-make-available-anonymised-patient-level-data-/","txt":"www.viiv-clinicaltrialregister.com","status":"new"},"http://www.who.int/hiv/topics/paediatric/en/index.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/december/viiv-healthcare-commits-34m-in-positive-action-for-children-fund/#ref","txt":"http://www.who.int/hiv/topics/paediatric/en/index.html","status":"new"},"http://www.clinicaltrials.gov/show/NCT01263015":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/october/viiv-healthcare-announces-us-regulatory-submission-for-a-single-/#ref","txt":"http://www.clinicaltrials.gov/show/NCT01263015","status":"new"},"http://clinicaltrials.gov/show/NCT01227824":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/october/viiv-healthcare-announces-us-regulatory-submission-for-a-single-/#ref","txt":"http://clinicaltrials.gov/show/NCT01227824","status":"new"},"http://clinicaltrials.gov/show/NCT01449929":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/october/viiv-healthcare-announces-us-regulatory-submission-for-a-single-/#ref","txt":"http://clinicaltrials.gov/show/NCT01449929","status":"new"},"http://clinicaltrials.gov/show/NCT01231516":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/october/viiv-healthcare-announces-us-regulatory-submission-for-a-single-/#ref","txt":"http://clinicaltrials.gov/show/NCT01231516","status":"new"},"http://clinicaltrials.gov/show/NCT01622790":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/october/viiv-healthcare-announces-us-regulatory-submission-for-a-single-/#ref","txt":"http://clinicaltrials.gov/show/NCT01622790","status":"new"},"http://clinicaltrials.gov/show/NCT01910402":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/october/viiv-healthcare-announces-us-regulatory-submission-for-a-single-/#ref","txt":"http://clinicaltrials.gov/show/NCT01910402","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Epzicom/pdf/EPZICOM-PI-MG.PDF":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/october/viiv-healthcare-announces-us-regulatory-submission-for-a-single-/#ref","txt":"https://www.viivhealthcare.com/media/70430/us_epzicom.pdf","status":"new"},"http://www.cdc.gov/hiv/resources/factsheets/us.htm":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/february0/viiv-healthcare-expands-positive-action-southern-initiative-to-f/#ref","txt":"http://www.cdc.gov/hiv/resources/factsheets/us.htm","status":"new"},"http://gis.cdc.gov/GRASP/NCHHSTPAtlas/main.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/february0/viiv-healthcare-expands-positive-action-southern-initiative-to-f/#ref","txt":"http://gis.cdc.gov/GRASP/NCHHSTPAtlas/main.html","status":"new"},"http://www.cdc.gov/hiv/topics/surveillance/basic.htm":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/february0/viiv-healthcare-expands-positive-action-southern-initiative-to-f/#ref","txt":"http://www.cdc.gov/hiv/topics/surveillance/basic.htm","status":"new"},"http://www.census.gov/prod/cen2010/briefs/c2010br-04.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/february0/viiv-healthcare-expands-positive-action-southern-initiative-to-f/#ref","txt":"http://www.census.gov/prod/cen2010/briefs/c2010br-04.pdf.","status":"new"},"http://www.unaids.org/believeitdoit/get-the-facts.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/November/viiv-healthcare-commits-nearly-4m-in-positive-action-for-children-fund-grants-for-programmes-focused-on-alleviating-burden-of-hiv-on-women-and-children/#ref","txt":"\"UNAIDS Fact Sheet.\" UNAIDS Believe It, Do It: Get the Facts. UNAIDS, 2009. Web. 3 Oct 2012.","status":"new"},"http://www.shionogi.co.jp/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/july/positive-phase-iib-data-on-investigational-once-daily-integrase-/","txt":"www.shionogi.co.jp","status":"new"},"https://www.cdc.gov/hiv/surveillance/resources/reports/2009report/pdf/table21.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/July/-viiv-healthcare-expands-support-for-hiv-prevention-and-educatio/#ref","txt":"Centers for Disease Control and Prevention. HIV Surveillance Report 2009, Table 21. 2011","status":"new"},"http://mylan.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/July/ViiV%20Healthcare%20Expands%20Commitment%20to%20Addressing%20Gaps%20in%20Paediatric%20HIV%20Research%20Care%20and%20Treatment/#ref","txt":"mylan.com","status":"new"},"https://www.viivhealthcare.com/?sc_lang=en":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/march/-regulatory-update-celsentriselzentry-maraviroc/","txt":"www.viivhealthcare.com","status":"new"},"http://www.cdc.gov/nchhstp/newsroom/docs/HIV-Infections-2006-2009.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/september/viiv-healthcare-reaffirms-commitment-to-us-regions-hardest-hit-b/#ref","txt":"http://www.cdc.gov/nchhstp/newsroom/docs/HIV-Infections-2006-2009.pdf","status":"new"},"http://www.kff.org/hivaids/upload/3029-12.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/september/viiv-healthcare-reaffirms-commitment-to-us-regions-hardest-hit-b/#ref","txt":"http://www.kff.org/hivaids/upload/3029-12.pdf","status":"new"},"http://www.cdc.gov/hiv/group/racialethnic/africanamericans/index.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/july/viiv-healthcare-announces-positive-action-us-southern-initiative/#ref","txt":"http://www.cdc.gov/hiv/group/racialethnic/africanamericans/index.html","status":"new"},"http://www.selzentry.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/march/-regulatory-update-celsentriselzentry-maraviroc/","txt":"www.selzentry.com","status":"new"},"http://www.pfizer.com/home/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/february/david-redfern-appointed-as-chairman-of-the-board-for-viiv-health/","txt":"www.pfizer.com","status":"new"},"http://www.vidadignamexico.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/february/positive-action-and-vida-digna-further-information/#ref","txt":"http://www.vidadignamexico.org/","status":"new"},"http://www.aidsalliance.org/about/our-donors":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/february/positive-action-and-vida-digna-further-information/#ref","txt":"http://www.aidsalliance.org/about/our-donors","status":"new"},"http://www.atlacatl.org.sv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2011/february/positive-action-and-vida-digna-further-information/#ref","txt":"http://www.atlacatl.org.sv/","status":"new"},"http://colectivosol.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vida-digna-life-with-dignity/#tab-01793913599-5","txt":"Colectivo Sol","status":"new"},"http://www.redtrasex.org.ar/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vida-digna-life-with-dignity/#tab-01793913599-5","txt":"Latin American Network of Sex Workers (RedTraSex)","status":"new"},"http://redlactrans.org.ar/site/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vida-digna-life-with-dignity/#tab-01793913599-5","txt":"Latin American Network of Transgender people (REDLACTRANS )","status":"new"},"http://www.nshpc.ucl.ac.uk/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/december/global-agenda-for-elimination-of-mother-to-child-transmission-of/","txt":"http://www.nshpc.ucl.ac.uk/","status":"new"},"http://www.aidsalliance.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vida-digna-life-with-dignity/#tab-01793913599-5","txt":"The International HIV/AIDS Alliance","status":"new"},"http://www.shionogi-inc.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/july/positive-phase-iib-data-on-investigational-once-daily-integrase-/","txt":"www.shionogi-inc.com","status":"new"},"http://www.welvista.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/october/ViiV%20Healthcare%20acts%20to%20improve%20access%20to%20HIV%20Medicines%20in%20United%20States%20for%20those%20most%20in%20need/#ref","txt":"www.welvista.org","status":"new"},"http://www.cdc.gov/washington/testimony/2010/t20100929.htm":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/october/ViiV%20Healthcare%20acts%20to%20improve%20access%20to%20HIV%20Medicines%20in%20United%20States%20for%20those%20most%20in%20need/#ref","txt":"http://www.cdc.gov/washington/testimony/2010/t20100929.htm","status":"new"},"http://www.kff.org/hivaids/upload/3029-10.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/september/viiv-healthcare-awards-southern-initiative-grants-to-reduce-hiv-/#ref","txt":"http://www.kff.org/hivaids/upload/3029-10.pdf","status":"new"},"http://data.worldbank.org/about/country-classifications":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/july/viiv-healthcare-announces-further-initiatives-to-improve-access-0/#ref","txt":"http://data.worldbank.org/about/country-classifications","status":"new"},"http://www.cdc.gov/hiv/hispanics/resources/factsheets/hispanic.htm":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/july/viiv-healthcare-announces-positive-action-us-southern-initiative/#ref","txt":"http://www.cdc.gov/hiv/hispanics/resources/factsheets/hispanic.htm","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/viiv-standard-terms-and-conditionspdf.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/contact-us/","txt":"Download a copy of our Standard Terms and Conditions","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/viiv-terms-and-conditions-of-purchase-240816.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/contact-us/","txt":"Download a copy of our Purchase Terms and Conditions","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/hcp-tov-report-010517-to-311017.xlsx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/transparency-reporting/","txt":"HCP Transfer of Value Report for the period 1/05/17 to 31/10/17","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/hcp-tov-report-011015-to-300416.xlsx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/transparency-reporting/","txt":"HCP Transfer of Value Report for the period 1/10/15 to 30/04/16","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/xxhcp-tov-010516-to-311016.xlsx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/transparency-reporting/","txt":"HCP Transfer of Value Report for the period 1/05/16 to 31/10/16","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/hcp-tov-report-011116-to-300417.xlsx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/transparency-reporting/","txt":"HCP Transfer of Value Report for the period 1/11/16 to 30/04/17","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/hcp-transactions-may_oct-17.xlsx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/transparency-reporting/","txt":"HCP Transfer of Value Report for the period of 1/05/17 to 31/10/17","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/hcp-tov-report-011117-to-300418.xlsx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/transparency-reporting/","txt":"HCP Transfer of Value Report for the period 1/11/17 to 30/04/18","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/third-party-sponsorship-report-011015-to-300416-final.xlsx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/transparency-reporting/","txt":"Third Party Sponsorship Report","status":"new"},"https://www.imaginamas.org/inicio/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/spanish-articles/conoce-a-los-protagonistas/#tab-0146898285-2","txt":"ImaginaMas ","status":"new"},"https://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Spain/original_pdfs/spanish-articles/sumate-a-conmenosesposiblemas/formulario-solicitud_08062018.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/spanish-articles/sumate-a-conmenosesposiblemas/","txt":"Descargar Formulario participación","status":"new"},"https://www.zincmapser.com/Jobs/JobView.aspx?Job.Id=877583":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-annuncia-i-risultati-positivi-di-fase-3-dello-st/","txt":"ITA/HIVP/0005/18","status":"new"},"https://www.zincmapser.com/Jobs/JobView.aspx?Job.Id=877594":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-presenta-i-risultati-positivi-a-48-settimane-del/#bottom","txt":"ITA/HIVP/0007/18","status":"new"},"https://youtu.be/2dExJhEjNPQ":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/contenuti-ita/il-nostro-essere-responsabili/","txt":"Sono Rosa, una vita tra carcere e HIV","status":"new"},"https://www.gsk.com/en-gb/about-us/policies-codes-and-standards/binding-corporate-rules/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/informativa-sulla-privacy/","txt":"il documento disponibile a questo link.","status":"new"},"https://www.gsk.it/cookie-policy/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/informativa-sulla-privacy/","txt":"Politica sui cookie","status":"new"},"https://www.gsk.com/en-gb/contact-us/worldwide/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/informativa-sulla-privacy/","txt":"Elenco dei contatti","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/France/Original_PDFs/bienvenue/541776_viiv_ins_infodigit_hsh_265x570-2508.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/lactualite-en-direct/","txt":"  déc. 04  \n       \n        \n       \n       \n       Infographie - HSH et Personnes Transgenres \n       Le programme Positive Action MSM and Transgender soutient les organisations qui agissent afin de réd... \n       ","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/France/Original_PDFs/bienvenue/529948_viiv_ins_infodigit_ado_265x795-2508.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/lactualite-en-direct/","txt":"  déc. 01  \n       \n        \n       \n       \n       Infographie - Impact du VIH sur les adolescents \n       Positive Action for adolescent à pour but d'aider à l’évaluation de l’impact de nouvelles interventi... \n       ","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/France/Original_PDFs/bienvenue/cp_informations-sur-la-perception-des-pvvih-_-nouveaux-resultats-de-l-enquete-mondiale-positive-perspectives.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/lactualite-en-direct/","txt":"  oct. 25  \n       \n        \n       \n       \n       Communiqué de presse 25/10/2017 \n       ViiV Healthcare présente les résultats de l’enquête mondiale Positive Perspectives qui apportent des... \n       ","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/France/Original_PDFs/bienvenue/cp_12012017.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/lactualite-en-direct/","txt":"  janv. 12  \n       \n        \n       \n       \n       Communiqué de Presse 12/01/2017 \n       Programme Positive Action Community Grants de ViiV Healthcare France : 100 000 € pour les premiers l... \n       ","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/France/Original_PDFs/bienvenue/cp_11012017.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/lactualite-en-direct/","txt":"  janv. 11  \n       \n        \n       \n       \n       Communiqué de presse 11/01/2017 \n       ViiV Healthcare verse des subventions pour les programmes de lutte contre le VIH gérés par et pour l... \n       ","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/France/Original_PDFs/bienvenue/cp_01122016.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/lactualite-en-direct/","txt":"  déc. 01  \n       \n        \n       \n       \n       Communiqué de presse 01/12/2016 \n       Paris lance le premier tableau de bord des villes participant à l'initiative Fast-Track Cities pour ... \n       ","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/France/Original_PDFs/bienvenue/infographies_iapac_viiv_franc-ais_0616.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/lactualite-en-direct/","txt":"  août 18  \n       \n        \n       \n       \n       Infographie IAPAC - ViiV Healthcare 18/08/2016 \n       16 villes engagées dans l'accélaration de la riposte contre le VIH (initiative ‘FAST-TRACK CITIES’).... \n       ","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/France/Original_PDFs/bienvenue/cp_29062016.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/lactualite-en-direct/","txt":"  juin 29  \n       \n        \n       \n       \n       Communiqué de presse 29/06/2016 \n       ViiV Healthcare s’associe à la fondation PENTA pour mettre au point des stratégies... \n       ","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/France/Original_PDFs/bienvenue/cp_03062016.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/lactualite-en-direct/","txt":"  juin 03  \n       \n        \n       \n       \n       Communiqué de presse 03/06/2016 \n       Le ministère de la santé du Botswana attribue à ViiV Healthcare un appel d'offres public portant sur... \n       ","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/France/Original_PDFs/bienvenue/cp_31052016.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/lactualite-en-direct/","txt":"  mai 31  \n       \n        \n       \n       \n       Communiqué de presse 31/05/2016 \n       ViiV Healthcare et l'Association internationale des prestataires de santé spécialisés dans le SIDA (...    \n       ","status":"new"},"https://www.sidaventure.re/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/#tab-01425121435-2","txt":"SID’AVENTURE","status":"new"},"http://www.sidaccueil.fr/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/#tab-01425121435-2","txt":"SID’ACCUEIL","status":"new"},"https://assonouvelleaube.wordpress.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/#tab-01425121435-2","txt":"NOUVELLE AUBE","status":"new"},"http://afrisante.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/#tab-01425121435-2","txt":"AFRISANTE","status":"new"},"http://www.ikambere.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/#tab-01425121435-2","txt":"IKAMBERE","status":"new"},"http://www.assamede.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/#tab-01425121435-2","txt":"ASSAMEDE","status":"new"},"https://www.youtube.com/channel/UCk2SxuZwTQswx6d1SZlj0hA/videos":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/#tab-01425121435-2","txt":"ici","status":"new"},"http://www.hf-prevention.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/#tab-01425121435-2","txt":"http://www.hf-prevention.com/","status":"new"},"http://www.unaids.org/fr/resources/documents/2014/90-90-90":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/#tab-01425121435-2","txt":"http://www.unaids.org/fr/resources/documents/2014/90-90-90","status":"new"},"https://fr.viivexchange.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/#tab-01425121435-2","txt":"ici.","status":"new"},"https://www.youtube.com/channel/UCVQ22WvF8uBYZiR-xu16gYg":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/#tab-01425121435-2","txt":"ici","status":"new"},"http://www.unaids.org/en/resources/campaigns/2014/2014gapreport/factsheet/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/mieux-nous-connaitre/#tab-0544765655-5","txt":"http://www.unaids.org/en/resources/campaigns/2014/2014gapreport/factsheet/","status":"new"},"http://data.unicef.org/hiv-aids/emtct.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/mieux-nous-connaitre/#tab-0544765655-5","txt":"http://data.unicef.org/hiv-aids/emtct.html","status":"new"},"http://www.unaids.org/sites/default/files/media_asset/09_ChildrenandpregnantwomenlivingwithHIV.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/mieux-nous-connaitre/#tab-0544765655-5","txt":"http://www.unaids.org/sites/default/files/media_asset/09_ChildrenandpregnantwomenlivingwithHIV.pdf","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/France/Original_PDFs/bienvenue/charte_vm_signee_15_10_2014.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/politique-qualite-en-matiere-dinformation-promotionnelle/","txt":"Charte de l’information par démarchage ou prospection visant à la promotion des médicaments","status":"new"},"http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=62094362":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/","txt":"CELSENTRI 150 mg","status":"new"},"http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=61182724":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/","txt":"CELSENTRI 300 mg","status":"new"},"http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=65521773":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/","txt":"COMBIVIR 150 mg/300 mg","status":"new"},"http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=62715513":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/","txt":"EPIVIR 150 mg","status":"new"},"http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=64777862":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/","txt":"EPIVIR 300 mg","status":"new"},"http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=68036070":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/","txt":"EPIVIR 10 mg/ml","status":"new"},"http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=69855489":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/","txt":"KIVEXA 600 mg/300 mg","status":"new"},"http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=69290545":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/","txt":"RETROVIR 100 mg","status":"new"},"http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=63894243":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/","txt":"RETROVIR 250 mg","status":"new"},"http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=60524598":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/","txt":"RETROVIR 100 mg/10 ml","status":"new"},"http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=60132743":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/","txt":"RETROVIR 10 mg/ml","status":"new"},"http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=61312477":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/","txt":"TELZIR 700 mg","status":"new"},"http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=63544054":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/","txt":"TELZIR 50 mg/ml","status":"new"},"http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=62685155":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/","txt":"TIVICAY 50 mg","status":"new"},"http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=64287253":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/","txt":"TRIUMEQ 50 mg/600 mg/300 mg","status":"new"},"http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=64976070":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/","txt":"TRIZIVIR 300 mg/150 mg/300 mg","status":"new"},"http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=68556562":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/","txt":"ZIAGEN 300 mg","status":"new"},"http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=62070450":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/","txt":"ZIAGEN 20 mg/ml","status":"new"},"http://www.unaids.org/sites/default/files/media_asset/90-90-90_fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/france-articles/viiv-healthcare-en-france/","txt":"http://www.unaids.org/sites/default/files/media_asset/90-90-90_fr.pdf","status":"new"},"https://ec.europa.eu/info/strategy/justice-and-fundamental-rights/data-protection/data-transfers-outside-eu/model-contracts-transfer-personal-data-third-countries_en":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles/#n6","txt":"ici","status":"new"},"http://www.aboutcookies.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/cookie-policy/","txt":"www.aboutcookies.org","status":"new"},"https://www.research-on-stage.de/video-detail.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/","txt":"https://www.research-on-stage.de/video-detail.html","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Germany/Original_PDFs/viiv-foerderpreis/2018_viiv_formular_foerderpreis_interaktiv.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/viiv-foerderpreis/","txt":"Jetzt herunterladen","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Germany/Original_PDFs/aktuelles/2018/2018-07-19-sam-pressemitteilung.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/test-auf-hiv-und-geschlechtskrankheiten-per-post/","txt":"in der offiziellen Pressemitteilung","status":"new"},"http://www.hiv-kontrovers.de/hivkontrovers/front_content.php":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"HIV Kontrovers","status":"new"},"http://www.virology-education.com/event/upcoming/international-workshop-hiv-women":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"HIV & Women 2018","status":"new"},"http://www.croiconference.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"CROI","status":"new"},"http://www.virology-meeting.de/registration-abstracts/registration/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"27th Annual Meeting of the Society for Virology (GfV)","status":"new"},"http://www.aids-tage.de/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"Münchner AIDS- und Hepatitis-Tage","status":"new"},"https://www.aidshilfe.de/event/bundesweites-treffen-hiv-positive-heterosexuelle-frauen-maenner-1-treffen":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"Bundesweites Treffen für HIV-positive heterosexuelle Frauen und Männer – 1. Treffen","status":"new"},"https://www.aidshilfe.de/event/themenwerkstatt-bilder-hiv-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"Themenwerkstatt „Bilder von HIV“","status":"new"},"https://www.aidshilfe.de/event/bundesweites-treffen-hiv-positiver-aidskranker-frauen-1-treffen-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"Bundesweites Treffen HIV-positiver und aidskranker Frauen – 1. Treffen","status":"new"},"https://www.aidshilfe.de/event/themenwerkstatt-reha-kommen-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"Themenwerkstatt „Reha, wir kommen!“","status":"new"},"http://www.virology-education.com/event/upcoming/14th-co-infection-workshop-2018/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"Co-Infection Workshop 2018","status":"new"},"https://www.aidshilfe.de/event/netzwerk-frauen-aids-1-treffen-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"Netzwerk Frauen und Aids – 1. Treffen","status":"new"},"https://www.waset.org/conference/2018/05/london/ICHA/home":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"ICHA 2018: 20th International Conference on HIV and AIDS","status":"new"},"http://www.virology-education.com/event/upcoming/16th-european-hiv-hepatitis-workshop-2018/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"European Meeting on HIV & Hepatitis","status":"new"},"https://www.asm.org/index.php/asm-microbe-2018":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"ASM Microbe (ICAAC)","status":"new"},"https://www.aidshilfe.de/event/bundesweites-positiventreffen-1-termin":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"Bundesweites Positiventreffen – 4. Termin","status":"new"},"http://www.kit2018.de/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"KIT 2018","status":"new"},"https://www.aidshilfe.de/event/bundesweites-positiventreffen-3-termin":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"Bundesweites Positiventreffen – 3. Termin","status":"new"},"https://www.aidshilfe.de/event/bundesweites-treffen-hiv-positive-heterosexuelle-frauen-maenner-2-treffen":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"Bundesweites Treffen für HIV-positive heterosexuelle Frauen und Männer – 2. Treffen","status":"new"},"https://www.aidshilfe.de/event/bundesweites-positiventreffen-2-termin":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"Bundesweites Positiventreffen – 2. Termin","status":"new"},"http://www.virology-education.com/event/upcoming/10th-workshop-hiv-pediatrics/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"International Workshop on HIV Pediatrics","status":"new"},"http://www.aids2018.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"AIDS 2018","status":"new"},"https://www.aidshilfe.de/event/bundesweites-treffen-hiv-positive-migrantinnen-kinder-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"Bundesweites Treffen für HIV-positive Migrant/innen und ihre Kinder","status":"new"},"https://www.aidshilfe.de/event/bundesweites-treffen-hiv-positiver-aidskranker-frauen-2-treffen-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"Bundesweites Treffen HIV-positiver und aidskranker Frauen – 2. Treffen","status":"new"},"https://www.aidshilfe.de/event/positive-begegnungen-konferenz-leben-hiv-0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"Positive Begegnungen – Konferenz zum Leben mit HIV","status":"new"},"https://www.dagnae.de/fortbildung-2/workshops-2/workshop-jahresversammlung/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"dagnä-Workshop","status":"new"},"http://www.hivhealthyliving.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"3rd European Healthy Living with HIV","status":"new"},"https://www.aidshilfe.de/event/netzwerk-frauen-aids-2-treffen-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"Netzwerk Frauen und Aids – 2. Treffen","status":"new"},"http://www.virology-education.com/event/upcoming/9th-international-workshop-hiv-aging-2018/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"9th International Workshop on HIV and Aging","status":"new"},"https://www.aidshilfe.de/event/bundesweites-positiventreffen-4-termin":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"Bundesweites Positiventreffen – 4. Termin","status":"new"},"http://www.idweek.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"Jahreskongress der Infectious Diseases Society of America (IDSA) (ID-Week)","status":"new"},"https://www.aidshilfe.de/event/your-buddy-zweiteilig-teil-1-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"I'm your Buddy – 1. Teil (zweiteiliges Seminar)","status":"new"},"https://www.aidshilfe.de/events?f-qc=&f-date=All&f-reg=All&f-type=All&f-target=38&page=2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"Bundesweites Treffen für HIV-positive heterosexuelle Frauen und Männer – 3. Treffen","status":"new"},"http://hivglasgow.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"HIV Drug Therapy","status":"new"},"https://www.aidshilfe.de/event/bundesweites-treffen-hiv-positiver-aidskranker-frauen-3-treffen-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"Bundesweites Treffen HIV-positiver und aidskranker Frauen – 3. Treffen","status":"new"},"https://www.aidshilfe.de/event/your-buddy-zweiteilig-teil-2-3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"I'm your Buddy – 1. Teil (zweiteiliges Seminar)","status":"new"},"https://www.aidshilfe.de/event/bundesweites-positiventreffen-5-termin":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"Bundesweites Positiventreffen – 5. Termin (Thema: Gesund, gesünder, gesündigt!)","status":"new"},"http://www.dzif-annual-meeting2018.de/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"Gemeinsame Jahrestagung DGI DZIF","status":"new"},"http://www.infektiologie-update.de/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"11. Deutsches Infektiologie-Update 2018","status":"new"},"http://www.doeak2019.de/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"Deutsch-Österreichischer AIDS-Kongress","status":"new"},"http://www.eacs-conference2019.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/kalender/","txt":"EACS","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Germany/Original_PDFs/viiv-foerderpreis/rote-hand-brief-dolutegravir.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/rote-hand-brief-zu-dolutegravir/","txt":"hier ebenfalls als PDF herunterladen","status":"new"},"http://createsend.com/t/j-69D27C8C6BE569452540EF23F30FEDED":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/viiv-ist-1-im-patientview-report/","txt":"Ergebnisbericht von PatientView","status":"new"},"https://pacf.secure.force.com/PAEGrantApplication":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/artikel/positive-action/","txt":"zum Bewerbungsformular","status":"new"},"http://www.adobe.com/de/privacy/opt-out.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/#9","txt":"http://www.adobe.com/de/privacy/opt-out.html","status":"new"},"https://de-de.facebook.com/help/568137493302217":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/#9","txt":"https://de-de.facebook.com/help/568137493302217","status":"new"},"http://tools.google.com/dlpage/gaoptout?hl=de":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/#9","txt":"http://tools.google.com/dlpage/gaoptout?hl=de","status":"new"},"http://www.google.com/settings/ads":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/#9","txt":"http://www.google.com/settings/ads","status":"new"},"http://careers.peopleclick.com/careerscp/client_gsk/external1931/en/search.do":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/contact-us/#1-905-819-3363","txt":"Postes vacants","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/community-grants-en.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/#3","txt":"Read the Community Grants Brochure","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/viiv_healthcare_canada_grants__charitable_contributions_2011en_fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/#3","txt":"2011","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/viiv_healthcare_canada_grants__charitable_contributions_2012en_fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/#3","txt":"2012","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/viiv_healthcare_canada_grants__charitable_contributions_2013en_fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/#3","txt":"2013","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/viiv_healthcare_canada_grants__charitable_contributions_2014_en_fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/#3","txt":"2014","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/2015-viiv-healthcare-canada-community-grants.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/#3","txt":"2015","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/2016-viiv-healthcare-canada-community-grants.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/#3","txt":"2016","status":"new"},"http://viivhealthcare.smartsimple.ca/s_Login.jsp":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#1a","txt":"ici","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/2017-positive-action-canada-innovation-program-overview.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/#3","txt":"here","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/pacip_-_2008en_fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/#3","txt":"2008","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/pacip_-_2009en_fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/#3","txt":"2009","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/pacip_-_2010en_fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/#3","txt":"2010","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/pacip_-_2011en_fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/#3","txt":"2011","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/pacip_-_2012en_fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/#3","txt":"2012","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/pacip_-_2013en_fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/#3","txt":"2013","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/2015-positive-action-canada-innovation-program-results.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/#3","txt":"2015","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/2016-positive-action-canada-innovation-program-results-final.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/#3","txt":"2016","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/2017-positive-action-canada-indigenous-initiative-program-overview.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/#3","txt":"here","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/northern_initiative_grant_list_-_2013en_fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/#3","txt":"2013","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/positive-action-canada-aboriginal-initiative-2014-results-final-english-and-french.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/#3","txt":"2014","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/2015-positive-action-canada-aboriginal-initiative-results.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/#3","txt":"2015","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/2016-pac-indigenous-initiative-results-final.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/#3","txt":"2016","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/18211_viiv_en.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/tivicay/","txt":"June 5, 2018 - Important Safety Information on TIVICAY, TRIUMEQ and JULUCA","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/mwf-press-release.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"CAHR launches a program to support Canadian researchers","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/honouring-the-memory-of-dr-mark-wainberg_en.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"Honouring the memory of Dr Mark Wainberg","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/world-aids-day-2016-media-release-english-final.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"World AIDS Day: Is Complacency the new HIV crisis?","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/penta-infographic-veng.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"VIIV Healthcare / PENTA Collaboration on the EPIICAL Consortium","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/ewec-pacc-shr-prize_comms-veng.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"Launch of the Empowering Girls in Emergency Settings Challenge","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/veng-infography_final-version.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"IAPAC / ViiV Healthcare Collaboration in 16 Fast-Track Cities","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/proud-sponsors-of-cahr-2016.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"Proud Sponsor of CAHR 2016","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/asian-community-aids-services.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"5 Year Sponsorship by ViiV Healthcare to the Asian Community AIDS Services","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/20160513-viiv-healthcare-mpp-dtg-extension.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"Dolutegravir Medicine Patent Pool License extension","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/pihvot_grant_program.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"PHIVOT Grant Program","status":"new"},"https://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/viivhc_lesotho-partnership_press-release-final-approved.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"Global Partnership in Lesotho","status":"new"},"https://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/msmt-call-for-proposal_loc-email_may-2016-final.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"Positive Action for MSM & Transgender","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/saskatoon-site-corporate_eng.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"ViiV Healthcare’s Canadian team gives a helping hand!","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/international_womens_day.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"International Women's Day","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/media_release_tri_approval_in_canada_en.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/media/press-releases/2014/","txt":"(2014) ViiV Healthcare receives approval for Triumeq® (dolutegravir/abacavir/lamivudine), in Canada - a new once-daily single-pill regimen for the treatment of HIV (1)  ","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/tivicay_media_release_english.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/media/press-releases/2013/january/","txt":"(2013) ViiV Healthcare receives approval for Tivicay® (dolutegravir) in Canada for the treatment of HIV  ","status":"new"},"https://www.fugues.com/251957-article-max-ottawa-et-viiv-healthcare-lancent-la-campagne-innovante-spill-the-tea.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/press-releases/2018/","txt":"MAX Ottawa et ViiV Healthcare lancent la campagne innovante Spill the Tea  ","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/18211_viiv_fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/press-releases/2018/","txt":"Renseignements importants en matière d’innocuité au sujet de TIVICAY, TRIUMEQ et JULUCA  ","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/mwf-press-release-fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"l’ACRV lance un programme d’aide aux chercheurs canadiens","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/honouring-the-memory-of-dr-mark-wainberg_fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"À la mémoire du Dr Mark Wainberg","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/journee-mondiale-sida-2016-communique-de-presse-francais-final.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"Journée mondiale du sida: La baisse de vigilance : la nouvelle crise du VIH?","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/penta-infographic-vfr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"Collaboration entre ViiV Soins de santé et PENTA dans le cadre du consortium avec EPIICAL","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/ewec-pacc-shr-prize_comms_vfr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"Every Woman Every Child et Positive Action lancent le défi Empowering Girls in Emergency Settings","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/vfr-infography_final-version.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"Initiative conjointe de l’IAPAC et de ViiV Soins de Santé dans 16 villes qui s’engagent","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/proud-sponsors-of-cahr-2016-vfr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"Fier Commanditaire de l’ARCV 2016","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/20160513-viiv-healthcare-mpp-dtg-extension-fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"Extension de l’accord de brevet pour le dolutégravir","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/pihvot_grant_program_fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"PIHVOT Programme de Subventions","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/viivhc_lesotho-partnership_press-release-final-approved-2_vfr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"Partenariat Global au Lesotho","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/msmt_call_for_proposal_loc_email_may2016_final_vfr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"Positive Action pour les HARSAH & les Transgenres","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/saskatoon-site-corporate_fra.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"L’équipe canadienne de ViiV Soins de santé donne un coup de main","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/international-womens-day-fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"(2014) Laval – ViiV Soins de santé obtient l’homologation de Triumeq® (dolutégravir-abacavir-lamivudine), un nouveau schéma posologique à comprimé unique et à prise uniquotidienne pour le traitement de l’infection par le VIH au Canada","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/tivicay_media_release_french.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/press-releases/2013/january/","txt":"(2013) Mississauga – ViiV Soins de santé obtient l’homologation de TIVICAY® (dolutégravir) en comprimés dosés à 50 mg  ","status":"new"},"https://www.viivhealthcare.ca/media/197780/asian-community-aids-services.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/media/","txt":"5-year-sponsorship-by-viiv-healthcare-to-the-asian-community-aids-services","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/2018-pihvot-leave-behind-en.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/healthcare-professionals/independent-grants-and-support-programs/","txt":"here","status":"new"},"http://viivhealthcare.smartsimple.ca/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/healthcare-professionals/independent-grants-and-support-programs/","txt":"here","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/juluca.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/juluca/","txt":"/Monographie de Juluca","status":"new"},"http://www.w3.org/TR/WCAG20/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/accessibility/","txt":"version 2.0 des lignes directrices sur l'accessibilité des contenus Web établies dans le cadre de l'Initiative sur l'accessibilité du Web du World Wide Web Consortium (WCAG-WAI) (en anglais)","status":"new"},"http://www.happiapp.nl/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/happi-app/","txt":"www.happiapp.nl","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-healthcare-company_california-compliance-declaration-for-01-jul-2018.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/","txt":"California Compliance Declaration","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/2018-vh-compliance-program-us-operations_01-jul-2018.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/","txt":"California Compliance Disclosure","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/ch-en/patientenbroschu-re-de.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/latest-news/2018/june-1/hiv-knowledge-builds-trust/","txt":"German Brochure","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/ch-en/patientenbroschu-re-fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/latest-news/2018/june-1/hiv-knowledge-builds-trust/","txt":"French Brochure","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/ch-en/patientenbroschu-re-it.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/latest-news/2018/june-1/hiv-knowledge-builds-trust/","txt":"Italian Brochure","status":"new"},"https://en-gb.facebook.com/help/568137493302217":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ch/privacy-notice/#7","txt":"https://en-gb.facebook.com/help/568137493302217","status":"new"},"http://www.soteni.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-community-led-hiv-aids-prevention-project-kenya/#tab-206278409-5","txt":"SOTENI Kenya","status":"new"},"https://www.hiv.gov/federal-response/national-hiv-aids-strategy/nhas-update":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/standing-together/#ref","txt":"https://www.hiv.gov/federal-response/national-hiv-aids-strategy/nhas-update","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/viivhc-hiv-in-the-us-final-6172016.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/standing-together/#ref","txt":"Click to enlarge the infographic above.","status":"new"},"http://www.cdc.gov/nchhstp/newsroom/docs/factsheets/hiv-data-trends-fact-sheet-508.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/standing-together/#ref","txt":"http://www.cdc.gov/nchhstp/newsroom/docs/factsheets/hiv-data-trends-fact-sheet-508.pdf","status":"new"},"http://www.blackaids.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-community-grants/","txt":"  ","status":"new"},"http://www.aidschicago.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-awards--1-million-in-grants-for-positive-action-/","txt":"AIDS Foundation of Chicago","status":"new"},"http://www.chicagohouse.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-community-grants/","txt":"  ","status":"new"},"http://www.sisterlove.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-community-grants/","txt":"  ","status":"new"},"http://www.apla.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-community-grants/","txt":"  ","status":"new"},"http://www.irishouse.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-commitment-to-latinx-communities-living-with-hiv/","txt":"Iris House","status":"new"},"http://www.boomhealth.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-community-grants/","txt":"  ","status":"new"},"http://www.treatmentactiongroup.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-community-grants/","txt":"  ","status":"new"},"https://www.latinoaids.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-community-grants/","txt":"  ","status":"new"},"https://pwnusa.wordpress.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-community-grants/","txt":"  ","status":"new"},"http://www.projectinform.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-community-grants/","txt":"  ","status":"new"},"https://www.nastad.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-community-grants/","txt":"  ","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/viiv-healthcare-pacg-2018-rfp.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-community-grants/","txt":"here","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/vhc_pasi-infographic_final_digital_4618.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-southern-initiative/","txt":"click here","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/cdc-hiv-surveillance-report-2016-vol-28.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-southern-initiative/","txt":"HIV Surveillance Report 2016","status":"new"},"http://southernaids.files.wordpress.com/2011/10/hiv-aids-in-the-us-deep-south-trends-from-2008-2013.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-southern-initiative/","txt":"HIV/AIDS in the U.S. Deep South: Trends from 2008-2013","status":"new"},"https://www.cdc.gov/hiv/group/gender/women/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-southern-initiative/","txt":"HIV Among Women","status":"new"},"http://dukespace.lib.duke.edu/dspace/bitstream/handle/10161/13807/State%20of%20the%20Deep%20Southrevised%20online2.pdf?sequence=4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-southern-initiative/","txt":"State of HIV in the US Deep South","status":"new"},"http://www.treatmentactiongroup.org/press/ete-southern":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-southern-initiative/","txt":"Treatment Action Group","status":"new"},"https://www.cdc.gov/hiv/pdf/policies/cdc-hiv-in-the-south-issue-brief.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-southern-initiative/","txt":"HIV in the Southern United States","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/networks-of-care_final-web-version-reduced.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-awards--1-million-in-grants-for-positive-action-/","txt":"social dynamics and isolation","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/pafw-backgrounder-final.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-awards--1-million-in-grants-for-positive-action-/","txt":"Positive Action for Women (PAFW)","status":"new"},"http://www.csrwire.com/press_releases/40314-ViiV-Healthcare-Awards-1-Million-in-Grants-for-Positive-Action-for-Women-in-the-U-S-":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-for-women/","txt":"press release","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/grantee-spotlight-flyer.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-for-women/","txt":"grantee snapshot","status":"new"},"https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2015-vol-27.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-awards--1-million-in-grants-for-positive-action-/","txt":"https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc- \n        \n          hiv \n        -surveillance-report-2015-vol-27.pdf","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/youth-hiv-fact-sheet-final.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-for-youth/#ref","txt":"Click here","status":"new"},"http://www.advocatesforyouth.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-for-youth/#ref","txt":"Advocates for Youth","status":"new"},"http://aidsalabama.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-for-youth/#ref","txt":"AIDS Alabama","status":"new"},"http://www.centeronhalsted.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-for-youth/#ref","txt":"Center on Halsted","status":"new"},"http://naesm.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-for-youth/#ref","txt":"National AIDS Education and Services for Minorities","status":"new"},"https://www.carolinarain.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-for-youth/#ref","txt":"RAIN, Inc.","status":"new"},"http://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-21-4.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-for-youth/#ref","txt":"HIV Surveillance Supplemental Report 2016","status":"new"},"http://www.cdc.gov/hiv/risk/age/youth/index.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-for-youth/#ref","txt":"HIV Among Youth","status":"new"},"https://www.chcf.org/publication/building-peer-support-programs-to-manage-chronic-disease-seven-models-for-success/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-for-youth/#ref","txt":"Building Peer Support Programs to Manage Chronic Disease: Seven Models for Success","status":"new"},"http://www.nastad.org/sites/default/files/Guide-LGBTQ-for-Adult-Healthcare-Providers-05-2012.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-expands-u-s--commitment-to-youth-living-with-hiv/#ref","txt":"http://www.nastad.org/sites/default/files/Guide-LGBTQ-for-Adult-Healthcare-Providers-05-2012.pdf","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/accelerate-backgrounder.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/","txt":"ACCELERATE! Backgrounder","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/accelerate-research-fact-sheet.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/","txt":"“Meet Me Where I Want to Be” Ethnographic Research Study Fact Sheet","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/accelerate-baltimore-fact-sheet-2018.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/","txt":"Setting the Scene: Characteristics of the HIV Epidemic Among Black Gay and Bisexual Men in Baltimore","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/accelerate-jackson-fact-sheet-2018.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/","txt":"Setting the Scene: Characteristics of the HIV Epidemic Among Black Gay and Bisexual Men in Jackson","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/accelerate-empowerment-fact-sheet.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/","txt":"Activating Insights: Community Investments to Boost Empowerment and Strengthen Networks.","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/accelerate-sex-ed-fact-sheet.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/","txt":"Activating Insights: Community Investments to Make Sex Education Relevant","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/accelerate-testing-fact-sheet.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/","txt":"Activating Insights: Community Investments to Make Testing a Bridge to Prevention, Care, and Treatment","status":"new"},"http://gskvideo.edgesuite.net/viivhealthcare/DTG/Videos/US/mp4/ViiV_Accelerate_Legal_Edits_V2.mp4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/","txt":"video.","status":"new"},"http://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2014-vol-26.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/accelerate--initiative/","txt":"HIV Surveillance Report","status":"new"},"http://publichealth.jmir.org/article/downloadSuppFile/5684/34193":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/accelerate--initiative/","txt":"Multimedia Appendix of Rates of Prevalent HIV Infection, Prevalent Diagnoses \n        \n          and \n         New Diagnoses Among Men Who Have Sex with Men (MSM) in the United States,","status":"new"},"http://publichealth.jmir.org/2016/1/e22":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/accelerate--initiative/","txt":"Rates of Prevalent HIV Infection, Prevalent Diagnoses \n        \n          and \n         New Diagnoses Among Men Who Have Sex With Men (MSM) in the United States,","status":"new"},"http://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-21-1.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/accelerate--initiative/","txt":"HIV Surveillance Supplemental Report","status":"new"},"https://us.juluca.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-medicines/","txt":"Juluca®","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Juluca/pdf/JULUCA-PI-PIL.PDF#page=1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-medicines/","txt":"Prescribing Information","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Juluca/pdf/JULUCA-PI-PIL.PDF#page=31":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-medicines/","txt":"Patient Information","status":"new"},"https://us.triumeq.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-medicines/","txt":"Triumeq®","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Triumeq/pdf/TRIUMEQ-PI-MG.PDF#page=1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-medicines/","txt":"Prescribing Information, including BOXED WARNING","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Triumeq/pdf/TRIUMEQ-PI-MG.PDF#page=42":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-medicines/","txt":"Medication Guide","status":"new"},"https://us.tivicay.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-medicines/","txt":"Tivicay®","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Tivicay/pdf/TIVICAY-PI-PIL.PDF#page=1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-medicines/","txt":"Prescribing Information","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Tivicay/pdf/TIVICAY-PI-PIL.PDF#page=39":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-medicines/","txt":"Patient Information","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Selzentry/pdf/SELZENTRY-PI-MG-IFU.PDF#page=1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-medicines/","txt":"Prescribing Information, including BOXED WARNING","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Selzentry/pdf/SELZENTRY-PI-MG-IFU.PDF#page=42":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-medicines/","txt":"Medication Guide","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Ziagen/pdf/ZIAGEN-PI-MG.PDF#page=27":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-medicines/","txt":"Medication Guide","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Ziagen/pdf/ZIAGEN-PI-MG.PDF":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/ziagen/","txt":"Prescribing information and medication guide for Ziagen","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Trizivir/pdf/TRIZIVIR-PI-MG.PDF":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/trizivir/","txt":"Prescribing information and medication guide for Trizivir","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Trizivir/pdf/TRIZIVIR-PI-MG.PDF#page=34":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-medicines/","txt":"Medication Guide","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Combivir/pdf/COMBIVIR.PDF":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/combivir/","txt":"Prescribing information for Combivir","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Epivir/pdf/EPIVIR-PI-PIL.PDF#page=32":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-medicines/","txt":"Patient Information","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Retrovir/pdf/RETROVIR-PI.PDF":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/retrovir-azt/","txt":"Prescribing Information for Retrovir oral & injection","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Lexiva/pdf/LEXIVA-PI-PIL.PDF":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/lexiva-telzir/","txt":"Prescribing information for Lexiva","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Lexiva/pdf/LEXIVA-PI-PIL.PDF#page=53":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-medicines/","txt":"Patient Information","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/viracept-uspi-sept-2016.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-medicines/","txt":"Prescribing Information","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/viracept-patient-information-sept-2016.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-medicines/","txt":"Patient Information","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Rescriptor/pdf/RESCRIPTOR-PI-PIL.PDF":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/rescriptor/","txt":"Prescribing information for Rescriptor","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Rescriptor/pdf/RESCRIPTOR-PI-PIL.PDF#page=28":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-medicines/","txt":"Patient Information","status":"new"},"http://www.cvent.com/events/viiv-medical-education-hiv-aging/custom-22-ce535d9309cd45b39c94a43b34ccf76e.aspx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/educating-healthcare-professionals/","txt":"ViiV Healthcare Medical Education","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/amaic-fact-sheet-june-2017.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/","txt":"ACCELERATE! \"As Much as I Can\" fact sheet","status":"new"},"https://www.hivplusmag.com/stigma/2018/5/11/immersive-project-about-hiv-comes-nyc":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/","txt":"HIV Plus Magazine","status":"new"},"http://www.newnownext.com/lgbt-plays-off-broadway-nyc-theater/05/2018/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/","txt":"soul-stirring.","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/meet-me-where-i-want-to-be-report-final.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/","txt":"“Meet Me Where I Want to Be” Full Ethnographic Research Study","status":"new"},"https://urldefense.proofpoint.com/v2/url?u=http-3A__www.newnownext.com_lgbt-2Dplays-2Doff-2Dbroadway-2Dnyc-2Dtheater_05_2018_&d=DwMFAg&c=9wxE0DgWbPxd1HCzjwN8Eaww1--ViDajIU4RXCxgSXE&r=jKuTeve0INNCpu92lJCYckHau6lp5OB0eqbH2Pg3ssY&m=JntzrdhnpHf5jEosznhe-9BByBOZ3_dwNqRKKWYGC_E&s=21kxbKPY1KNtayoa5e5WfR6jRxOE4Jef0Pp9Sus7zIA&e=":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/","txt":"5 New Must-See Queer Plays In NYC","status":"new"},"https://urldefense.proofpoint.com/v2/url?u=https-3A__www.theroot.com_powerful-2Dimmersive-2Dplay-2Das-2Dmuch-2Das-2Di-2Dcan-2Dbrings-2Dvoices-2D1826023725&d=DwMFAg&c=9wxE0DgWbPxd1HCzjwN8Eaww1--ViDajIU4RXCxgSXE&r=jKuTeve0INNCpu92lJCYckHau6lp5OB0eqbH2Pg3ssY&m=JntzrdhnpHf5jEosznhe-9BByBOZ3_dwNqRKKWYGC_E&s=WT2QqsSRPqnWwuFLIbgALQRVVCXWjMYA_oWEQKZANSw&e=":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/","txt":"Powerful, Immersive Play As Much as I Can Brings Voices of Southern Gay Black Men and HIV/AIDS Awareness to Harlem","status":"new"},"https://urldefense.proofpoint.com/v2/url?u=https-3A__www.hivplusmag.com_stigma_2018_5_11_immersive-2Dproject-2Dabout-2Dhiv-2Dcomes-2Dnyc&d=DwMFAg&c=9wxE0DgWbPxd1HCzjwN8Eaww1--ViDajIU4RXCxgSXE&r=5VK8tbQzGP3ijz5oJvoxPdWvWQv_VKPksLwFzpGaRrc&m=0N_H0DN__F8bnGqyd0oBYii6v6TxG_e4lYK65iKZLzM&s=bTvBNF4UKPLGUgRNvrKk_BTS5tZ-W7lXT_BpVX0fLtY&e=":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/","txt":"Immersive Project About HIV Comes To NYC","status":"new"},"https://www.yesbroadway.com/archivefeed/asmuchasican":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/","txt":"As Much As I Can","status":"new"},"https://urldefense.proofpoint.com/v2/url?u=http-3A__swaysuniverse.com_hiv-2Daids-2Dawareness-2Dwith-2Demil-2Dwilbekin-2Dand-2Dmarc-2Dmeachem_&d=DwMFAg&c=9wxE0DgWbPxd1HCzjwN8Eaww1--ViDajIU4RXCxgSXE&r=5VK8tbQzGP3ijz5oJvoxPdWvWQv_VKPksLwFzpGaRrc&m=0N_H0DN__F8bnGqyd0oBYii6v6TxG_e4lYK65iKZLzM&s=7kFoe-NaSrJnO8C_xvDGZD4idX-gpk_H0_ad7_9tY-k&e=":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/","txt":"New Theatrical play, As Much As I Can discussing HIV/AIDS Awareness with Emil Wilbekin and Marc Meachem","status":"new"},"https://urldefense.proofpoint.com/v2/url?u=https-3A__www.poz.com_article_immersive-2Dtheater-2Dhiv-2Dgay-2Dblack-2Dmen-2Dreturns-2Dstage&d=DwMFAg&c=9wxE0DgWbPxd1HCzjwN8Eaww1--ViDajIU4RXCxgSXE&r=5VK8tbQzGP3ijz5oJvoxPdWvWQv_VKPksLwFzpGaRrc&m=0N_H0DN__F8bnGqyd0oBYii6v6TxG_e4lYK65iKZLzM&s=az_4i6XcL5uzLOv-s5y5ozSHTsOKWYejpGh-Xtts9gw&e=":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/","txt":"Immersive Theater About HIV and Gay Black Men Returns to the Stage","status":"new"},"https://urldefense.proofpoint.com/v2/url?u=http-3A__instinctmagazine.com_post_nyc-2Dtheatre-2Dgoers-2Dare-2Dexcited-2Dnew-2Dinteractive-2Dplay-2Dabout-2Dhiv-2Dblack-2Dgay-2Dcommunity_&d=DwMFAg&c=9wxE0DgWbPxd1HCzjwN8Eaww1--ViDajIU4RXCxgSXE&r=CobvSBKGqGmgB3t93oNM-xt5o9vBEpOeGFrzImOXKqs&m=uXxcme3ssxy1J0fz5TVzYLRI0qmMCzbBonKuXY--H4Y&s=aOf5eCRmuWZvVg_bE6uMdmq5DplW79trQdZy-3awchk&e=":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/","txt":"NYC Theatre Goers Are Excited For A New Interactive Play About HIV In the Black Gay Community","status":"new"},"https://urldefense.proofpoint.com/v2/url?u=https-3A__www.billboard.com_articles_news_pride_8454709_as-2Dmuch-2Das-2Di-2Dcan-2Dtheater-2Dnew-2Dyork-2Dhiv-2Dblack-2Dgay-2Dmen&d=DwMFAg&c=9wxE0DgWbPxd1HCzjwN8Eaww1--ViDajIU4RXCxgSXE&r=5VK8tbQzGP3ijz5oJvoxPdWvWQv_VKPksLwFzpGaRrc&m=0N_H0DN__F8bnGqyd0oBYii6v6TxG_e4lYK65iKZLzM&s=wVEKFa3lPExtz1RTZ4JzI8LIQuyrm3Gdlm4VyzvXNwE&e=":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/","txt":"'As Much As I Can' Immersive Theater Show Shines Light on HIV Gay Black Men","status":"new"},"https://urldefense.proofpoint.com/v2/url?u=https-3A__blavity.com_this-2Dinteractive-2Dnew-2Dplay-2Dexplores-2Dhivs-2Deffect-2Don-2Dgay-2Dblack-2Dmen&d=DwMFAg&c=9wxE0DgWbPxd1HCzjwN8Eaww1--ViDajIU4RXCxgSXE&r=5VK8tbQzGP3ijz5oJvoxPdWvWQv_VKPksLwFzpGaRrc&m=0N_H0DN__F8bnGqyd0oBYii6v6TxG_e4lYK65iKZLzM&s=RO2K2vSNJ1XOL9lwIjMslnXt72h6PJB0cQaIvSMJIRI&e=":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/","txt":"This Interactive New Play Explores HIV's Effect On Gay Black Men","status":"new"},"https://clinicaltrials.gov/ct2/show/NCT03299049":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/#ref","txt":"https://clinicaltrials.gov/ct2/show/NCT03299049","status":"new"},"https://clinicaltrials.gov/ct2/show/NCT02120352":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-presents-three-year-data-for-investigational-lon/#ref","txt":"https://clinicaltrials.gov/ct2/show/NCT02120352","status":"new"},"http://www.networkadvertising.org/choices/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/privacy-policy/","txt":"NAI website","status":"new"},"http://www.aboutads.info/choices/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/privacy-policy/","txt":"DAA website","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/US/general-conditions-of-sale-viiv-belgium-fr-nl-01-07-2012.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/terms-and-conditions/","txt":"Sales Terms & Conditions","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/US/general-conditions-of-purchase-viiv-belgium-fr-nl-01-07-2012.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/terms-and-conditions/","txt":"Purchase Order Terms & Conditions","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/US/cga-viiv-cerps-mai-2012-france.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/terms-and-conditions/","txt":"Purchase Order Terms & Conditions","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/US/aeb_viiv.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/terms-and-conditions/","txt":"Purchase Order Terms & Conditions","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/US/viiv-acquistobeniservizicondizionigenerali_italiano.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/terms-and-conditions/","txt":"Purchase Order Terms & Condition (Italian)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/US/viiv-general-terms-and-conditions-4.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/terms-and-conditions/","txt":"Purchase Order Terms & Condition (English)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/US/netherlands-algemene-inkoop-voorwaarden-01-10-2010.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/terms-and-conditions/","txt":"Purchase Order Terms & Conditions","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/US/singapore-terms-and-conditions.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/terms-and-conditions/","txt":"Purchase Order Terms & Condition (English)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/US/condiciones-pedido-espanol-viiv.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/terms-and-conditions/","txt":"Purchase Order Terms & Conditions (Spanish)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/US/condiciones-pedido-ingles-viiv.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/terms-and-conditions/","txt":"Purchase Order Terms & Conditions (English)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/juluca_pm-2018-08-27.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/juluca/","txt":"Product Monograph for Juluca/","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/juluca_pm-french-2018-08-27.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/juluca/","txt":"Monographie de Juluca","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/18211_viiv_en.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/tivicay/","txt":"Healthcare Professional Letter for Tivicay","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/18211_viiv_fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/tivicay/","txt":"Lettre aux professionnels de la santé sur Tivicay","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/tivicay-paed-wwrs-11oct2018-for-external-use.PDF":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/triumeq/","txt":"regulatory filings and registration of paediatric Tivicay","status":"new"},"https://www.viivexchange.com/routing":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-at-hiv-glasgow/","txt":"ViiV Exchange  ","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/triumeq_pm-2018-08-27.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/triumeq/","txt":"Product Monograph for Triumeq/","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/triumeq_french-pm-2018-08-27.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/triumeq/","txt":"Monographie de Triumeq","status":"new"},"http://www.medicines.org.uk/emc/medicine/29178":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/triumeq/","txt":"European Summary of Prescribing Information","status":"new"},"http://www.medicines.org.uk/emc/medicine/29174":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/triumeq/","txt":"European Patient Information Leaflet","status":"new"},"http://glaxosmithkline.co.jp/viiv/medical/medical.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/tivicay/","txt":"Information for Healthcare Professionals","status":"new"},"http://www.msds-gsk.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/lexiva-telzir/","txt":"Safety Data Sheet","status":"new"},"http://abacavirhsr.viivhealthcare.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/trizivir/","txt":"Abacavir HSR Support","status":"new"},"http://www.tivicay.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/tivicay/","txt":"please visit our promotional website.","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/tivicay_pm-2018-08-27.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/tivicay/","txt":"Product Monograph for Tivicay/","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/tivicay_french_pm-2018-08-27.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/tivicay/","txt":"Monographie de Tivicay","status":"new"},"http://www.medicines.org.uk/emc/medicine/28546":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/tivicay/","txt":"European Patient Information Leaflet","status":"new"},"https://maraviroc.viivhealthcare.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/selzentry-celsentri/","txt":"please visit our promotional website.","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/celsentri_pm-2018-05-02.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/selzentry-celsentri/","txt":"Product Monograph for Celsentri","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/celsentri-french_pm-2018-05-02.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/selzentry-celsentri/","txt":"Monographie de Celsentri","status":"new"},"https://www.medicines.org.uk/emc/product/6159/smpc":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/selzentry-celsentri/","txt":"Celsentri tablet summary of product characteristics","status":"new"},"https://www.medicines.org.uk/emc/product/6159/pil":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/selzentry-celsentri/","txt":"Celsentri 300mg & 150mg tablets Patient Information Leaflet (PIL)","status":"new"},"http://glaxosmithkline.co.jp/viiv/medical/index.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/lexiva-telzir/","txt":"Information for Healthcare Professionals","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/CELSENTRI-film-coated-tablets-EN.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/selzentry-celsentri/","txt":"Safety Data Sheet for Selzentry/Celsentri film-coated tablets","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/CELSENTRI-oral-solution-EN.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/selzentry-celsentri/","txt":"Safety Data Sheet for Selzentry/Celsentri oral solution","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/kivexa_pm-2018-01-15.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/epzicom-kivexa/","txt":"Product Monograph for Kivexa®/","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/kivexa-french_pm-2018-01-15.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/epzicom-kivexa/","txt":"Monographie de Kivexa®","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Healthcare-Professional-Letter-for-KivexaR-Kivexa_Trizivir_Ziagen_HCPL_18_June_2008.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/epzicom-kivexa/","txt":"Healthcare Professional Letter for Kivexa®","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Lettre-aux-professionnels-de-la-sante-sur-KivexaR-Kivexa_Trizivir_Ziagen_HCPL_18_June_2008_French.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/epzicom-kivexa/","txt":"Lettre aux professionnels de la santé sur Kivexa®","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Public-Advisory-on-KivexaR-Kivexa_Trizivir_Ziagen_PA_18_June_2008.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/epzicom-kivexa/","txt":"Public Advisory on Kivexa®","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Avis-public-sur-KivexaRKivexa_Trizivir_Ziagen_PA_18_June_2008_French.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/epzicom-kivexa/","txt":"Avis public sur Kivexa®","status":"new"},"http://www.medicines.org.uk/EMC/medicine/15707/SPC/Kivexa+film-coated+tablets/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/epzicom-kivexa/","txt":"Summary of Product Characteristics","status":"new"},"http://www.medicines.org.uk/emc/medicine/15628/PIL/Kivexa%20600mg/300mg%20Tablets/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/epzicom-kivexa/","txt":"Patient Information Leaflet","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/epzicomwarncard.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/epzicom-kivexa/","txt":"Epzicom warning card","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/3TC_Ziagen_HCPL_30_Sept_2003Canada.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/epivir-3tc/","txt":"Healthcare Professional Letter for 3TC","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/ziagen_pm-french-2018-07-23.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/ziagen/","txt":"Monographie de Ziagen","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/3TC_Ziagen_HCPL_30_Sept_2003_FrenchCanada.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/epivir-3tc/","txt":"Lettre aux professionnels de la santé sur 3TC","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Kivexa_Trizivir_Ziagen_HCPL_18_June_2008Canada.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/trizivir/","txt":"Healthcare Professional Letter for Trizivir®","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Kivexa_Trizivir_Ziagen_HCPL_18_June_2008_FrenchCanada.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/trizivir/","txt":"Lettre aux professionnels de la santé sur Trizivir®","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Kivexa_Trizivir_Ziagen_PA_18_June_2008Canada.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/trizivir/","txt":"Public Advisory on Trizivir®","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Kivexa_Trizivir_Ziagen_PA_18_June_2008_FrenchCanada.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/trizivir/","txt":"Avis public sur Trizivir®","status":"new"},"http://www.medicines.org.uk/EMC/medicine/2476/SPC/Ziagen+300+mg+Film+Coated+Tablets/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/ziagen/","txt":"Ziagen tablets summary of Product Characteristics","status":"new"},"http://www.medicines.org.uk/emc/medicine/4426/PIL/Ziagen+300+mg+Film+Coated+Tablets/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/ziagen/","txt":"Ziagen tablets Patient Information Leaflet","status":"new"},"http://www.medicines.org.uk/EMC/medicine/2475/SPC/Ziagen+20+mg+ml+Oral+Solution/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/ziagen/","txt":"Ziagen oral solution summary of Product Characteristics","status":"new"},"http://www.medicines.org.uk/emc/medicine/9001/PIL/Ziagen+20+mg+ml+Oral+Solution/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/ziagen/","txt":"Ziagen oral solution patient information leaflet","status":"new"},"https://www.gsksource.com/gskprm/htdocs/documents/ZIAGENWARNCARD.PDF":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/ziagen/","txt":"Ziagen warning card","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/trizivir_pm-2018-01-15.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/trizivir/","txt":"Product Monograph for Trizivir®","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/trizivir-french_pm-2018-07-31.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/trizivir/","txt":"Monographie de Trizivir®","status":"new"},"http://www.medicines.org.uk/EMC/medicine/4453/SPC/Trizivir+film-coated+tablets/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/trizivir/","txt":"Summary of Product Characteristics","status":"new"},"http://www.medicines.org.uk/emc/medicine/9200/PIL/Trizivir+film-coated+tablets/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/trizivir/","txt":"Patient Information Leaflet","status":"new"},"https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Trizivir/pdf/TRIZIVIRWARNCARD.PDF":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/trizivir/","txt":"Trizivir warning card for US residents","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/combivir_pm-2017-05-12.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/combivir/","txt":"Product Monograph for Combivir®","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/combivir-french_pm-2017-05-12.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/combivir/","txt":"Monographie de Combivir®","status":"new"},"http://www.medicines.org.uk/EMC/medicine/725/SPC/Combivir+Film+Coated+Tablets/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/combivir/","txt":"Summary of Product Characteristics for Combivir","status":"new"},"http://www.medicines.org.uk/emc/medicine/3857/PIL/Combivir+Film+Coated+Tablets/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/combivir/","txt":"Patient information leaflet for Combivir","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/3tc_pm-2017-05-12.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/epivir-3tc/","txt":"Product Monograph for 3TC/","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/3tc_french-pm-12-may-2017.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/epivir-3tc/","txt":"Monographie de 3TC","status":"new"},"https://www.medicines.org.uk/emc/product/943/pil":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/epivir-3tc/","txt":"Epivir 300mg tablets patient information leaflet","status":"new"},"http://www.medicines.org.uk/EMC/medicine/744/SPC/Epivir+150+mg+film-coated+tablets/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/epivir-3tc/","txt":"Epivir 150 mg tablets summary of product characteristics","status":"new"},"https://www.medicines.org.uk/emc/product/8048/pil":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/epivir-3tc/","txt":"Epivir 150mg tablets patient information leaflet","status":"new"},"http://www.medicines.org.uk/EMC/medicine/743/SPC/Epivir+Oral+Solution/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/epivir-3tc/","txt":"Epivir oral solution summary of product characteristics","status":"new"},"https://www.medicines.org.uk/emc/product/942/pil":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/epivir-3tc/","txt":"Epivir oral solution patient information leaflet","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/retrovir_pm-2018-07-19.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/retrovir-azt/","txt":"Product Monograph for Retrovir","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/retrovir-french_pm-2018-07-19.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/retrovir-azt/","txt":"Monographie de Retrovir","status":"new"},"http://www.medicines.org.uk/EMC/medicine/12444/SPC/Retrovir+250mg+Capsules/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/retrovir-azt/","txt":"Retrovir 250mg capsules summary of product characteristics","status":"new"},"https://www.medicines.org.uk/emc/product/2211/pil":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/retrovir-azt/","txt":"Retrovir 250mg capsules patient information leaflet","status":"new"},"http://www.medicines.org.uk/emc/medicine/3855/PIL/Retrovir10%20mg/ml%20IV%20for%20Infusion/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/retrovir-azt/","txt":"Retrovir IV for infusion patient information leaflet","status":"new"},"http://www.medicines.org.uk/EMC/medicine/10419/SPC/Retrovir+100+mg+10ml%2c+oral+solution/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/retrovir-azt/","txt":"Retrovir oral solution summary of product characteristics","status":"new"},"http://www.medicines.org.uk/emc/medicine/13678/PIL/Retrovir+100+mg+10ml%2c+oral+solution/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/retrovir-azt/","txt":"Retrovir oral solution patient information leaflet","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/telzir_pm-2017-11-23.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/lexiva-telzir/","txt":"Product Monograph for Telzir /","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/telzir-french_pm-2017-11-23.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/lexiva-telzir/","txt":"Monographie de Telzir","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Telzir_HCPL_17_July_2009-Canda.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/lexiva-telzir/","txt":"Healthcare Professional Letter for Telzir®","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Telzir_HCPL_17_July_2009_French-Canda.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/lexiva-telzir/","txt":"Lettre aux professionnels de la santé sur Telzir®","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Telzir_PA_17_July_2009-Canda.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/lexiva-telzir/","txt":"Public Advisory on Telzir®","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Telzir_PA_17_July_2009_French-Canada.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/lexiva-telzir/","txt":"Avis public sur Telzir","status":"new"},"http://www.medicines.org.uk/EMC/medicine/14819/SPC/Telzir+700+mg+film-coated+tablets/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/lexiva-telzir/","txt":"Telzir 700mg tablets summary of product characteristics","status":"new"},"https://www.medicines.org.uk/emc/product/5555/pil":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/lexiva-telzir/","txt":"Telzir 700mg tablets patient information leaflet","status":"new"},"http://www.medicines.org.uk/EMC/medicine/14818/SPC/Telzir+Oral+Suspension/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/lexiva-telzir/","txt":"Telzir oral suspension summary of product characteristics","status":"new"},"http://www.medicines.org.uk/emc/medicine/15419/PIL/Telzir%20Oral%20Suspension%2050mg/ml/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/lexiva-telzir/","txt":"Telzir oral suspension patient information leaflet","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viracept-uspi-sept-2016.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/viracept/","txt":"Prescribing information for Viracept","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viracept-patient-information-sept-2016.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/viracept/","txt":"Patient Product Information for Viracept","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Viracept-oral-powde-EN-Safety-Data-Sheet.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/viracept/","txt":"Safety Data Sheet for Viracept oral powder","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Viracept-Tablets-ENSafety-Data-Sheet.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/viracept/","txt":"Safety Data Sheet for Viracept tablets","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Rescriptor-MktPM-20130305Canada.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/rescriptor/","txt":"Product Monograph for Rescriptor","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Rescriptorfrench-MktPM-20130305Canada.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/rescriptor/","txt":"Monographie de Rescriptor","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Rescriptor-tablets-ENSafety-Data-Sheet.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-medicines/rescriptor/","txt":"Safety Data Sheet for Rescriptor tablets","status":"new"},"http://vimeo.com/69072969":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/hiv-treatment-and-care/european-network-of-young-hiv-experts/","txt":"Watch the highlights from the European Network of Young HIV Experts in Paris in 2012","status":"new"},"https://www.enyhe.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/hiv-treatment-and-care/european-network-of-young-hiv-experts/","txt":"Join the ENYHE network","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/iapac_infographic_jan_2018_final.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/working-towards-90-90-90/fast-track-cities/","txt":"  ","status":"new"},"https://free.unaids.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-adolescents/#Bottom","txt":"Start Free, Stay Free, AIDS Free","status":"new"},"https://positiveaction.force.com/pacf/login":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-girls-and-women/#Bottom","txt":"Positive Action online community","status":"new"},"https://positiveaction.force.com/pacf/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/#bottom","txt":"PACF Online Community","status":"new"},"http://www.mtvstayingalive.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/#bottom","txt":"MTV/Staying Alive Foundation","status":"new"},"http://www.iasociety.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/#bottom","txt":"International AIDS Society","status":"new"},"https://www.aids2018.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/#bottom","txt":"International AIDS Conference","status":"new"},"https://www.youtube.com/watch?v=jRa2yo8rT2E":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/announcing-the-2016-every-footsteps-counts-winners/#bottom","txt":"Pro-Life Advancement and Education Partners (PLAEP) – Esther, A Beacon of Hope!","status":"new"},"https://www.youtube.com/watch?v=Vojhm9frrko":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/announcing-the-2016-every-footsteps-counts-winners/#bottom","txt":"World Vision Uganda – TTC Contribution in the Elimination of Mother to Child Transmission of HIV/AIDS","status":"new"},"https://www.youtube.com/watch?v=N7rKolYiDO0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/announcing-the-2016-every-footsteps-counts-winners/#bottom","txt":"India Health Action Trust (IHAT) – A Tale To Tell","status":"new"},"https://www.youtube.com/watch?v=bIFHyjHOxSI":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund-french/#tab-1615331907-4","txt":"Public Health Research Institute of India (PHRII) – Change Makers","status":"new"},"https://www.youtube.com/playlist?list=PLGo14vcHL4DcK_1pUbkPOcrQtpao6dzGK":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/#bottom","txt":"2016 Every Footstep Counts Playlist","status":"new"},"https://www.youtube.com/watch?v=88H5vyc_D3Y&list=PLGo14vcHL4Ddj5RZYvub_I_P26aY4e4Lh&index=3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/#bottom","txt":"2014 Every Footstep Counts Playlist","status":"new"},"https://www.iasociety.org/Web/WebContent/File/CIPHER_policy_brief_ado_EN.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-adolescents/#Bottom","txt":"CIPHER/WHO Global Research Agenda for Adolescents Living With HIV","status":"new"},"http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2015/february/20150217_PR_all-in":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-adolescents/#Bottom","txt":"http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2015/february/20150217_PR_all-in","status":"new"},"http://www.who.int/mediacentre/factsheets/fs345/en/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-adolescents/#Bottom","txt":"http://www.who.int/mediacentre/factsheets/fs345/en/","status":"new"},"http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/unaidspublication/2014/UNAIDS_Gap_report_en.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-girls-and-women/#Bottom","txt":"http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/unaidspublication/2014/UNAIDS_Gap_report_en.pdf","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/pagw-call-for-proposals-guidance-notes-final-en.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-girls-and-women/#Bottom","txt":"guidance notes","status":"new"},"http://sentebale.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/spark--igniting-change/#Access","txt":"Sentebale","status":"new"},"http://www.amfar.org/treatasia.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/spark--igniting-change/#Access","txt":"TREAT Asia","status":"new"},"https://www.chiva.org.uk/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/spark--igniting-change/#Access","txt":"CHIVA","status":"new"},"http://desmondtutuhivfoundation.org.za/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/spark--igniting-change/#Access","txt":"Desmond Tutu HIV foundation","status":"new"},"https://www.iasociety.org/adolescent-hiv-treatment-coalition":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/spark--igniting-change/#Access","txt":"Adolescent HIV Coalition","status":"new"},"https://www.iasociety.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/celebrating-the-25th-year-of-community-partnerships-and-collabor/#Avert","txt":"International AIDS Society","status":"new"},"http://www.who.int/mediacentre/news/releases/2014/focus-adolescent-health/en/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/spark--igniting-change/#Access","txt":"http://www.who.int/mediacentre/news/releases/2014/focus-adolescent-health/en/","status":"new"},"https://www.unicef.org/publicpartnerships/files/HIVAIDS_and_Children_2013_Thematic_Report.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/spark--igniting-change/#Access","txt":"https://www.unicef.org/publicpartnerships/files/HIVAIDS_and_Children_2013_Thematic_Report.pdf","status":"new"},"https://www.viivhealthcare.com/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/every-footstep-counts.aspx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/the-fight-to-end-mother-to-child-transmission-of-hiv/","txt":"Positive Action for Children’s Fund","status":"new"},"http://www.teampata.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/the-fight-to-end-mother-to-child-transmission-of-hiv/","txt":"Paediatric & Adolescent Treatment Africa (PATA)","status":"new"},"https://pata.proversity.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/the-fight-to-end-mother-to-child-transmission-of-hiv/","txt":"online course","status":"new"},"https://teampata.org/c3/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/the-fight-to-end-mother-to-child-transmission-of-hiv/","txt":"https://teampata.org/c3/","status":"new"},"https://soundcloud.com/viiv-healthcare/annette-sohn-treat-asia-pt1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/#tab-1917279609-4","txt":"Annette Sohn TREAT Asia Pt1 060513","status":"new"},"http://soundcloud.com/viiv-healthcare":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/beats-for-life/#tab-0926977016-5","txt":"ViiV Healthcare Effect","status":"new"},"https://soundcloud.com/viiv-healthcare/anette-sohn-treat-asia-pt2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/#tab-1917279609-4","txt":"Anette Sohn TREAT Asia Pt2 060513","status":"new"},"http://soundcloud.com/viiv-healthcare/annette-sohn-treat-asia-pt3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/#tab-1917279609-4","txt":"Annette Sohn TREAT Asia Pt3 060513","status":"new"},"https://soundcloud.com/viiv-healthcare/annette-sohn-treat-asia-pt4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/#tab-1917279609-4","txt":"Annette Sohn TREAT Asia Pt4 060513","status":"new"},"https://soundcloud.com/viiv-healthcare/annette-sohn-treat-asia-pt5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/#tab-1917279609-4","txt":"Annette Sohn TREAT Asia Pt5 060513","status":"new"},"http://www.amfar.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-msm-initiative/#tab-1363341348-5","txt":"amfAR, the Foundation for AIDS Research","status":"new"},"https://www.avert.org/professionals/hiv-around-world/latin-america/brazil#footnote67_twszu4g":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/striking-the-right-balance/#references","txt":"https://www.avert.org/professionals/hiv-around-world/latin-america/brazil#footnote67_twszu4g","status":"new"},"http://www.unaids.org/en/regionscountries/countries/botswana":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/helping-botswana-treat-all-people-living-with-hiv/#references","txt":"http://www.unaids.org/en/regionscountries/countries/botswana","status":"new"},"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204790lbl.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/helping-botswana-treat-all-people-living-with-hiv/#references","txt":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204790lbl.pdf","status":"new"},"https://www.viivhealthcare.com/supporting-the-community/positive-action-programmes/positive-action-for-children-fund.aspx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/hiv--a-virus-that-thrives-on-inequality/#unaids","txt":"Positive Action for Children Fund","status":"new"},"http://www.unaids.org/sites/default/files/media_asset/20170720_Data_book_2017_en.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/hiv--a-virus-that-thrives-on-inequality/#unaids","txt":"http://www.unaids.org/sites/default/files/media_asset/20170720_Data_book_2017_en.pdf","status":"new"},"https://www.avert.org/professionals/hiv-social-issues/key-affected-populations/transgender":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/hiv--a-virus-that-thrives-on-inequality/#unaids","txt":"https://www.avert.org/professionals/hiv-social-issues/key-affected-populations/transgender","status":"new"},"http://www.unaids.org/en/resources/campaigns/2014/2014gapreport/gapreport/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/hiv--a-virus-that-thrives-on-inequality/#unaids","txt":"http://www.unaids.org/en/resources/campaigns/2014/2014gapreport/gapreport/","status":"new"},"http://atlas2018.org/cambodia-transgenders/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-msm-transgender-people/#tab-02071038744-2","txt":"here","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/pa-msmt-strategy-paper-2018-2019-final.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-msm-transgender-people/#tab-02071038744-2","txt":"Strategy Paper","status":"new"},"https://www.facebook.com/groups/positiveaction.msmt/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-msm-transgender-people/#tab-02071038744-2","txt":"join our group","status":"new"},"https://pacf.secure.force.com/PAEGrantApplication/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/#pae","txt":"Find out more about the grants and apply online.","status":"new"},"http://www.who.int/features/factfiles/hiv/en/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/#pae","txt":"http://www.who.int/features/factfiles/hiv/en/","status":"new"},"http://www.euro.who.int/__data/assets/pdf_file/0019/324370/HIV-AIDS-surveillance-Europe-2015.pdf?ua=1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/#pae","txt":"http://www.euro.who.int/__data/assets/pdf_file/0019/324370/HIV-AIDS-surveillance-Europe-2015.pdf?ua=1","status":"new"},"http://www.euro.who.int/en/health-topics/communicable-diseases/hivaids/publications/2016/hivaids-surveillance-in-europe-2015-2016":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/#pae","txt":"http://www.euro.who.int/en/health-topics/communicable-diseases/hivaids/publications/2016/hivaids-surveillance-in-europe-2015-2016","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-eu-statement-retention-in-care-final.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/#pae","txt":"Retention in care","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-eu-statement-testing.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/#pae","txt":"Exploring Issues around Testing in Europe","status":"new"},"https://vimeo.com/92973193":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action/#tab-2018185174-1","txt":"https://vimeo.com/92973193 ","status":"new"},"http://vimeo.com/99562770":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action/#tab-2018185174-1","txt":"http://vimeo.com/99562770 ","status":"new"},"https://www.youtube.com/watch?v=vUgl_38YopA":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-southern-initiative/","txt":"https://www.youtube.com/watch?v=vUgl_38YopA","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/MTV-Shuga-Peer-Educators-Training-Guide.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-shuga/#tab-1414086804-4","txt":"here","status":"new"},"https://www.greaterthan.org/campaigns/empowered/empowered-trans-women-and-hiv-about/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kaiser-family-foundation/#tab-0203130052-4","txt":"Empowered: Trans Women & HIV","status":"new"},"http://www.kff.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kaiser-family-foundation/#tab-0203130052-4","txt":"Kaiser Family Foundation","status":"new"},"https://www.youtube.com/playlist?list=PLMg9scXawOhQJMOJADZ_zvtuuKCS-2ceP":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kaiser-family-foundation/#tab-0203130052-4","txt":"YouTube channel","status":"new"},"http://www.ceshhar.org.zw/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-centre-for-sexual-health-and-hivaids-research-ceshhar-zimbab/#tab-0285113211-4","txt":"here","status":"new"},"http://www.africaid-zvandiri.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/celebrating-the-25th-year-of-community-partnerships-and-collabor/#Avert","txt":"AFRICAID","status":"new"},"https://amplifychange.org/grantees/grants/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amplifychange/#tab-01060490740-4","txt":"https://amplifychange.org/grantees/grants/","status":"new"},"https://www.aids-pomoc.cz/information-in-english.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/czech-aids-help-association/#tab-0659845762-4","txt":"Czech AIDS Help Association","status":"new"},"http://www.iskorak.hr/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/iskorak/#Bottom","txt":"‘Positive Living’","status":"new"},"http://ecdc.europa.eu/en/publications/Publications/hiv-aids-surveillance-report-2012-20131127.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/iskorak/#Bottom","txt":"http://ecdc.europa.eu/en/publications/Publications/hiv-aids-surveillance-report-2012-20131127.pdf","status":"new"},"http://www.nat.org.uk/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/national-aids-trust-nat/#tab-01974929249-4","txt":"NAT","status":"new"},"http://www.nat.org.uk/sites/default/files/publications/Jun_16_Tackling_HIV_Stigma.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/national-aids-trust-nat/#tab-01974929249-4","txt":"our paper","status":"new"},"https://www.changethefaceofhiv.co.uk/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/national-aids-trust-nat/#tab-01974929249-4","txt":"stigma in General Practice","status":"new"},"http://www.diacentrs.lv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/diapluslogs/#tab-337664619-4","txt":"Dia+Logs","status":"new"},"http://www.ippf.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/adolescents-count-today-kenya/#tab-1884591214-5","txt":"International Planned Parenthood Federation (IPPF)","status":"new"},"http://www.fhok.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/adolescents-count-today-kenya/#tab-1884591214-5","txt":"Member Association Family Health Options Kenya (FHOK)","status":"new"},"https://soundcloud.com/viiv-healthcare/sonalini-mirchandani-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/#tab-0252253153-5","txt":"Sonalini Mirchandani","status":"new"},"https://soundcloud.com/viiv-healthcare/anne-stangl-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/#tab-0252253153-5","txt":"Anne Stangl","status":"new"},"http://www.imstilljosh.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/#tab-0252253153-5","txt":"www.ImStillJosh.com","status":"new"},"http://soundcloud.com/viiv-healthcare/josh-robbins-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/#tab-0252253153-5","txt":"Josh Robbins","status":"new"},"http://soundcloud.com/viiv-healthcare/anne-stangl-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/#tab-0252253153-5","txt":"Anne Stangl","status":"new"},"https://www.facebook.com/StigmaActionNetwork":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/#tab-0252253153-5","txt":"Facebook page","status":"new"},"https://twitter.com/stigmaactionnet":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/#tab-0252253153-5","txt":"Twitter","status":"new"},"http://soundcloud.com/viiv-healthcare/sonalini-mirchandani-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/#tab-0252253153-5","txt":"Sonalini Mirchandani","status":"new"},"http://soundcloud.com/viiv-healthcare/josh-robbins-2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/#tab-0252253153-5","txt":"Josh Robbins","status":"new"},"http://www.stigmaactionnetwork.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/#tab-0252253153-5","txt":"The Stigma Action Network","status":"new"},"http://www.vnhs.net/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-dudes--club/#tab-01470568235-3","txt":"Vancouver Native Health Society","status":"new"},"https://soundcloud.com/viiv-healthcare/george-ayala-msmgf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/global-forum-on-msm-and-hiv-speaking-out/#tab-01630504229-4","txt":"George Ayala, MSMGF","status":"new"},"https://soundcloud.com/viiv-healthcare/george-ayala-msmgf-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/global-forum-on-msm-and-hiv-speaking-out/#tab-01630504229-4","txt":"George Ayala, MSMGF","status":"new"},"https://soundcloud.com/viiv-healthcare/noah-metheny-msmgf-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/global-forum-on-msm-and-hiv-speaking-out/#tab-01630504229-4","txt":"Noah Metheny, MSMGF","status":"new"},"https://soundcloud.com/viiv-healthcare/george-ayala-msmgf-5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/global-forum-on-msm-and-hiv-speaking-out/#tab-01630504229-4","txt":"George Ayala, MSMGF 5","status":"new"},"http://www.youtube.com/watch?v=Q1I1i1h0u9Q&feature=player_embedded":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/global-forum-on-msm-and-hiv-speaking-out/#tab-01630504229-4","txt":"Javier Medina, Executive Director of Asociacion Kukulcan, Speaking Out training co-facilitator, Honduras, 2011, 2012, and 2013-05-17","status":"new"},"http://www.youtube.com/watch?v=1S8WBAXUZPI&feature=player_embedded":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/global-forum-on-msm-and-hiv-speaking-out/#tab-01630504229-4","txt":"Alfredo Ocampo Ortega, Advocate, Speaking Out training participant, Tela, Honduras, March 2012","status":"new"},"http://www.msmgf.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/global-forum-on-msm-and-hiv-speaking-out/#tab-01630504229-4","txt":"The Global Forum on MSM and HIV (MSMGF)","status":"new"},"https://soundcloud.com/viiv-healthcare/mdeschutter1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-action-europe/#tab-1079477429-5","txt":"Martine de Schutter, AIDS Action Europe, on the HIV epidemic in Eastern Europe and Central Asia","status":"new"},"http://www.euro.who.int/__data/assets/pdf_file/0011/147746/wd19E_HIV_111428.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-action-europe/#tab-1079477429-5","txt":"Summary of the European action plan for HIV/AIDS 2012–2015. World Health Organization (WHO). Published on June 22, 2011.","status":"new"},"https://soundcloud.com/viiv-healthcare/mdeschutter2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-action-europe/#tab-1079477429-5","txt":"Martine de Schutter on the AIDS Action Europe clearinghouse to share information","status":"new"},"http://www.hivaidsclearinghouse.eu/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-action-europe/#tab-1079477429-5","txt":"The Clearinghouse on HIV and AIDS","status":"new"},"https://soundcloud.com/viiv-healthcare/mdeschutter3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-action-europe/#tab-1079477429-5","txt":"Martine de Schutter, AIDS Action Europe, on the benefits of good practice seminars","status":"new"},"https://soundcloud.com/viiv-healthcare/mdeschutter4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-action-europe/#tab-1079477429-5","txt":"Martine de Schutter, AIDS Action Europe, on the lessons learned along the way","status":"new"},"http://www.aidsactioneurope.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-action-europe/#tab-1079477429-5","txt":"AIDS Action Europe","status":"new"},"https://www.whitehouse.gov/sites/default/files/uploads/NHAS.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/#tab-0732943346-5","txt":"National HIV/AIDS strategy","status":"new"},"https://soundcloud.com/viiv-healthcare/ayana-eady-patterson":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/#tab-0732943346-5","txt":"Ayana Eady-Patterson on what the Positive Action Southern Initiative grant meant to Union Mission","status":"new"},"http://youtu.be/mYbgfBJTa8g":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/#tab-0732943346-5","txt":"Video: watch on YouTube","status":"new"},"http://youtu.be/uH2lwij5fU8":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/#tab-0732943346-5","txt":"Video: watch on YouTube","status":"new"},"http://youtu.be/VQT6B7zYBrk":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/#tab-0732943346-5","txt":"Video: watch on YouTube","status":"new"},"http://youtu.be/5lkNi8EBVYw":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/#tab-0732943346-5","txt":"Video: watch on YouTube","status":"new"},"http://youtu.be/8AQEEq980QE":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/#tab-0732943346-5","txt":"Video: watch on YouTube","status":"new"},"http://youtu.be/8kcyect77WU":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/#tab-0732943346-5","txt":"Video: watch on YouTube","status":"new"},"http://youtu.be/ustjf_cMEWs":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/#tab-0732943346-5","txt":"Video: watch on YouTube","status":"new"},"http://youtu.be/EqU33Q74-C0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/positive-action-southern-initiative/#tab-0732943346-5","txt":"Video: watch on YouTube","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/AIDS-2012-leaflet.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-2012-global-village/#tab-1122387326-3","txt":"download a brief description","status":"new"},"http://youtu.be/T-jl9yQGiLQ":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-2012-global-village/#tab-1122387326-3","txt":"Video: watch on YouTube","status":"new"},"http://youtu.be/WNaC2NzZfN4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-2012-global-village/#tab-1122387326-3","txt":"Video: watch on YouTube","status":"new"},"http://youtu.be/CYYnnwi2qCE":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-2012-global-village/#tab-1122387326-3","txt":"Video: watch on YouTube","status":"new"},"http://youtu.be/200lnMsM3Iw":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-2012-global-village/#tab-1122387326-3","txt":"Video: watch on YouTube","status":"new"},"http://youtu.be/JX1RXQpzE7c":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-2012-global-village/#tab-1122387326-3","txt":"Video: watch on YouTube","status":"new"},"http://youtu.be/vfp0yzbGoP8":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-2012-global-village/#tab-1122387326-3","txt":"Video: watch on YouTube","status":"new"},"http://youtu.be/EpGRSB7IQ6c":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-2012-global-village/#tab-1122387326-3","txt":"Video: watch on YouTube","status":"new"},"http://youtu.be/4UhzIVxBxb8":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/aids-2012-global-village/#tab-1122387326-3","txt":"Video: watch on YouTube","status":"new"},"http://www.icrw.org/publications/meet-them-where-they-are":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vitu-newala--newala-youth-can-/#tab-1132099289-5","txt":"summary","status":"new"},"http://www.icrw.org/publications/vijana-tunaweza-newala":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vitu-newala--newala-youth-can-/#tab-1132099289-5","txt":"in-depth findings","status":"new"},"http://www.icrw.org/publications/using-participatory-research-and-action-address-hiv-related-vulnerabilities-adolescent-":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vitu-newala--newala-youth-can-/#tab-1132099289-5","txt":"participatory action research process.","status":"new"},"http://www.icrw.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/vitu-newala--newala-youth-can-/#tab-1132099289-5","txt":"International Center for Research on Women (ICRW)","status":"new"},"https://soundcloud.com/viiv-healthcare/caitlin-quote2-042412":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/hiv-young-leaders-fund/#tab-060819069-5","txt":"Caitlin Chandler, HIV Young Leaders Fund","status":"new"},"http://www.youtube.com/watch?v=nWIkzHgR87Y":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/hiv-young-leaders-fund/#tab-060819069-5","txt":"Youth AIDS Fillipinas Alliance (YAFA)","status":"new"},"http://www.youtube.com/watch?v=uampZP-P-aQ":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/hiv-young-leaders-fund/#tab-060819069-5","txt":"Youth Speak Out! A youth-led project of SPN+","status":"new"},"http://www.youtube.com/watch?v=gHe65uSrm6I":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/hiv-young-leaders-fund/#tab-060819069-5","txt":"Pioneer Institute for Social Change","status":"new"},"http://www.youtube.com/watch?v=-hcVWcHKCHg":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/hiv-young-leaders-fund/#tab-060819069-5","txt":"Vietnam Youth Network on HIV","status":"new"},"http://www.youtube.com/watch?v=CITwhfyhOkw":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/hiv-young-leaders-fund/#tab-060819069-5","txt":"Raks Thai Power Teen Network","status":"new"},"http://www.youtube.com/watch?v=uFqLdJOlcck":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/hiv-young-leaders-fund/#tab-060819069-5","txt":"short film on YouTube.","status":"new"},"https://soundcloud.com/viiv-healthcare/jacob-lief-ubuntu-education":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/ubuntu-education-fund-living-positively/#tab-01130444701-5","txt":"Jacob Lief, Ubuntu Education Fund, on what Living Positively is all about","status":"new"},"https://soundcloud.com/viiv-healthcare":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/ubuntu-education-fund-living-positively/#tab-01130444701-5","txt":"ViiV Healthcare Effect","status":"new"},"https://soundcloud.com/viiv-healthcare/jacob-lief-2-ubuntu-education":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/ubuntu-education-fund-living-positively/#tab-01130444701-5","txt":"Jacob Lief on the best thing about the Ubuntu Education Fund","status":"new"},"http://www.ubuntufund.org/blog/we-are-all-responsible-mens.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/ubuntu-education-fund-living-positively/#tab-01130444701-5","txt":"website","status":"new"},"http://soundcloud.com/viiv-healthcare/5-1-0-kent-klindera1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-msm-initiative/#tab-1363341348-5","txt":"Kent Klindera, amfAR, on HIV epidemic amongst MSM in the Asia Pacific region","status":"new"},"https://soundcloud.com/viiv-healthcare/5-1-0-kent-klindera2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-msm-initiative/#tab-1363341348-5","txt":"Kent Klindera, amfAR, on the impact of the MSM Initiative","status":"new"},"https://soundcloud.com/viiv-healthcare/5-1-0-kent-klindera3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-msm-initiative/#tab-1363341348-5","txt":"Kent Klindera, amfAR, thanks Positive Action's support of the MSM Initiative","status":"new"},"http://aidsmap.com/e-atlas":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-initiative/#tab-0309376999-5","txt":"Electronic-Atlas","status":"new"},"https://soundcloud.com/viiv-healthcare/5-2-0-caspar-thomson1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-initiative/#tab-0309376999-5","txt":"Caspar Thomson on the Positive Action - ViiV Healthcare partnership","status":"new"},"https://soundcloud.com/viiv-healthcare/5-2-0-caspar-thomson4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-initiative/#tab-0309376999-5","txt":"Caspar Thomson, NAM Initiative, on what quality information means for HIV/AIDS patients","status":"new"},"http://www.aidsmap.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-initiative/#tab-0309376999-5","txt":"NAM","status":"new"},"http://www.unicef.org/infobycountry/lesotho_statistics.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/partners-in-health-lesotho-project/#tab-01747846173-5","txt":"http://www.unicef.org/infobycountry/lesotho_statistics.html","status":"new"},"https://www.pih.org/article/removing-user-fees-dramatically-increases-patient-visits-in-lesotho":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/partners-in-health-lesotho-project/#tab-01747846173-5","txt":"https://www.pih.org/article/removing-user-fees-dramatically-increases-patient-visits-in-lesotho","status":"new"},"http://www.pih.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/partners-in-health-lesotho-project/#tab-01747846173-5","txt":"Partners In Health","status":"new"},"http://foundation.staying-alive.org/en/news/london_training":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-staying-alive-initiative/#tab-1008080202-5","txt":"Hear what grantees had to say about their experience at the London capacity-building workshop, October 2010","status":"new"},"https://soundcloud.com/viiv-healthcare/5-3-0-sara-piot3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-staying-alive-initiative/#tab-1008080202-5","txt":"Sara Piot on the impact of the MTV Staying Alive Initiative","status":"new"},"https://soundcloud.com/viiv-healthcare/5-3-0-sara-piot4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-staying-alive-initiative/#tab-1008080202-5","txt":"Sara Piot on the progression of the MTV Staying Alive Foundation grant programme","status":"new"},"http://stayingalivefoundation.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-staying-alive-initiative/#tab-1008080202-5","txt":"Staying Alive Foundation","status":"new"},"http://www.pedaids.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/elizabeth-glaser-pediatric-aids-foundation-partnership/#tab-217368194-4","txt":"Elizabeth Glaser Pediatric AIDS Foundation","status":"new"},"https://soundcloud.com/viiv-healthcare/5-5-0-alice-fay1-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/save-the-children-drc/#tab-01368398217-4","txt":"Alice Fay, Save the Children on the key drivers of HIV amongst women in Africa","status":"new"},"https://soundcloud.com/viiv-healthcare/5-5-0-alice-fay2":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/save-the-children-drc/#tab-01368398217-4","txt":"Alice Fay, Save the Children, on innovative ways to prevent mother-to-child transmission","status":"new"},"https://soundcloud.com/viiv-healthcare/5-5-0-alice-fay3-1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/save-the-children-drc/#tab-01368398217-4","txt":"Alice Fay, Save the Children, on helping people to understand HIV in the DRC","status":"new"},"http://www.savethechildren.org.uk/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/save-the-children-drc/#tab-01368398217-4","txt":"Save the Children","status":"new"},"https://soundcloud.com/viiv-healthcare/5-6-0-uli-meurer1-english":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/beats-for-life/#tab-0926977016-5","txt":"Uli Meurer, Netzwerk Plus, talks about the risks of HIV/AIDS","status":"new"},"https://soundcloud.com/viiv-healthcare/beats-for-life-spot-mp3":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/beats-for-life/#tab-0926977016-5","txt":"Beats for Life radio advertisement","status":"new"},"https://soundcloud.com/viiv-healthcare/gib-aids-keine-chance":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/beats-for-life/#tab-0926977016-5","txt":"Beats for Life song","status":"new"},"http://www.beatsforlife.de/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/beats-for-life/#tab-0926977016-5","txt":"http://www.beatsforlife.de","status":"new"},"http://www.facebook.com/#!/pages/Beats-for-Life/141952392521276":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/beats-for-life/#tab-0926977016-5","txt":"Visit the Beats for Life Facebook page","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/positive-perspective-survey_-plhiv-infographic.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/positive-perspectives/","txt":"*** IMAGE WITHOUT ALT TEXT ***","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/positive-perspective-survey_-partner-infographic.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/positive-perspectives/","txt":"*** IMAGE WITHOUT ALT TEXT ***","status":"new"},"https://www.viivhealthcare.com/our-stories/advancing-hiv-treatment-and-care/overcoming-the-challenges-for-partners-of-people-living-with-hiv.aspx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/hiv-treatment-and-care/the-positive-perspectives-survey/","txt":"Overcoming the challenges for partners of people living with HIV","status":"new"},"https://www.viivhealthcare.com/our-stories/advancing-hiv-treatment-and-care/understanding-the-concerns-of-people-living-with-hiv.aspx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/hiv-treatment-and-care/the-positive-perspectives-survey/","txt":"Understanding the concerns of people living with HIV","status":"new"},"https://www.viivhealthcare.com/our-stories/advancing-hiv-treatment-and-care/hiv-is-a-global-issue-that-needs-an-ongoing-collaborative-response.aspx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/hiv-treatment-and-care/the-positive-perspectives-survey/","txt":"HIV is a global issue that needs an ongoing collaborative response","status":"new"},"https://www.viivhealthcare.com/our-stories/innovation-hiv-science/preliminary-positive-perspectives-survey-data-released-at-9th-international-aids-society-conference.aspx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/hiv-treatment-and-care/the-positive-perspectives-survey/","txt":"*** IMAGE WITHOUT ALT TEXT ***","status":"new"},"http://www.livlife.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/new-results-from-the-positive-perspectives-global-survey-provide/#ref","txt":"www.LiVLife.com","status":"new"},"https://www.preventionaccess.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/u-u--undetectable-equals-untransmittable/","txt":"https://www.preventionaccess.org/","status":"new"},"http://www.pinknews.co.uk/2017/08/17/uganda-pride-cancelled-amid-threats-police-arrest-and-physical-harm/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/pride-around-the-world/#references","txt":"http://www.pinknews.co.uk/2017/08/17/uganda-pride-cancelled-amid-threats-police-arrest-and-physical-harm/","status":"new"},"https://www.unity-tool.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/how-the-unity-tool-can-help-conversations-between-plhiv-and-thei/#references","txt":"Unity Tool","status":"new"},"https://livlife.com/living-with-hiv/treatment.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/how-the-unity-tool-can-help-conversations-between-plhiv-and-thei/#references","txt":"LiVLife.com","status":"new"},"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096184/?tool":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/how-the-unity-tool-can-help-conversations-between-plhiv-and-thei/#references","txt":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096184/?tool","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/iapac-fast-track-cities.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/accelerating-city-hiv-aids-responses-through-collaboration/#references","txt":"  ","status":"new"},"http://www.unaids.org/sites/default/files/media_asset/JC2687_TheCitiesReport_en.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/accelerating-city-hiv-aids-responses-through-collaboration/#references","txt":"http://www.unaids.org/sites/default/files/media_asset/JC2687_TheCitiesReport_en.pdf","status":"new"},"http://www.sciencedirect.com/science/journal/23523018/2/5":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/viiv-healthcare_s-commitment-to-implementation-science/#Top","txt":"Volume 2, Issue 5","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/positive-perspectives-survey-preliminary-insights-infographic.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/preliminary-positive-perspectives-survey-data-released-at-9th-in/#references","txt":"this infographic","status":"new"},"http://www.iasociety.org/CIPHER":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/paediatric-innovation-seed-fund/","txt":"unrestricted grant to the International AIDS Society (IAS) CIPHER research programme","status":"new"},"https://www.gsk.com/en-gb/behind-the-science/access-to-healthcare/30-years-and-counting-the-fight-against-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/advancing-hiv-science-through-collaboration/#reference","txt":"the first HIV treatment","status":"new"},"https://hivimplementationscience.com/get-involved/supporting-implementation1.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/metrics-matter--measuring-impact-in-hiv-implementation/","txt":"sign up to attend","status":"new"},"https://hivimplementationscience.com/get-involved.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/metrics-matter--measuring-impact-in-hiv-implementation/","txt":"join our implementation science network online","status":"new"},"http://www.adharasevilla.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/overcoming-the-challenges-for-partners-of-people-living-with-hiv/#ref","txt":"Sevilla Checkpoint","status":"new"},"http://programme.ias2017.org/Abstract/Abstract/3103":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/preliminary-positive-perspectives-survey-data-released-at-9th-in/#references","txt":"http://programme.ias2017.org/Abstract/Abstract/3103","status":"new"},"http://www.positiveperspectives.info/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/preliminary-positive-perspectives-survey-data-released-at-9th-in/#references","txt":"LiV Life website","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/our-work-in-africa.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/how-we_re-addressing-the-challenges-of-the-hiv-epidemic-in-afric/#Bottom","txt":"  ","status":"new"},"http://www.hayaresearchunit.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/how-we_re-addressing-the-challenges-of-the-hiv-epidemic-in-afric/#Bottom","txt":"CLICK HERE FOR MORE INFO ON THE HAYA PROGRAMME","status":"new"},"http://files.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2014/UNAIDS_Gap_report_en.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/how-we_re-addressing-the-challenges-of-the-hiv-epidemic-in-afric/#Bottom","txt":"http://files.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2014/UNAIDS_Gap_report_en.pdf","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/iapac_infographic_updated-16-nov-2016.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/fighting-hiv-together--collaboration-is-driving-progress-with-th/#references","txt":"  ","status":"new"},"http://www.hivdigital.ee/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/positive-partnerships-initiative-launches-in-estonia1/#references","txt":"Click here","status":"new"},"http://www.unaids.org/sites/default/files/country/documents/EST_narrative_report_2016.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/positive-partnerships-initiative-launches-in-estonia1/#references","txt":"http://www.unaids.org/sites/default/files/country/documents/EST_narrative_report_2016.pdf","status":"new"},"http://ecdc.europa.eu/en/publications/Publications/hiv-aids-surveillance-in-Europe-2014.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/positive-partnerships-initiative-launches-in-estonia1/#references","txt":"http://ecdc.europa.eu/en/publications/Publications/hiv-aids-surveillance-in-Europe-2014.pdf","status":"new"},"http://programme.ias2017.org/Programme/Session/104":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/see-you-in-paris--viiv-healthcare---the-international-aids-socie/","txt":"Treat to Care: Evolving the management of HIV","status":"new"},"http://programme.ias2017.org/Programme/Session/200":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/see-you-in-paris--viiv-healthcare---the-international-aids-socie/","txt":"Plenary session","status":"new"},"https://www.positiveactionchallenges.com/challenges/combating-stigma-discrimination-in-healthcare-settings.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/see-you-in-paris--viiv-healthcare---the-international-aids-socie/","txt":"Positive Action Challenge Stigma Prize","status":"new"},"http://programme.ias2017.org/Programme/Session/95":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/see-you-in-paris--viiv-healthcare---the-international-aids-socie/","txt":"Accelerating Access to New HIV Medicines in Developing Countries","status":"new"},"http://programme.ias2017.org/Programme/Session/13":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/see-you-in-paris--viiv-healthcare---the-international-aids-socie/","txt":"The New $90-$90-$90: Drugs Affordable for All","status":"new"},"https://twitter.com/ViiVHC?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/see-you-in-paris--viiv-healthcare---the-international-aids-socie/","txt":"Twitter","status":"new"},"https://www.ias2017.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/viiv-healthcare-to-host-inaugural-implementation-science-network/#references","txt":"IAS Conference in Paris","status":"new"},"http://www.ias2017.org/Programme/Abstracts/Track-Categories":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/viiv-healthcare-to-host-inaugural-implementation-science-network/#references","txt":"own scientific track","status":"new"},"https://twitter.com/ViiVHC?lang=en-gb":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/viiv-healthcare-to-host-inaugural-implementation-science-network/#references","txt":"@ViiVHC","status":"new"},"http://www.ias2017.org/Conference-Objectives":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/viiv-healthcare-to-host-inaugural-implementation-science-network/#references","txt":"http://www.ias2017.org/Conference-Objectives","status":"new"},"http://www.sanitapenitenziaria.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/hiv-behind-bars--supporting-hiv-research--education-and-testing-/","txt":"www.sanitapenitenziaria.org","status":"new"},"http://www.npsitalia.net/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/hiv-behind-bars--supporting-hiv-research--education-and-testing-/","txt":"www.npsitalia.net","status":"new"},"http://www.unive.it/pag/13526/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/hiv-behind-bars--supporting-hiv-research--education-and-testing-/","txt":"Ca' Foscari University","status":"new"},"http://www.unive.it/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/hiv-behind-bars--supporting-hiv-research--education-and-testing-/","txt":"www.unive.it","status":"new"},"http://jflag.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/celebrating-the-25th-year-of-community-partnerships-and-collabor/#Avert","txt":"J-FLAG","status":"new"},"https://www.positiveactionchallenges.com/challenges/Zvandiri.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/celebrating-the-25th-year-of-community-partnerships-and-collabor/#Avert","txt":"Zvandiri Challenge","status":"new"},"https://www.positiveactionchallenges.com/Winners/Every-Hour-Matters.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/celebrating-the-25th-year-of-community-partnerships-and-collabor/#Avert","txt":"winners","status":"new"},"https://www.togetherforgirls.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/celebrating-the-25th-year-of-community-partnerships-and-collabor/#Avert","txt":"Together for Girls","status":"new"},"http://hni.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/celebrating-the-25th-year-of-community-partnerships-and-collabor/#Avert","txt":"Human Network International","status":"new"},"http://www.unfpa.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/celebrating-the-25th-year-of-community-partnerships-and-collabor/#Avert","txt":"the United Nations Population Fund","status":"new"},"https://www.positiveactionchallenges.com/Winners/Combating-Stigma-and-Discrimination-in-Healthcare-Settings.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/celebrating-the-25th-year-of-community-partnerships-and-collabor/#Avert","txt":"Zero Stigma, Discrimination & Violence to Zero HIV","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/youth-hiv-fact-sheet-final.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/celebrating-the-25th-year-of-community-partnerships-and-collabor/#Avert","txt":"Click here","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/networks-of-care_final-web-version-reduced.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/celebrating-the-25th-year-of-community-partnerships-and-collabor/#Avert","txt":"ethnographic research here","status":"new"},"https://www.avert.org/professionals/hiv-social-issues/key-affected-populations":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/celebrating-the-25th-year-of-community-partnerships-and-collabor/#Avert","txt":"https://www.avert.org/professionals/hiv-social-issues/key-affected-populations","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-hc-pa-adolescents-infographic-v3-05-07-2016.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/addressing-hiv-in-adolescents/#References","txt":"*** IMAGE WITHOUT ALT TEXT ***","status":"new"},"https://i-preview-cf5.gskstatic.com/content/dam/cf-viiv/viiv-healthcare/master/table/adolescents.png?auto=format":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/addressing-hiv-in-adolescents/#references","txt":"*** IMAGE WITHOUT ALT TEXT ***","status":"new"},"http://apps.who.int/iris/bitstream/10665/94334/1/9789241506168_eng.pdf?ua=1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/addressing-hiv-in-adolescents/#References","txt":"http://apps.who.int/iris/bitstream/10665/94334/1/9789241506168_eng.pdf?ua=1","status":"new"},"http://www.who.int/maternal_child_adolescent/epidemiology/adolescence/en/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/addressing-hiv-in-adolescents/#References","txt":"http://www.who.int/maternal_child_adolescent/epidemiology/adolescence/en/","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/understanding-hiv-in-women-infographic_final.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/understanding-hiv-in-women--spotlight-on-the-gender-gap-in-hiv-r/#our","txt":"*** IMAGE WITHOUT ALT TEXT ***","status":"new"},"https://www.youtube.com/watch?v=4sJQ7RfQby0":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/young-britons-break-down-hiv-stigma---isolation-to-be-the--genen/","txt":"Listening to Charlize Theron’s speech","status":"new"},"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/401662/2014_PHE_HIV_annual_report_draft_Final_07-01-2015.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/young-britons-break-down-hiv-stigma---isolation-to-be-the--genen/","txt":"Public Health England, 2014","status":"new"},"http://www.chiva.org.uk/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/young-britons-break-down-hiv-stigma---isolation-to-be-the--genen/","txt":"Children’s HIV Association","status":"new"},"http://www.chiva.org.uk/our-work/support-camp/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/young-britons-break-down-hiv-stigma---isolation-to-be-the--genen/","txt":"Annual CHIVA Support Camp","status":"new"},"http://www.chiva.org.uk/our-work/schools":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/young-britons-break-down-hiv-stigma---isolation-to-be-the--genen/","txt":"Educate Yourself: Working Towards HIV Friendly Schools","status":"new"},"http://genendit.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/young-britons-break-down-hiv-stigma---isolation-to-be-the--genen/","txt":"‘#GenEndIt’","status":"new"},"https://twitter.com/search?src=typd&q=%23millionpositivefaces":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/our-people/one-million-positive-faces/","txt":"#MillionPositiveFaces","status":"new"},"http://www.unaids.org/en/resources/documents/2017/2017-agenda-zero-discrimination-health-care":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/our-people/one-million-positive-faces/","txt":"Zero Discrimination Agenda","status":"new"},"http://bit.ly/2FroqwS":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/our-people/one-million-positive-faces/","txt":"putting your face to the campaign.","status":"new"},"https://www.millionpositivefaces.nl/en/we-are-already-taking-part":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/our-people/one-million-positive-faces/","txt":"Take part","status":"new"},"https://www.linkedin.com/jobs/viiv-healthcare-jobs":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/our-people/sabena-solomon-pursues-diverse-career-opportunities-at-viiv-heal/","txt":"check out our postings on LinkedIn","status":"new"},"https://uk.gsk.com/en-gb/careers/undergraduates/industrial-placements/viiv-healthcare/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/our-people/from-classroom-to-congress-hall-my-year-at-viiv/","txt":"apply online","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/3tc-oral-solution-cmi.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/3tc-/","txt":"3TC Oral Solution Consumer Medicine Information (PDF)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/3tc-tablets-cmi.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/3tc-/","txt":"3TC Tablets Consumer Medicine Information (PDF)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/3tc-product-information.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/3tc-/","txt":"3TC Product Information (PDF)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/celsentri_tablets_cmi_au_006_approved.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/celsentri-/","txt":"Celsentri Consumer Medicine Information (PDF) ","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/celsentri_tablets_pi_013_approved.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/celsentri-/","txt":"Celsentri Product Information (PDF)","status":"new"},"https://au.viivexchange.com/hcp/celsentri/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/celsentri-/","txt":"Celsentri clinical data and webcasts (Website)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/combivir-tablets-cmi.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/combivir-/","txt":"Combivir Consumer Medicine Information (PDF)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/combivir-tablets-product-information.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/combivir-/","txt":"Combivir Product Information (PDF)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/juluca_cmi_au_002_approved.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/juluca-/","txt":"Juluca Consumer Medicine Information (PDF)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/juluca_pi_002_approved.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/juluca-/","txt":"Juluca Product Information (PDF)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/kivexa_cmi_au_009_approved.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/kivexa-/","txt":"Kivexa Consumer Medicine Information (PDF)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/kivexa_pi_014_approved.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/kivexa-/","txt":"Kivexa Product Information (PDF)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/retrovir-capsules-and-syrup-cmi.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/retrovir-/","txt":"Retrovir Consumer Medicine Information (PDF)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/retrovir-product-information.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/retrovir-/","txt":"Retrovir Product Information (PDF)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/telzir_tablets_cmi_au_012_clean_approved.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/telzir-/","txt":"Telzir Consumer Medicine Information (PDF)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/telzir_pi_015_approved_clean.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/telzir-/","txt":"Telzir Product Information (PDF)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/tivicay_tablet_cmi_au_007_approved.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/tivicay-/","txt":"Tivicay Consumer Medicine Information (PDF)","status":"new"},"https://au.viivexchange.com/hcp/patient-support/tivicay-patient-booklet/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/tivicay-/","txt":"Tivicay Consumer Medicine Information (HTML)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/tivicay_tablet_pi_-008_approved.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/tivicay-/","txt":"Tivicay Product Information (PDF)","status":"new"},"https://au.viivexchange.com/hcp/tivicay/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/tivicay-/","txt":"Tivicay clinical data and webcasts (Website)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/triumeq_tablets_cmi_au_010_approved.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/triumeq-/","txt":"Triumeq Consumer Medicine Information (PDF)","status":"new"},"https://au.viivexchange.com/hcp/patient-support/triumeq-patient-booklet/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/triumeq-/","txt":"Triumeq Consumer Medicine Information (HTML)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/triumeq_tablet_pi_010_approved.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/triumeq-/","txt":"Triumeq Product Information (PDF)","status":"new"},"https://au.viivexchange.com/hcp/triumeq/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/triumeq-/","txt":"Triumeq clinical data and webcasts (Website)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/trizivir_tablets_cmi_au_008_approved.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/trizivir-/","txt":"Trizivir Consumer Medicine Information (PDF)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/trizivir_tablets_pi_014_approved.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/trizivir-/","txt":"Trizivir Product Information (PDF)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/ziagen_oral-solution_cmi_au_008_approved_clean.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/ziagen-/","txt":"Ziagen Oral Solution Consumer Medicine Information (PDF)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/ziagen-tablets-cmi.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/ziagen-/","txt":"Ziagen Tablets Consumer Medicine Information (PDF)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/ziagen_oral-solution_pi_015_approved_clean.docx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/ziagen-/","txt":"Ziagen Product Information (PDF)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/au/juluca_pi_001_approved-002.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/first-two-drug-pill-now-available-for-australians-with-hiv/#references","txt":"https://www.viivhealthcare.com.au/media/124219/juluca_pi_001_approved-002.pdf","status":"new"},"https://kirby.unsw.edu.au/sites/default/files/kirby/report/KI_Annual-Surveillance-Report-2018.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/first-two-drug-pill-now-available-for-australians-with-hiv/#references","txt":"https://kirby.unsw.edu.au/sites/default/files/kirby/report/KI_Annual-Surveillance-Report-2018.pdf","status":"new"},"https://www.hiv.gov/hiv-basics/overview/about-hiv-and-aids/what-are-hiv-and-aids":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/first-two-drug-pill-now-available-for-australians-with-hiv/#references","txt":"https://www.hiv.gov/hiv-basics/overview/about-hiv-and-aids/what-are-hiv-and-aids","status":"new"},"http://www.who.int/features/qa/71/en/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/first-two-drug-pill-now-available-for-australians-with-hiv/#references","txt":"http://www.who.int/features/qa/71/en/","status":"new"},"http://www.who.int/en/news-room/fact-sheets/detail/hiv-aids":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/first-two-drug-pill-now-available-for-australians-with-hiv/#references","txt":"http://www.who.int/en/news-room/fact-sheets/detail/hiv-aids","status":"new"},"https://www.viivhealthcare.com.au/media/124219/juluca_pi_001_approved-002.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/first-two-drug-single-pill-for-hiv-now-approved-for-use-in-austr/#Bottom","txt":"https://www.viivhealthcare.com.au/media/124219/juluca_pi_001_approved-002.pdf","status":"new"},"http://tga-search.clients.funnelback.com/s/search.html?collection=tga-artg&profile=record&meta_i=291356":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/first-two-drug-single-pill-for-hiv-now-approved-for-use-in-austr/#Bottom","txt":"http://tga-search.clients.funnelback.com/s/search.html?collection=tga-artg&profile=record&meta_i=291356","status":"new"},"https://www.afao.org.au/wp-content/uploads/2017/12/HIV-in-Australia-2018.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/first-two-drug-single-pill-for-hiv-now-approved-for-use-in-austr/#Bottom","txt":"https://www.afao.org.au/wp-content/uploads/2017/12/HIV-in-Australia-2018.pdf","status":"new"},"http://www.viivhealthcare.com.au/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/october/viiv-healthcare-awards-new-grants-to-accelerate-community-led-so/#ref","txt":"www.viivhealthcare.com.au","status":"new"},"https://www.acon.org.au/wp-content/uploads/2017/09/HOS-Ageing-2017_V6_web.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/october/viiv-healthcare-awards-new-grants-to-accelerate-community-led-so/#ref","txt":"http://www.acon.org.au/wp-content/uploads/2017/09/HOS-Ageing-2017_V6_web.pdf","status":"new"},"https://onlinelibrary.wiley.com/doi/pdf/10.1111/cei.12814":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/october/viiv-healthcare-awards-new-grants-to-accelerate-community-led-so/#ref","txt":"http://onlinelibrary.wiley.com/doi/10.1111/cei.12814/pdf","status":"new"},"https://kirby.unsw.edu.au/report/annual-surveillance-report-hiv-viral-hepatitis-stis-2016":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/october/viiv-healthcare-awards-new-grants-to-accelerate-community-led-so/#ref","txt":"https://kirby.unsw.edu.au/report/annual-surveillance-report-hiv-viral-hepatitis-stis-2016","status":"new"},"http://www.viivhealthcare.com/?_ga=2.184407462.1692100571.1540457268-611046378.1540288069":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2016/viiv-healthcare-to-progress-collaboration-with-janssen-to-develo/","txt":"www.viivhealthcare.com","status":"new"},"http://trabajandoenpositivo.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/trabajando-en-positivo/","txt":"Trabajando en Positivo","status":"new"},"https://www.imaginamas.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/imagina-mas/","txt":"Imagina MÁS","status":"new"},"http://www.gsk.it/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/luglio/viiv-healthcare-presenta-ad-aids-2018-i-dati-di-fase-iii-per-gli/#bottom","txt":"www.gsk.it","status":"new"},"https://www.zincmapser.com/Jobs/JobView.aspx?Job.Id=877588":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-presenta-i-dati-relativi-a-tre-anni-di-trattamen/#bottom","txt":"ITA/HIVP/0006/18","status":"new"},"https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-phase-3-results-from-the-brighte-study-of-fostemsavir-in-heavily-treatment-experienced-patients-with-hiv/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/it-it/sala-stampa/2017/ottobre/viiv-healthcare-annuncia-i-risultati-positivi-dello-studio-di-fa/","txt":"qui","status":"new"},"https://www.aidshilfe.de/event/bundesweites-treffen-hiv-positive-jugendliche":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/bundesweites-treffen-fuer-hiv-positive-jugendliche/","txt":"https://www.aidshilfe.de/event/bundesweites-treffen-hiv-positive-jugendliche","status":"new"},"http://www.doeak.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/deutsch-oesterreichischer-aids-kongress/","txt":"http://www.doeak.com/","status":"new"},"https://www.ncbi.nlm.nih.gov/pubmed/15989434":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/schulung-und-selbstmanagement-koennen-die-adhaerenz-verbessern/#references","txt":"AIMS-System","status":"new"},"https://www.welt-aids-tag.de/kampagne-2017/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/deutsche-aids-hilfe-startet-die-informationskampagne-zum-welt-ai/#references","txt":"https://www.welt-aids-tag.de/kampagne-2017/","status":"new"},"https://kein-aids-fuer-alle.de/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/auf-dem-weg-zu-90-90-90-wie-sieht-es-in-europa-aus/#references","txt":"Kein AIDS für alle!","status":"new"},"http://www.unaids.org/en/resources/documents/2014/JC2686_WAD2014report":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/deutsche-aids-hilfe-startet-die-informationskampagne-zum-welt-ai/#references","txt":"UNAIDS 2014: Ending the Epidemic by 2030","status":"new"},"http://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2017/Ausgaben/39_17.pdf?__blob=publicationFile":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/deutsche-aids-hilfe-startet-die-informationskampagne-zum-welt-ai/#references","txt":"Robert-Koch-Institut, Epidemiologisches Bulletin 39/2017","status":"new"},"https://www.aidshilfe.de/meldung/ende-aids-2020-erreichen-kampagnenstart-deutschen-aids-hilfe":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/deutsche-aids-hilfe-startet-die-informationskampagne-zum-welt-ai/#references","txt":"Deutsche AIDS-Hilfe","status":"new"},"http://ecdc.europa.eu/en/publications/Publications/Continuum-of-HIV-care-2017.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/auf-dem-weg-zu-90-90-90-wie-sieht-es-in-europa-aus/#references","txt":"http://ecdc.europa.eu/en/publications/Publications/Continuum-of-HIV-care-2017.pdf","status":"new"},"https://www.chip.dk/Portals/0/files/Conferences/EACS%202017/Kamilla%20Laut%20Late%20Persentation_EACS_poster%2020.10.17.pdf?ver=2017-10-24-094235-067&timestamp=1508947980562":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/auf-dem-weg-zu-90-90-90-wie-sieht-es-in-europa-aus/#references","txt":"Laut K et al. EACS Mailand 2017; # PE 26/6","status":"new"},"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555438/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/antiretrovirale-kombinationstherapie-eine-erfolgsgeschichte/#references","txt":"The Antiretroviral Cohort Collaboration Lancet HIV 2017 Aug. 4(8): e349-e356","status":"new"},"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555438/figure/fig3/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/antiretrovirale-kombinationstherapie-eine-erfolgsgeschichte/#references","txt":"Lebenserwartung","status":"new"},"https://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Bevoelkerung/Sterbefaelle/Tabellen/TabellenLebenserwartung.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2017/antiretrovirale-kombinationstherapie-eine-erfolgsgeschichte/#references","txt":"Statistisches Bundesamt, Lebenserwartung in Deutschland","status":"new"},"http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2017/november/20171121_righttohealth_report":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/art-erreicht-mehr-als-20-mio-menschen/","txt":"Pressemeldung","status":"new"},"http://www.unaids.org/sites/default/files/media_asset/RighttoHealthReport_Full_web%2020%20Nov.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/art-erreicht-mehr-als-20-mio-menschen/","txt":"Report","status":"new"},"http://journals.lww.com/aidsonline/Abstract/publishahead/Effect_of_immediate_initiation_of_antiretroviral.97360.aspx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/geringes-resistenzrisiko-auch-bei-sofortigem-art-beginn/","txt":"Lodi S et al. AIDS: Post Acceptance: November 10, 2017 doi: 10.1097/QAD.0000000000001692","status":"new"},"http://journals.lww.com/aidsonline/Abstract/publishahead/Temporal_trends_of_transmitted_HIV_drug_resistance.97362.aspx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/uebertragene-hiv-resistenzen-seltener/","txt":"Olsen A et al. AIDS: Post Acceptance: November 02, 2017 doi: 10.1097/QAD.0000000000001689","status":"new"},"http://www.ctu.mrc.ac.uk/cascade/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/uebertragene-hiv-resistenzen-seltener/","txt":"CASCADE-Serokonverter-Kohorte","status":"new"},"https://www.viivhealthcare.com/umbraco/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/patienten-mit-hohen-cd4-zellzahlen-wer-profitiert-am-meisten-von/","txt":"Save","status":"new"},"http://i-base.info/start/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/patienten-mit-hohen-cd4-zellzahlen-wer-profitiert-am-meisten-von/","txt":"http://i-base.info/start/","status":"new"},"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569751/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/patienten-mit-hohen-cd4-zellzahlen-wer-profitiert-am-meisten-von/","txt":"Molina JM et al. Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial Lancet HIV 2018 [epub ahead of print]","status":"new"},"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1105243":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/frueher-therapiebeginn-kann-resistenzentwicklung-verhindern/","txt":"Cohen MS et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11;365(6):493-505","status":"new"},"https://journals.lww.com/jaids/Abstract/publishahead/Hiv_Drug_Resistance_in_Adults_Receiving_Early.96773.aspx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/frueher-therapiebeginn-kann-resistenzentwicklung-verhindern/","txt":"Palumbo P et al. HIV Drug Resistance in Adults Receiving Early Versus Delayed Antiretroviral Therapy: HPTN 052. J Acquir Immune Defic Syndr: Post Acceptance: December 28, 2017. doi: 10.1097/QAI.0000000000001623","status":"new"},"https://journals.lww.com/jaids/Abstract/2018/01010/Belief_in_Treatment_as_Prevention_and_Its.2.aspx":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/therapie-als-praevention-tasp-wie-gross-ist-das-wissen-bei-msm/","txt":"Card KG et al. Belief in Treatment as Prevention and Its Relationship to HIV Status and Behavioral Risk. J Acquir Immune Defic Syndr: January 1, 2018 - Volume 77 - Issue 1 - p 8–16","status":"new"},"https://academic.oup.com/jid/article/216/12/1525/4743770":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/aktuelles/2018/begleiterkrankungen-bei-hiv-patienten-daten-aus-den-usa/","txt":"Gallant J et al. Comorbidities Among US Patients With Prevalent HIV Infection—A Trend Analysis. The Journal of Infectious Diseases, Volume 216, Issue 12, 19 December 2017, Pages 1525–1533","status":"new"},"http://www.wir-ruhr.de/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/das-innovative-zentrum-fuer-sexuelle-gesundheit-und-medizin-wir-/","txt":"hier","status":"new"},"http://www.hiv-sti-fortbildung.de/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/let-s-talk-about-sex/","txt":"hier","status":"new"},"http://www.viiv-clinicalstudyregister.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/healthcare-professionals/viiv-healthcare-clinical-study-register/","txt":"Accéder au Registre des essais cliniques de ViiV Healthcare","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/10028_vii_disclosure_juin18_en_v03_cln.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/healthcare-professionals/voluntary-disclosure-of-viiv-healthcare-canada-payments-to-hcps-/","txt":"Click here to download this document as a pdf","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/community-grants-fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#1a","txt":"Lisez notre brochure des Subventions Communautaires","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/viiv_healthcare_canada_grants__charitable_contributions_2011fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#1a","txt":"2011","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/viiv_healthcare_canada_grants__charitable_contributions_2012fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#1a","txt":"2012","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/viiv_healthcare_canada_grants__charitable_contributions_2013fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#1a","txt":"2013","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/viiv_healthcare_canada_grants__charitable_contributions_2014_fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#1a","txt":"2014","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/2015-viiv-soins-de-sante-canada-subventions-communautaires.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#1a","txt":"2015","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/2016-viiv-soins-de-sante-canada-subventions-communautaires.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#1a","txt":"2016","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/2017-programme-d_innovation-positive-action-canada-aperau-du-programme.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#1a","txt":"ici","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/pacip_-_2008fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#1a","txt":"2008","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/pacip_-_2009fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#1a","txt":"2009","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/pacip_-_2010fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#1a","txt":"2010","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/pacip_-_2011fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#1a","txt":"2011","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/pacip_-_2012fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#1a","txt":"2012","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/pacip_-_2013fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#1a","txt":"2013","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/2015-programme-dinnovation-positive-action-canada-resultats.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#1a","txt":"2015","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/2016-programme-dinnovation-positive-action-canada-resultats-final.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#1a","txt":"2016","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/2017-initiative-autochtone-positive-action-canada-aperau-du-programme.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#1a","txt":"ici","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/northern_initiative_grant_list_-_2013fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#1a","txt":"2013","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/2014_initiative_vih_sida_autochtone_de_positive-_action_canada_2014_resultats.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#1a","txt":"2014","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/2015-initiative-autochtone-positive-action-canada-resultats.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#1a","txt":"2015","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/2016-initiative-autochtone-pac-resultats-final.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/community-partnerships/community-involvement/#1a","txt":"2016","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/2018-pihvot-leave-behind-fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/healthcare-professionals/independent-grants-and-support-programs/","txt":"ici","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/juluca-french.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/juluca/","txt":"Monographie de JULUCA","status":"new"},"http://healthycanadians.gc.ca/publications/diseases-conditions-maladies-affections/hiv-aids-estimates-2014-vih-sida-estimations/index-eng.php":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/about-hivaids/about-hivaids-in-canada/#references","txt":"Estimates of HIV incidence, prevalence and proportion undiagnosed in Canada, 2014 (2016). Accessed August 24, 2016.","status":"new"},"http://www.phac-aspc.gc.ca/aids-sida/pr/index-eng.php":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/about-hivaids/about-hivaids-in-canada/#references","txt":"Public Health Agency of Canada. Populations at Risk. Accessed April 10, 2015.","status":"new"},"http://www.hiv411.ca/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/about-hivaids/canadian-resources/","txt":"www.hiv411.ca","status":"new"},"http://www.catie.ca/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/about-hivaids/canadian-resources/","txt":"www.catie.ca","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/3tc.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/3tc/","txt":"Product Monograph for 3TC®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/3tc-french.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/3tc/","txt":"/Monographie de 3TC®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/celsentri.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/celsentri/","txt":"Product Monograph for CELSENTRI®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/celsentri-french.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/celsentri/","txt":"/Monographie de CELSENTRI®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/combivir.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/combivir/","txt":"Product Monograph for COMBIVIR®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/combivir-french.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/combivir/","txt":"/Monographie de COMBIVIR®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/kivexa.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/kivexa/","txt":"Product Monograph for KIVEXA®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/kivexa-french.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/kivexa/","txt":"/Monographie de KIVEXA®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/rescriptor.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/rescriptor/","txt":"Product Monograph for RESCRIPTOR®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/rescriptor-french.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/rescriptor/","txt":"/Monographie de RESCRIPTOR®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/retrovir.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/retrovirazt/","txt":"Product Monograph for RETROVIR/AZT®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/retrovir-french.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/retrovirazt/","txt":"/Monographie de RETROVIR/AZT®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/telzir.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/telzir/","txt":"Product Monograph for TELZIR®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/telzir-french.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/telzir/","txt":"/Monographie de TELZIR®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/triumeq.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/triumeq/","txt":"Product Monograph for Triumeq®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/triumeq-french.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/triumeq/","txt":"/Monographie de Triumeq®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/tivicay.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/tivicay/","txt":"Product Monograph for Tivicay®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/tivicay_french.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/tivicay/","txt":"/Monographie de Tivicay®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/trizivir.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/trizivir/","txt":"Product Monograph for TRIZIVIR®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/trizivir-french.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/trizivir/","txt":"/Monographie de TRIZIVIR®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/ziagen.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/ziagen/","txt":"Product Monograph for ZIAGEN®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-EN/ziagen-french.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/our-medicines/ziagen/","txt":"/Monographie de ZIAGEN®","status":"new"},"https://patientview-plus.wetransfer.com/downloads/e77cde296ebb41cdbd26905d64e45dfe20170316212814/ec838e":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-ca/media/press-releases/2017/viiv-healthcare-ranks-1-in-patientview-corporate-reputation-surv/","txt":"Click here to read the full PatientView press release","status":"new"},"http://hteam.nl/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/amsterdam-op-weg-naar-een-toekomst-zonder-nieuwe-hiv-infecties/","txt":"www.hteam.nl","status":"new"},"http://www.hivuitdekast.nl/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/hiv-uit-de-kast-campagne/","txt":"www.hivuitdekast.nl","status":"new"},"http://www.hivnet.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/de-mensen-van-de-hiv-vereniging/","txt":"www.hivnet.org","status":"new"},"https://www.pozandproud.nl/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-jorgen--vrijwilliger-voor-poz-proud/","txt":"Poz&Proud","status":"new"},"http://the-power-of-love.webflow.io/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/nl-nl/rethink-verhalen/de-leukste-dag-van-het-jaar-om-hiv-te-hebben/","txt":"De Leukste Dag","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/1q-4q-2010-hcp-fee-disclosure-report-033111.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-states/us-healthcare-professional-fee-disclosures/","txt":"Q1-Q4 2010 HCP fee disclosure (PDF 62 KB) ","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-final-1q-4q-2011-hcp-fee-disclosure-report-to-pdf-031312.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-states/us-healthcare-professional-fee-disclosures/","txt":"Q1-Q4 2011 HCP fee disclosure (PDF 109 KB) ","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/2012-viivq4_hcp-physicans-pmt-v2.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-states/us-healthcare-professional-fee-disclosures/","txt":"Q1-Q4 2012 HCP fee disclosure (PDF 416 KB) ","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/q1-q4-2013-physician-payment-report.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-states/us-healthcare-professional-fee-disclosures/","txt":"Q1-Q4 2013 HCP fee disclosure (PDF 1.8 MB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-healthcare-us-research-payments-2010-final-report.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-states/research-and-development-payments-in-the-us/","txt":"US Research Payments 2010 (PDF 211 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/2011-ViiV-Reportable-HCP-Transactions.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-states/research-and-development-payments-in-the-us/","txt":"US Research Payments 2011 (PDF 300 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/ViiV-Research-Payments-YTD-2012-Disclosure.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-states/research-and-development-payments-in-the-us/","txt":"US Research Payments 2012 (PDF 524 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/ViiV-Research-Payments-YTD-Dec-2013.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-states/research-and-development-payments-in-the-us/","txt":"US Research Payments 2013 (PDF 459 KB)","status":"new"},"https://www.gsk.com/en-gb/responsibility/operating-responsibly/engaging-with-healthcare-professionals/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-kingdom/viiv-healthcare---disclosure-of-payments-to-uk-based-healthcare-/","txt":"GSK disclosure page","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/ch-de/patientenbroschu-re-de.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/latest-news/2018/june-1/hiv-knowledge-builds-trust/","txt":"Broschüre Deutsch","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/ch-de/patientenbroschu-re-fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/latest-news/2018/june-1/hiv-knowledge-builds-trust/","txt":"Broschüre Französisch","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/ch-de/patientenbroschu-re-it.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/latest-news/2018/june-1/hiv-knowledge-builds-trust/","txt":"Broschüre Italienisch","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Australia-Patient-Group-Reporting-2011.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Australia (PDF 36 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Belgium-Patient-Group-Reporting-2011.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Belgium (PDF 35 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Canada-Patient-Group-Reporting-2011.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Canada (PDF 154 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/France-Patient-Group-Reporting-2011.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"France (PDF 38 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Germany-Patient-Group-Reporting-2011-Updated.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Germany (PDF 32 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Global-Group-Patient-Group-Reporting-2011.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Global (PDF 44 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Italy-Patient-Group-Reporting-2011.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Italy (PDF 61 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Mexico-Patient-Group-Reporting-2011.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Mexico (PDF 94 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Netherlands-Patient-Group-Reporting-2011.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Netherlands (PDF 10 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/PACF-Patient-Group-Reporting-2011.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Positive Action for Children Fund (PDF 117 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Portugal-Patient-Group-Reporting-2011.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Portugal (PDF 11 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Positive-Action-Patient-Group-Reporting-2011.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Positive Action (PDF 58 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Russia-Patient-Group-Reporting-2011.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Russia Patient (PDF 119 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Spain-Patient-Group-Reporting-2011.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Spain (PDF 28 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Swiss-Patient-Reporting-2011.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Switzerland (PDF 95 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/UK-Patient-Group-Reporting-2011.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"United Kingdom (PDF 200 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/US-Patient-Group-Reporting-2011.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"United States (PDF 121 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-to-Australia-Based-Groups.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Australia (PDF 122 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-Belgium.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Belgium (PDF 66 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-Canada.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Canada (PDF 396 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-France.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"France (PDF 123 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-Germany.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Germany (PDF 236 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-to-Global-HIV-Groups-2.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Global HIV organisations (PDF 308 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-Italy.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Italy (PDF 132 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-Japan.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Japan (PDF 134 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-Mexico.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Mexico (PDF 304 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-Netherlands.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Netherlands (PDF 133 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-Paediatric-Seed-Fund.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Paediatric Innovation Seed Fund (PDF 274 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-Portugal.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Portugal (PDF 124 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-Positive-Action-Fund.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Positive Action (PDF 349 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/grants-and-charitable-contributions-pacf-updated-17-06-13.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Positive Action for Children Fund (PDF 560 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-Spain.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Spain (PDF 154 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-Switzerland.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Switzerland (PDF 129 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-US.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"United States (PDF 57 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/grants-and-charitable-donations-to-uk-based-patient-groups-in-2012.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"United Kingdom (PDF 86 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/australia.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Australia (PDF 285 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/belgium.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Belgium (PDF 59 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/canada.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Canada (PDF 434 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/france.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"France (PDF 63 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/germany.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Germany (PDF 17 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/italy.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Italy (PDF 63 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/japan.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Japan (PDF 25 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/netherlands.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Netherlands (PDF 10 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/positive-action.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Positive Action (PDF 188 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/pacf.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Positive Action for Children Fund (PDF 218 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/pan-eu.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Pan European (PDF 150 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/portugal.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Portugal (PDF 13 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/russia.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Russia (PDF 141 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/spain.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Spain (PDF 72 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/switzerland.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Switzerland (PDF 61 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/viiv-3q-2013.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"United States (PDF 34 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/uk.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"UK (PDF 49 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/spain.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Spain (PDF 114 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/australia.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Australia (PDF 106 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/belgium.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Belgium (PDF 99 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/canada.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Canada (PDF 306 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/france.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"France (PDF 116 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/germany.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Germany (PDF 116 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/japan.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Japan (PDF 104 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/netherlands.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Netherlands (PDF 97 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/portugal.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Portugal (PDF 180 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/russia.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Russia (PDF 100 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/positive-action.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Positive Action (PDF 216 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/switzerland.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Switzerland (PDF 103 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/annual-2014-viiv-grants-pdf-based-on-v60.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"United States (PDF 55 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/pan-eu-patient-group-reporting-2014.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Pan-European (PDF 151 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/pacf-2014.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Positive Action for Children Fund (PDF 151 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/italy.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Italy (PDF 193 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/uk-2014.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"UK (PDF 193 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/eu-2015.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Above Country EU (PDF 52 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/australia.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Australia (PDF 105 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/belgium.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Belgium (PDF 98 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/france.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"France (PDF 113 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/gappa-core-reporting.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"GAPPA Core Reporting (PDF 47 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/germany.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Germany (PDF 103 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/italy.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Italy (PDF 165 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/japan.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Japan (PDF 231 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/netherlands.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Netherlands (PDF 43 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/portugal.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Portugal (PDF 101 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/spain.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Spain (PDF 181 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/switzerland.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Switzerland (PDF 257 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/canada.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Canada (PDF 177 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/positive-action-for-adolescents.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Positive Action for Adolescents (PDF 96 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/positive-action-for-msmt.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Positive Action for MSMT (PDF 105 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/pacf.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"PACF (PDF 326 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/united-states.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"UNITED STATES.pdf (PDF 61 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/belgium.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Belgium.pdf (PDF 8 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/germany.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Germany.pdf (PDF 23 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/france.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"France.pdf (PDF 26 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/netherlands.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Netherlands.pdf (PDF 52 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/italy.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Italy.pdf (PDF 70 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/positive-action-for-girls-and-women.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Positive Action for Girls and Women.pdf (PDF 58 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/positive-action-msm-transgender-programme.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Positive Action MSM & Transgender Programme.pdf (PDF 31 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/uk.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"UK.pdf (PDF 163 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/gappa-core-reporting.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"GAPPA Core Reporting.pdf (PDF 132 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/pan-european.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Pan-European.pdf (PDF 90 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/switzerland.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Switzerland.pdf (PDF 11 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/spain.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Spain.pdf (PDF 27 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/positive-action-for-children-fund.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Positive Action for Children Fund.pdf (PDF 53 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/positive-action-for-adolescents.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Positive Action for Adolescents.pdf (PDF 90 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/annual-2016-viiv-executive-summary-grant-listing.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Annual 2016 ViiV Executive Summary Grant Listing.pdf (PDF 143 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/joint-working-agreements-global-strategic-initiatives-2017.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Joint Working Agreements - Global Strategic Initiatives 2017.pdf (PDF 88 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-pagw.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Patient Group Reporting - PAGW.pdf (PDF 99 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-pacf.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Patient Group Reporting - PACF.pdf (PDF 150 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-germany.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Patient Group Reporting - Germany.pdf (PDF 80 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-msmt.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Patient Group Reporting - MSMT.pdf (PDF 202 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-belgium.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Patient Group Reporting - Belgium.pdf (PDF 70 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-paa.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Patient Group Reporting - PAA.pdf (PDF 228 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-canada.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Patient Group Reporting - Canada.pdf (PDF 116 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-japan.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Patient Group Reporting - Japan.pdf (PDF 272 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-australia.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Patient Group Reporting - Australia.pdf (PDF 245 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-spain.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Patient Group Reporting - Spain.pdf (PDF 196 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-italy.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Patient Group Reporting - Italy.pdf (PDF 158 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-netherlands.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Patient Group Reporting - Netherlands.pdf (PDF 177 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-pae.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Patient Group Reporting - PAE.pdf (1) (PDF 177 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-switzerland.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Patient Group Reporting - Switzerland.pdf (PDF 22 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/gappa-core-grants-budget-allocation-tracker.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"GAPPA Core Grants Budget Allocation Tracker.pdf (PDF 190 KB)","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/charitable-grants-to-us-entities.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/","txt":"Charitable Grants to US Entities.pdf (PDF 43 KB)","status":"new"},"http://www.microsoft.com/windows/ie/default.asp":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/careers/how-to-apply/","txt":"http://www.microsoft.com/windows/ie/default.asp","status":"new"},"http://home.netscape.com/download/index.html?cp=dju1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/careers/how-to-apply/","txt":"http://home.netscape.com/download/index.html?cp=dju1","status":"new"},"https://gsk.wd5.myworkdayjobs.com/ViiV_Careers":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/careers/job-search/","txt":"please click here","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/ch-fr/patientenbroschu-re-de.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/latest-news/2018/june-1/hiv-knowledge-builds-trust/","txt":"Brochure en allemand","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/ch-fr/patientenbroschu-re-fr.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/latest-news/2018/june-1/hiv-knowledge-builds-trust/","txt":"Brochure en français","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/ch-fr/patientenbroschu-re-it.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/latest-news/2018/june-1/hiv-knowledge-builds-trust/","txt":"Brochure en italien","status":"new"},"http://www.adobe.com/fr/privacy/opt-out.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/privacy-notice/#7","txt":"http://www.adobe.com/fr/privacy/opt-out.html","status":"new"},"https://fr-fr.facebook.com/help/568137493302217":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/privacy-notice/#7","txt":"https://fr-fr.facebook.com/help/568137493302217","status":"new"},"http://tools.google.com/dlpage/gaoptout?hl=fr":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ch/privacy-notice/#7","txt":"http://tools.google.com/dlpage/gaoptout?hl=fr","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/US/meet-me-where-i-want-to-be-ethnographic-research-study-infographic_may-17-2017-300.jpg":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/","txt":"“Meet Me Where I Want to Be” Ethnographic Research Study Infographic","status":"new"},"https://prezi.com/view/6IDewyFX8eIE9wAqZRNQ/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/","txt":"\"As Much as I Can\" Prezi: Overview of the Immersive Theater Experience","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/viiv_pasi_grantee_brotherhood_final_8302017.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-southern-initiative-resources/","txt":"Brotherhood, Inc.","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/viiv_pasi_grantee_friends-for-life_final_8302017.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-southern-initiative-resources/","txt":"Friends For Life","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/viiv_pasi_grantee_grace-house_final_8302017.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-southern-initiative-resources/","txt":"Grace House","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/viiv_pasi_grantee_jasmyn_final_8302017.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-southern-initiative-resources/","txt":"JASMYN","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/viiv_pasi_grantee_rain_final_8302017.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-southern-initiative-resources/","txt":"RAIN","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/viiv_pasi_grantee_rwhp_final_8302017.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-southern-initiative-resources/","txt":"Rural Women’s Health Project","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/viiv_pasi_grantee_sisterlove_final_8302017.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-southern-initiative-resources/","txt":"SisterLove, Inc.","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/viiv_pasi_grantee_someone-cares_final_8302017.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-southern-initiative-resources/","txt":"Someone Cares, Inc.","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/vhc-pasi-grantee-nashville-cares-story-final-101017.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-southern-initiative-resources/","txt":"Nashville CARES","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/viivus-pasi-infographic-final.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/positive-action-southern-initiative-resources/","txt":"view our infographic.","status":"new"},"https://www.cdc.gov/hiv/group/age/youth/index.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-expands-u-s--commitment-to-youth-living-with-hiv/#ref","txt":"https://www.cdc.gov/hiv/group/age/youth/index.html","status":"new"},"https://www.chcf.org/wp-content/uploads/2017/12/PDF-BuildingPeerSupportPrograms.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-expands-u-s--commitment-to-youth-living-with-hiv/#ref","txt":"https://www.chcf.org/wp-content/uploads/2017/12/PDF-BuildingPeerSupportPrograms.pdf","status":"new"},"http://www.thebody.com/content/79787/black-gay-and-bisexual-men-create-an-immersive-int.html?getPage=1":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/as-much-as-i-can/","txt":"Black Gay and Bisexual Men Create an Immersive, Intimate Performance in Two Southern Cities","status":"new"},"http://www.hivplusmag.com/stigma/2017/2/06/stories-black-gay-men-south-are-seldom-told-until-now":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/as-much-as-i-can/","txt":"Stories of Black Gay Men in the South are Seldom Told, Until Now","status":"new"},"http://aumag.org/2017/03/30/accelerates-as-much-as-i-can/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/as-much-as-i-can/","txt":"All the World’s a Stage: ACCELERATE!’s “As Much As I Can” Amplifies the Voices of Black Gay Men through the Arts to Expand the Dialogue About HIV","status":"new"},"http://www.euro.who.int/en/health-topics/communicable-diseases/hivaids/data-and-statistics/infographic-newly-diagnosed-hiv-infections-in-the-who-european-region":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-/#ref","txt":"http://www.euro.who.int/en/health-topics/communicable-diseases/hivaids/data-and-statistics/infographic-newly-diagnosed-hiv-infections-in-the-who-european-region","status":"new"},"http://www.christiesplace.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-awards--1-million-in-grants-for-positive-action-/","txt":"Christie’s Place","status":"new"},"https://pwn-usa.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-awards--1-million-in-grants-for-positive-action-/","txt":"Positive Women’s Network","status":"new"},"https://transgenderlawcenter.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-awards--1-million-in-grants-for-positive-action-/","txt":"Transgender Law Center","status":"new"},"http://www.thewellproject.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-awards--1-million-in-grants-for-positive-action-/","txt":"The Well Project","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/tivicay-pi-pil.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-extends-medicines-patent-pool-licence-agreement/#ref","txt":"https://www.viivhealthcare.com/media/58599/us_tivicay.pdf","status":"new"},"https://www.latinoaids.org/about/about.php":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/closing-the-gap-in-the-latinx-community/","txt":"https://www.latinoaids.org/about/about.php","status":"new"},"http://www.amatuvida.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-commitment-to-latinx-communities-living-with-hiv/","txt":"Ama Tu Vida","status":"new"},"http://www.bienestar.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/our-commitment-to-latinx-communities-living-with-hiv/","txt":"Bienestar Human Services","status":"new"},"http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/closing-the-gap-in-the-latinx-community/","txt":"http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html","status":"new"},"https://facebook.com/ViiVHealthcare/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-at-hiv-glasgow/","txt":"Facebook","status":"new"},"https://www.linkedin.com/company/viiv-healthcare/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-at-hiv-glasgow/","txt":"LinkedIn","status":"new"},"https://www.viivhealthcare.com/media/125766/hiv-tb_infographic-final.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-at-hiv-glasgow/","txt":"Global Challenges of Fighting HIV/TB Co-Infection  ","status":"new"},"http://www.inquisithealth.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/q-a-with-heather-brogan--piloting-a-new-mentoring-app-for-hiv-pa/","txt":"InquisitHealth","status":"new"},"http://fight.org/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/q-a-with-heather-brogan--piloting-a-new-mentoring-app-for-hiv-pa/","txt":"Philadelphia FIGHT","status":"new"},"https://www.linkedin.com/vsearch/j?keywords=ViiV%20Healthcare&f_C=612511&sb=Jobs%20at%20ViiV%20Healthcare&trk=tyah&trkInfo=clickedVertical%3Asuggestion%2CclickedEntityId%3A612511%2Cidx%3A1-3-3%2CtarId%3A1464088405307%2Ctas%3Aviiv%20healthcare%20":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/q-a-with-heather-brogan--piloting-a-new-mentoring-app-for-hiv-pa/","txt":"job opportunities on LinkedIn","status":"new"},"http://positiveactionchallenges.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/viiv-healthcare-s-the-hive-and-positive-action-community-challenge-seek-outside-collaborations-in-order-to-innovate-for-people-living-with-hiv/","txt":"the first Positive Action Community Challenge","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viivhc-timeline-infographic_-180117.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/viiv-healthcare--aids-2016/","txt":"  ","status":"new"},"https://www.youtube.com/watch?v=lUuyAKoB3co&list=PLGo14vcHL4DcK_1pUbkPOcrQtpao6dzGK&index=8":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/announcing-the-2016-every-footsteps-counts-winners/#bottom","txt":"Public Health Research Institute of India (PHRII) – Change Makers","status":"new"},"http://www.who.int/mediacentre/news/releases/2007/pr37/en/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/announcing-the-2016-every-footsteps-counts-winners/#bottom","txt":"http://www.who.int/mediacentre/news/releases/2007/pr37/en/","status":"new"},"https://www.youtube.com/watch?v=f4GLt7SersY&list=PLGo14vcHL4DcK_1pUbkPOcrQtpao6dzGK":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/a-look-back-at-aids-2016/","txt":"Every Footstep Counts video competition","status":"new"},"http://www.pepfar.gov/press/releases/260085.htm":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/innovation---hiv-science/a-look-back-at-aids-2016/","txt":"DREAMS, also announced the winners of its Innovation Challenge","status":"new"},"http://www.afao.org.au/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/afao-national-african-australian-hiv-network/","txt":"www.afao.org.au","status":"new"},"https://www.aacqa.gov.au/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/wa-aids-council-ageing-and-hiv/#ref","txt":"Australian Aged Care Quality Agency","status":"new"},"http://www.waaids.com/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/wa-aids-council-ageing-and-hiv/#ref","txt":"http://www.waaids.com/","status":"new"},"http://www.positivewomen.org.au/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-women-victoria-community-camp/#ref","txt":"http://www.positivewomen.org.au/","status":"new"},"http://www.positivewomen.org.au/women-and-hiv/an-overview/in-australia":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/community-partnerships/positive-women-victoria-community-camp/#ref","txt":"http://www.positivewomen.org.au/women-and-hiv/an-overview/in-australia","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/10028_vii_disclosure_juin18_fr_v03_cln.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/healthcare-professionals/voluntary-disclosure-of-viiv-healthcare-canada-payments-to-hcps-/","txt":"Cliquez ici pour télécharger le fichier PDF","status":"new"},"http://canadiensensante.gc.ca/publications/diseases-conditions-maladies-affections/hiv-aids-estimates-2014-vih-sida-estimations/index-fra.php":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/about-hivaids/about-hivaids-in-canada/#ref","txt":"Agence de la santé publique du Canada. Résumé : Estimations de l'incidence de la prévalence, et de la proportion non diagnostiquée au VIH au Canada, 2014 (2016). Consulté le 24 aoȗt 2016.","status":"new"},"http://www.phac-aspc.gc.ca/aids-sida/pr/index-fra.php":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/about-hivaids/about-hivaids-in-canada/#ref","txt":"Agence de la santé publique du Canada. Populations à risque. Consulté le 10 avril 2015.","status":"new"},"http://www.aso411.ca/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/about-hivaids/canadian-resources/","txt":"www.aso411.ca  ","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/3tc-french.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/3tc/","txt":"Monographie de 3TC®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/celsentri-french.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/celsentri/","txt":"Monographie de CELSENTRI®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/combivir-french.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/combivir/","txt":"Monographie de COMBIVIR®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/kivexa-french.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/kivexa/","txt":"Monographie de KIVEXA®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/rescriptor-french.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/rescriptor/","txt":"Monographie de RESCRIPTOR®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/retrovir-french.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/retrovirazt/","txt":"Monographie de RETROVIR/AZT®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/telzir-french.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/telzir/","txt":"Monographie de TELZIR®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/tivicay_french.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/tivicay/","txt":"Monographie de TIVICAY®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/triumeq-french.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/triumeq/","txt":"Monographie de TRIUMEQ®","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/Canada-FR/trizivir-french.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/our-medicines/ziagen/","txt":"Monographie de ZIAGEN®","status":"new"},"https://www.latinoaids.org/programs/latino_religious/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/closing-the-gap-in-the-latinx-community/","txt":"Latino Religious Leadership Project","status":"new"},"https://www.latinoaids.org/programs/deepsouth/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/closing-the-gap-in-the-latinx-community/","txt":"Latinos in the Deep South","status":"new"},"https://www1.nyc.gov/site/doh/about/press/pr2017/pr003-17.page":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/closing-the-gap-in-the-latinx-community/","txt":"announced","status":"new"},"https://www.cdc.gov/hiv/group/racialethnic/hispaniclatinos/":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/closing-the-gap-in-the-latinx-community/","txt":"https://www.cdc.gov/hiv/group/racialethnic/hispaniclatinos/","status":"new"},"http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/US/viiv_healthcare-narrative_spanish.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/nuestro-compromiso-con-la-poblacion-hispana-y-latina-que-vive-co/#ref","txt":"haga clic aquí","status":"new"},"https://eu5.salesforce.com/0012400000DiLUs":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-collaborathon-grants-announced/","txt":"Give Hope Ethiopia","status":"new"},"https://eu5.salesforce.com/0012400000hXknD":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-collaborathon-grants-announced/","txt":"Centre de Recherches et d'Informations Pour la Santé au TOGO (ONG CRIPS-TOGO)","status":"new"},"https://www.cell.com/cms/attachment/2119249305/2091176163/mmc6.mp4":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/latest-news/2018/may-1/new-insights-into-hiv-transmission/","txt":"Link zum Video","status":"new"},"https://www.spektrum.de/news/hiv-bei-den-ersten-infektionsschritten-gefilmt/1564318":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/latest-news/2018/may-1/new-insights-into-hiv-transmission/","txt":"https://www.spektrum.de/news/hiv-bei-den-ersten-infektionsschritten-gefilmt/1564318","status":"new"},"https://www.cell.com/cell-reports/fulltext/S2211-1247(18)30570-9":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/latest-news/2018/may-1/new-insights-into-hiv-transmission/","txt":"https://www.cell.com/cell-reports/fulltext/S2211-1247(18)30570-9","status":"new"},"http://gskvideo.edgesuite.net//Viiv/viivhealthcare/pdf_files/US/viiv_healthcare-narrative_spanish.pdf":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/es/#ref","txt":"haga clic aquí","status":"new"}},"mailto":{"mailto:viivhc.globalcomms@viivhealthcare.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-reports-positive-48-week-results-for-second-phas/#ref","txt":"Isabelle Scali","status":"new"},"mailto:cara.m.vivarelli-o'neill@viivhealthcare.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-reports-positive-48-week-results-for-second-phas/#ref","txt":"cara.m.vivarelli-o'neill@viivhealthcare.com","status":"new"},"mailto:viivhc.globalcoms@viivhealthcare.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/committed-to-data-transparency/","txt":"ViiV Healthcare Global Communications","status":"new"},"mailto:viiv.partnering@viivhealthcare.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-collaborate-to-innovate/","txt":"viiv.partnering@viivhealthcare.com","status":"new"},"mailto:marc.s.meachem@viivhealthcare.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-sword-100-week-data-for-juluca-dolute/#ref","txt":"marc.s.meachem@viivhealthcare.com","status":"new"},"mailto:press@clintonhealthaccess.org":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/May/press-release/","txt":"press@clintonhealthac-cess.org","status":"new"},"mailto:ir@aurobindo.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2015/May/press-release/","txt":"ir@aurobindo.com","status":"new"},"mailto:positiveaction@viivhealthcare.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/february0/viiv-healthcare-expands-positive-action-southern-initiative-to-f/#ref","txt":"positiveaction@viivhealthcare.com","status":"new"},"mailto:positiveactionforchildren@viivhealthcare.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2013/december/viiv-healthcare-commits-34m-in-positive-action-for-children-fund/#ref","txt":"positiveactionforchildren@viivhealthcare.com","status":"new"},"mailto:positiveactionforchildrenfund@viivhealthcare.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2012/November/viiv-healthcare-commits-nearly-4m-in-positive-action-for-children-fund-grants-for-programmes-focused-on-alleviating-burden-of-hiv-on-women-and-children/#ref","txt":"register their interest","status":"new"},"mailto:usgrants@viivhealthcare.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/july/viiv-healthcare-announces-positive-action-us-southern-initiative/#ref","txt":"usgrants@viivhealthcare.com","status":"new"},"mailto:cub.barrett@amfar.org":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/june/viiv-healthcare-and-amfar-partner-to-optimize-hiv-treatment-for-/","txt":"cub.barrett@amfar.org","status":"new"},"mailto:Marc.s.meachem@Viivhealthcare.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/june/viiv-healthcare-and-elizabeth-glaser-pediatric-aids-foundation-p/","txt":"Marc.s.meachem@Viivhealthcare.com","status":"new"},"mailto:Scott.d.purdon@Viivhealthcare.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/june/viiv-healthcare-and-elizabeth-glaser-pediatric-aids-foundation-p/","txt":"Scott.d.purdon@Viivhealthcare.com","status":"new"},"mailto:sbowen@pedaids.org":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/Media/Press%20releases/2010/june/viiv-healthcare-and-elizabeth-glaser-pediatric-aids-foundation-p/","txt":"sbowen@pedaids.org","status":"new"},"mailto:Australia.medinfo@viivhealthcare.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/our-medicines/ziagen-/","txt":"Australia.medinfo@viivhealthcare.com","status":"new"},"mailto:antoinette.x.lee@gsk.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/october/viiv-healthcare-awards-new-grants-to-accelerate-community-led-so/#ref","txt":"antoinette.x.lee@gsk.com","status":"new"},"mailto:menosesmas.proyectosong@viivhealthcare.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/es-es/spanish-articles/sumate-a-conmenosesposiblemas/","txt":"menosesmas.proyectosong@viivhealthcare.com","status":"new"},"mailto:viiv.med.info@viivhealthcare.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/datenschutzerklaerung/#6","txt":"viiv.med.info@viivhealthcare.com","status":"new"},"mailto:DE.Datenschutz-ViiVHealthcare@viivhealthcare.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-de/datenschutzerklaerung/#6","txt":"DE.Datenschutz-ViiVHealthcare@viivhealthcare.com","status":"new"},"mailto:Medical.Education@viivhealthcare.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/fr-ca/healthcare-professionals/independent-grants-and-support-programs/","txt":"Medical.Education@viivhealthcare.com","status":"new"},"mailto:swiss.cpa@gsk.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/de-ch/privacy-notice/#9","txt":"swiss.cpa@gsk.com","status":"new"},"mailto:viiv@tccgrp.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/local-partnerships/","txt":"viiv@tccgrp.com","status":"new"},"mailto:isabelle.x.scali@viivhealthcare.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-phase-ii-study-results-for-first-two-d/#ref","txt":"isabelle.x.scali@viivhealthcare.com","status":"new"},"mailto:dolutegravir-eap@parexel.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/dolutegravir-expanded-access-program/#tab-02006000839-5","txt":"dolutegravir-eap@parexel.com","status":"new"},"mailto:katy.j.hayward@viivhealthcare.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/spark--igniting-change/#Access","txt":"katy.j.hayward@viivhealthcare.com","status":"new"},"mailto:positiveaction.msmt@viivhealthcare.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-msm-transgender-people/#tab-02071038744-2","txt":"positiveaction.msmt@viivhealthcare.com","status":"new"},"mailto:positiveaction.europe@viivhealthcare.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/#pae","txt":"positiveaction.europe@viivhealthcare.com","status":"new"},"mailto:chldel@tin.it":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/hiv-behind-bars--supporting-hiv-research--education-and-testing-/","txt":"chldel@tin.it","status":"new"},"mailto:abattistella@unive.it":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/hiv-behind-bars--supporting-hiv-research--education-and-testing-/","txt":"abattistella@unive.it","status":"new"},"mailto:fabio.perocco@unive.it":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/hiv-behind-bars--supporting-hiv-research--education-and-testing-/","txt":"fabio.perocco@unive.it","status":"new"},"mailto:nazionale@npsitalia.net":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/our-stories/partnerships---key-populations/hiv-behind-bars--supporting-hiv-research--education-and-testing-/","txt":"nazionale@npsitalia.net","status":"new"},"mailto:lhebditch@buchanwe.com.au":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/october/viiv-healthcare-awards-new-grants-to-accelerate-community-led-so/#ref","txt":"lhebditch@buchanwe.com.au","status":"new"},"mailto:abonetti@buchanwe.com.au":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/october/viiv-healthcare-awards-new-grants-to-accelerate-community-led-so/#ref","txt":"abonetti@buchanwe.com.au","status":"new"},"mailto:UK.EFPIA-Disclosure-Customer@gsk.com":{"firstFound":"https://viivhealthcare-com-preview-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-kingdom/viiv-healthcare---disclosure-of-payments-to-uk-based-healthcare-/","txt":"UK.EFPIA-Disclosure-Customer@gsk.com","status":"new"}},"errors":[]}